[Skip to nav](https://www.moffitt.org/research-science/researchers/eric-padron#menu-mobile) [Skip to content](https://www.moffitt.org/research-science/researchers/eric-padron#main-content)
[ ![Moffitt Cancer Center](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-full-white.svg) ](https://www.moffitt.org/ "Moffitt Cancer Center")
Schedule
[New Patients](https://www.moffitt.org/eforms/patientregistrationform/ "New Patients") [Referring Physicians](https://www.moffitt.org/eforms/referapatient/ "Referring Physicians")
[ Find a Doctor ](https://www.moffitt.org/find-a-doctor/ "Find a Doctor")
Patient Portal
[Log In](https://mymoffitt.iqhealth.com/ "Log In") [Enroll](https://mymoffitt.iqhealth.com/self-enroll/)
[ Careers ](https://www.moffitt.org/careers/ "Careers")
[ Locations ](https://www.moffitt.org/locations-directions/ "Locations")
[ 1-888-663-3488 ](tel:1-888-663-3488 "Call 1-888-663-3488")
English
[English](https://www.moffitt.org/research-science/researchers/eric-padron/ "English") [Spanish](https://www.moffitt.org/es/research-science/researchers/eric-padron/ "Spanish")
[ ](https://www.moffitt.org/research-science/researchers/?campaign=567103 "Donate") Search
  * [Cancer Types & Treatments](https://www.moffitt.org/research-science/researchers/eric-padron)
    * [ Cancers ](https://www.moffitt.org/cancers/)
      * [Acute Lymphocytic Leukemia (ALL)](https://www.moffitt.org/cancers/acute-lymphocytic-leukemia-all/ "Acute Lymphocytic Leukemia \(ALL\)")
      * [Acute Myelogenous Leukemia (AML)](https://www.moffitt.org/cancers/acute-myelogenous-leukemia/ "Acute Myelogenous Leukemia \(AML\)")
      * [Acute Promyelocytic Leukemia (APL)](https://www.moffitt.org/cancers/acute-promyelocytic-leukemia-apl/ "Acute Promyelocytic Leukemia \(APL\)")
      * [Adrenal Cancer](https://www.moffitt.org/cancers/adrenal-cancer/ "Adrenal Cancer")
      * [Anal Cancer](https://www.moffitt.org/cancers/anal-cancer/ "Anal Cancer")
      * [Appendiceal (Appendix) Cancer](https://www.moffitt.org/cancers/appendiceal-appendix-cancer/ "Appendiceal \(Appendix\) Cancer")
      * [Astrocytoma](https://www.moffitt.org/cancers/astrocytoma/ "Astrocytoma")
      * [Basal Cell Carcinoma](https://www.moffitt.org/cancers/basal-cell-carcinoma/ "Basal Cell Carcinoma")
      * [Bladder Cancer](https://www.moffitt.org/cancers/bladder-cancer/ "Bladder Cancer")
      * [Bone Metastasis](https://www.moffitt.org/cancers/bone-metastasis/ "Bone Metastasis")
      * [Brain Cancer](https://www.moffitt.org/cancers/brain-cancer/ "Brain Cancer")
      * [Brain Tumor](https://www.moffitt.org/cancers/brain-tumor/ "Brain Tumor")
      * [Brain Metastases](https://www.moffitt.org/cancers/brain-metastases/ "Brain Metastases")
      * [Breast Cancer](https://www.moffitt.org/cancers/breast-cancer/ "Breast Cancer")
      * [Cervical Cancer](https://www.moffitt.org/cancers/cervical-cancer/ "Cervical Cancer")
      * [Cholangiocarcinoma (Bile Duct Cancer)](https://www.moffitt.org/cancers/cholangiocarcinoma-bile-duct-cancer/ "Cholangiocarcinoma \(Bile Duct Cancer\)")
      * [Chronic Lymphocytic Leukemia (CLL)](https://www.moffitt.org/cancers/chronic-lymphocytic-leukemia/ "Chronic Lymphocytic Leukemia \(CLL\)")
      * [Colon Cancer](https://www.moffitt.org/cancers/colon-cancer/ "Colon Cancer")
      * [Colorectal Cancer](https://www.moffitt.org/cancers/colorectal-cancer/ "Colorectal Cancer")
      * [Chronic Myelogenous Leukemia (CML)](https://www.moffitt.org/cancers/chronic-myelogenous-leukemia-cml/ "Chronic Myelogenous Leukemia \(CML\)")
      * [Cutaneous Lymphoma (CTCL)](https://www.moffitt.org/cancers/cutaneous-t-cell-lymphoma/ "Cutaneous Lymphoma \(CTCL\)")
      * [Diffuse Large B-Cell Lymphoma](https://www.moffitt.org/cancers/diffuse-large-b-cell-lymphoma/ "Diffuse Large B-Cell Lymphoma")
      * [Ductal Carcinoma In Situ](https://www.moffitt.org/cancers/ductal-carcinoma-in-situ/ "Ductal Carcinoma In Situ")
      * [Endometrial (Uterine) Cancer](https://www.moffitt.org/cancers/endometrial-uterine-cancer/ "Endometrial \(Uterine\) Cancer")
      * [Esophageal Cancer](https://www.moffitt.org/cancers/esophageal-cancer/ "Esophageal Cancer")
      * [Follicular Lymphoma](https://www.moffitt.org/cancers/follicular-lymphoma/ "Follicular Lymphoma")
      * [Gallbladder Cancer](https://www.moffitt.org/cancers/gallbladder-cancer/ "Gallbladder Cancer")
      * [Gastrointestinal Carcinoid Tumor](https://www.moffitt.org/cancers/gastrointestinal-carcinoid-tumor/ "Gastrointestinal Carcinoid Tumor")
      * [GIST (Gastrointestinal Stromal Tumor)](https://www.moffitt.org/cancers/gist-gastrointestinal-stromal-tumor/ "GIST \(Gastrointestinal Stromal Tumor\)")
      * [Glioblastoma](https://www.moffitt.org/cancers/glioblastoma/ "Glioblastoma")
      * [Head and Neck Cancer](https://www.moffitt.org/cancers/head-and-neck-cancer/ "Head and Neck Cancer")
      * [HER2 Positive Breast Cancer](https://www.moffitt.org/cancers/her2-positive-breast-cancer/ "HER2 Positive Breast Cancer")
      * [Hodgkin Lymphoma](https://www.moffitt.org/cancers/hodgkin-lymphoma/ "Hodgkin Lymphoma")
      * [Inflammatory Breast Cancer](https://www.moffitt.org/cancers/inflammatory-breast-cancer/ "Inflammatory Breast Cancer")
      * [Invasive Ductal Carcinoma](https://www.moffitt.org/cancers/invasive-ductal-carcinoma/ "Invasive Ductal Carcinoma")
      * [Kidney (Renal Cell) Cancer](https://www.moffitt.org/cancers/kidney-renal-cell-cancer/ "Kidney \(Renal Cell\) Cancer")
      * [Leukemia](https://www.moffitt.org/cancers/leukemia/ "Leukemia")
      * [Liver (Hepatocellular) Cancer](https://www.moffitt.org/cancers/liver-hepatocellular-cancer/ "Liver \(Hepatocellular\) Cancer")
      * [Low-Grade Glioma](https://www.moffitt.org/cancers/low-grade-glioma/ "Low-Grade Glioma")
      * [Lung Cancer](https://www.moffitt.org/cancers/lung-cancer/ "Lung Cancer")
      * [Lymphomas (Hodgkin and Non-Hodgkin)](https://www.moffitt.org/cancers/lymphomas-hodgkin-and-non-hodgkin/ "Lymphomas \(Hodgkin and Non-Hodgkin\)")
      * [Mantle Cell Lymphoma](https://www.moffitt.org/cancers/mantle-cell-lymphoma/ "Mantle Cell Lymphoma")
      * [Melanoma](https://www.moffitt.org/cancers/melanoma/ "Melanoma")
      * [Meningioma](https://www.moffitt.org/cancers/meningioma/ "Meningioma")
      * [Merkel Cell Carcinoma](https://www.moffitt.org/cancers/merkel-cell-carcinoma/ "Merkel Cell Carcinoma")
      * [Mesothelioma](https://www.moffitt.org/cancers/mesothelioma/ "Mesothelioma")
      * [Metastatic Breast Cancer](https://www.moffitt.org/cancers/metastatic-breast-cancer/ "Metastatic Breast Cancer")
      * [Monoclonal Gammopathy of Undetermined Significance (MGUS)](https://www.moffitt.org/cancers/monoclonal-gammopathy-of-undetermined-significance-mgus/ "Monoclonal Gammopathy of Undetermined Significance \(MGUS\)")
      * [Multiple Myeloma-Plasma Cell Tumor](https://www.moffitt.org/cancers/multiple-myeloma-plasma-cell-tumor/ "Multiple Myeloma-Plasma Cell Tumor")
      * [Myelodysplastic Syndromes (MDS)](https://www.moffitt.org/cancers/myelodysplastic-syndromes-mds/ "Myelodysplastic Syndromes \(MDS\)")
      * [Neuroendocrine Tumor](https://www.moffitt.org/cancers/neuroendocrine-tumor/ "Neuroendocrine Tumor")
      * [Neurofibromatosis](https://www.moffitt.org/cancers/neurofibromatosis/ "Neurofibromatosis")
      * [Non-Hodgkin Lymphoma](https://www.moffitt.org/cancers/non-hodgkin-lymphoma/ "Non-Hodgkin Lymphoma")
      * [Oral Cavity (Mouth) Cancer](https://www.moffitt.org/cancers/oral-cavity-mouth-cancer/ "Oral Cavity \(Mouth\) Cancer")
      * [Insurance and Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/ "Insurance and Financial Information")
      * [Oral Cavity or Throat Cancer](https://www.moffitt.org/cancers/oral-cavity-or-throat-cancer/ "Oral Cavity or Throat Cancer")
      * [Osteosarcoma](https://www.moffitt.org/cancers/osteosarcoma/ "Osteosarcoma")
      * [Ovarian Cancer](https://www.moffitt.org/cancers/ovarian-cancer/ "Ovarian Cancer")
      * [Pancoast Tumor](https://www.moffitt.org/cancers/pancoast-tumor/ "Pancoast Tumor")
      * [Pancreatic Cancer](https://www.moffitt.org/cancers/pancreatic-cancer/ "Pancreatic Cancer")
      * [Penile Cancer](https://www.moffitt.org/cancers/penile-cancer/ "Penile Cancer")
      * [Pituitary Adenoma](https://www.moffitt.org/cancers/pituitary-adenoma/ "Pituitary Adenoma")
      * [Prostate Cancer](https://www.moffitt.org/cancers/prostate-cancer/ "Prostate Cancer")
      * [Rectal Cancer](https://www.moffitt.org/cancers/rectal-cancer/ "Rectal Cancer")
      * [Sarcoma](https://www.moffitt.org/cancers/sarcoma/ "Sarcoma")
      * [Skin Cancer (Nonmelanoma)](https://www.moffitt.org/cancers/skin-cancer-nonmelanoma/ "Skin Cancer \(Nonmelanoma\)")
      * [Skull Base Tumors](https://www.moffitt.org/cancers/skull-base-tumors/ "Skull Base Tumors")
      * [Small Intestine Cancer](https://www.moffitt.org/cancers/small-intestine-cancer/ "Small Intestine Cancer")
      * [Spinal Tumor](https://www.moffitt.org/cancers/spinal-tumor/ "Spinal Tumor")
      * [Squamous Cell Carcinoma](https://www.moffitt.org/cancers/squamous-cell-carcinoma/ "Squamous Cell Carcinoma")
      * [Smoldering Multiple Myeloma](https://www.moffitt.org/cancers/smoldering-multiple-myeloma-smm/ "Smoldering Multiple Myeloma")
      * [Stomach (Gastric) Cancer](https://www.moffitt.org/cancers/stomach-gastric-cancer/ "Stomach \(Gastric\) Cancer")
      * [Testicular Cancer](https://www.moffitt.org/cancers/testicular-cancer/ "Testicular Cancer")
      * [Throat Cancer](https://www.moffitt.org/cancers/throat-cancer/ "Throat Cancer")
      * [Thymoma](https://www.moffitt.org/cancers/thymoma/ "Thymoma")
      * [Thyroid Cancer](https://www.moffitt.org/cancers/thyroid-cancer/ "Thyroid Cancer")
      * [Tongue Cancer](https://www.moffitt.org/cancers/tongue-cancer/ "Tongue Cancer")
      * [Tracheal Cancer](https://www.moffitt.org/cancers/tracheal-cancer/ "Tracheal Cancer")
      * [Triple Negative Breast Cancer](https://www.moffitt.org/cancers/triple-negative-breast-cancer/ "Triple Negative Breast Cancer")
      * [Vaginal Cancer](https://www.moffitt.org/cancers/vaginal-cancer/ "Vaginal Cancer")
      * [Vulvar Cancer](https://www.moffitt.org/cancers/vulvar-cancer/ "Vulvar Cancer")
    * [ Treatments ](https://www.moffitt.org/treatments/)
      * [Blood Bone Marrow Transplant](https://www.moffitt.org/treatments/blood-bone-marrow-transplant/ "Blood Bone Marrow Transplant")
      * [Bloodless Medicine and Surgery](https://www.moffitt.org/treatments/bloodless-medicine-and-surgery/ "Bloodless Medicine and Surgery")
      * [Cardio-Oncology](https://www.moffitt.org/treatments/cardio-oncology/ "Cardio-Oncology")
      * [Chemotherapy](https://www.moffitt.org/treatments/chemotherapy/ "Chemotherapy")
      * [Clinical Pathways](https://www.moffitt.org/treatments/clinical-pathways/ "Clinical Pathways")
      * [Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/ "Clinical Trials")
      * [Diagnostic Services](https://www.moffitt.org/diagnostic-services/ "Diagnostic Services")
      * [Endoscopic Procedures](https://www.moffitt.org/treatments/endoscopic-procedures/ "Endoscopic Procedures")
      * [Fertility Preservation](https://www.moffitt.org/treatments/fertility-preservation/ "Fertility Preservation")
      * [Gynecologic Oncology](https://www.moffitt.org/treatments/gynecologic-oncology/ "Gynecologic Oncology")
      * [Immunotherapy](https://www.moffitt.org/treatments/immunotherapy/ "Immunotherapy")
      * [Interventional Pain Management](https://www.moffitt.org/treatments/interventional-pain-management/ "Interventional Pain Management")
      * [Interventional Radiology](https://www.moffitt.org/treatments/interventional-radiology/ "Interventional Radiology")
      * [Precision Medicine](https://www.moffitt.org/treatments/precision-medicine/ "Precision Medicine")
      * [Pharmacy](https://www.moffitt.org/treatments/pharmacy/ "Pharmacy")
      * [Radiation Therapy](https://www.moffitt.org/treatments/radiation-therapy/ "Radiation Therapy")
      * [Rehabilitation Services](https://www.moffitt.org/treatments/rehabilitation-services/ "Rehabilitation Services")
      * [Supportive Care Medicine](https://www.moffitt.org/treatments/supportive-care-medicine/ "Supportive Care Medicine")
      * [Surgical Care](https://www.moffitt.org/treatments/surgical-care/ "Surgical Care")
      * [Systemic Therapy](https://www.moffitt.org/treatments/systemic-therapy/ "Systemic Therapy")
      * [Targeted Therapy](https://www.moffitt.org/treatments/targeted-therapy/ "Targeted Therapy")
      * [Tumor Board](https://www.moffitt.org/treatments/tumor-board/ "Tumor Board")
    * [ Clinical Trials ](https://www.moffitt.org/clinical-trials-research/clinical-trials/)
      * [Am I A Candidate?](https://www.moffitt.org/clinical-trials-research/clinical-trials/am-i-a-candidate/ "Am I A Candidate?")
      * [Clinical Research Unit](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-research-unit/ "Clinical Research Unit")
      * [Clinical Trials Administration](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-administration/ "Clinical Trials Administration")
      * [Clinical Trials: Are They Right for You?](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-are-they-right-for-you/ "Clinical Trials: Are They Right for You?")
      * [Patient Protection](https://www.moffitt.org/clinical-trials-research/clinical-trials/patient-protection/ "Patient Protection")
      * [Phase 1 Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/phase-1-clinical-trials/ "Phase 1 Clinical Trials")
    * [ Diagnostic Services ](https://www.moffitt.org/diagnostic-services/)
      * [Cancer Screenings](https://www.moffitt.org/diagnostic-services/cancer-screenings/ "Cancer Screenings")
      * [Genetic Counseling and Genetic Testing](https://www.moffitt.org/diagnostic-services/genetic-counseling-and-genetic-testing/ "Genetic Counseling and Genetic Testing")
      * [Labwork and Bloodwork](https://www.moffitt.org/diagnostic-services/labwork-and-bloodwork/ "Labwork and Bloodwork")
      * [Pathology](https://www.moffitt.org/diagnostic-services/pathology/ "Pathology")
      * [Radiology – Diagnostic Imaging and Interventional Radiology](https://www.moffitt.org/diagnostic-services/radiology-diagnostic-imaging-and-interventional-radiology/ "Radiology – Diagnostic Imaging and Interventional Radiology")
      * [Cancer Treatments](https://www.moffitt.org/treatments/ "Cancer Treatments")
    * [ ![](https://www.moffitt.org/contentassets/5f17f2115eca48a1aa7faa610608f778/clinical-trials.jpg) Search Clinical Trials  Moffitt participates in over 400 clinical trials. Find a trial that is right for you. ](https://www.moffitt.org/clinical-trials-research/clinical-trials/ "Search Clinical Trials")
  * [Patients & Families](https://www.moffitt.org/research-science/researchers/eric-padron)
    * [ Patient & Family ](https://www.moffitt.org/patient-family/)
    * [ Preparing For Your Appointment ](https://www.moffitt.org/patient-family/preparing-for-your-appointment/)
      * [Patient and Family Orientation](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-and-family-orientation/ "Patient and Family Orientation")
      * [Medical Records](https://www.moffitt.org/patient-family/preparing-for-your-appointment/medical-records/ "Medical Records")
      * [Appointment Reminder Service](https://www.moffitt.org/patient-family/preparing-for-your-appointment/appointment-reminder-service/ "Appointment Reminder Service")
      * [MyMoffitt Patient Portal](https://www.moffitt.org/patient-family/preparing-for-your-appointment/mymoffitt-patient-portal/ "MyMoffitt Patient Portal")
      * [New Cancer Diagnosis](https://www.moffitt.org/patient-family/preparing-for-your-appointment/new-cancer-diagnosis/ "New Cancer Diagnosis")
      * [Online Registration Frequently Asked Questions](https://www.moffitt.org/patient-family/preparing-for-your-appointment/online-registration-frequently-asked-questions/ "Online Registration Frequently Asked Questions")
      * [Scheduling Your Appointment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/scheduling-your-appointment/ "Scheduling Your Appointment")
      * [Traveling for Cancer Treatment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/traveling-for-cancer-treatment/ "Traveling for Cancer Treatment")
      * [Preparing For Your Hospitalization](https://www.moffitt.org/patient-family/preparing-for-your-hospitalization/ "Preparing For Your Hospitalization")
      * [Preparing For Your Surgery](https://www.moffitt.org/patient-family/preparing-for-your-surgery/ "Preparing For Your Surgery")
      * [Visitor Policy](https://www.moffitt.org/patient-family/preparing-for-your-appointment/visitor-policy/ "Visitor Policy")
      * [Patient Rights and Responsibilities](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-rights-and-responsibilities/ "Patient Rights and Responsibilities")
      * [What to Know About Your Appointments During Hurricane Season](https://www.moffitt.org/patient-family/hurricane/appointments-during-hurricane-season/ "What to Know About Your Appointments During Hurricane Season")
    * [ Insurance & Financial Information ](https://www.moffitt.org/patient-family/insurance-financial-information/)
      * [Copay Assistance Program](https://www.moffitt.org/patient-family/insurance-financial-information/copay-assistance-program/ "Copay Assistance Program")
      * [Financial Assistance](https://www.moffitt.org/patient-family/insurance-financial-information/financial-assistance/ "Financial Assistance")
      * [Glossary of Terms](https://www.moffitt.org/patient-family/insurance-financial-information/glossary-of-terms/ "Glossary of Terms")
      * [Health Exchange](https://www.moffitt.org/patient-family/insurance-financial-information/health-exchange/ "Health Exchange")
      * [Insurance Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/insurance-coverage/ "Insurance Coverage")
      * [Medicare Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/medicare-coverage/ "Medicare Coverage")
      * [Obtain a Cost Estimate](https://www.moffitt.org/patient-family/insurance-financial-information/obtain-a-cost-estimate/ "Obtain a Cost Estimate")
      * [Questions to Ask Your Insurance Company](https://www.moffitt.org/patient-family/insurance-financial-information/questions-to-ask-your-insurance-company/ "Questions to Ask Your Insurance Company")
      * [Understanding Your Bill](https://www.moffitt.org/patient-family/insurance-financial-information/understanding-your-bill/ "Understanding Your Bill")
      * [Frequently Asked Questions](https://www.moffitt.org/patient-family/insurance-financial-information/frequently-asked-questions/ "Frequently Asked Questions")
      * [Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/financial-information/ "Financial Information")
    * [ Programs & Support Services ](https://www.moffitt.org/patient-family/programs-support-services/)
      * [Advance Care Planning](https://www.moffitt.org/patient-family/programs-support-services/advance-care-planning/ "Advance Care Planning")
      * [AYA: Adolescent Young Adult Program](https://www.moffitt.org/patient-family/programs-support-services/aya-adolescent-young-adult-program/ "AYA: Adolescent Young Adult Program")
      * [Chaplaincy Spiritual Care](https://www.moffitt.org/patient-family/programs-support-services/chaplaincy-spiritual-care/ "Chaplaincy Spiritual Care")
      * [Community Resources](https://www.moffitt.org/patient-family/programs-support-services/online-resources/ "Community Resources")
      * [Counseling and Support](https://www.moffitt.org/patient-family/programs-support-services/counseling-and-support/ "Counseling and Support")
      * [Language Services](https://www.moffitt.org/patient-family/programs-support-services/language-services/ "Language Services")
      * [Nutrition](https://www.moffitt.org/patient-family/programs-support-services/nutrition/ "Nutrition")
      * [Senior Adult Oncology Program](https://www.moffitt.org/patient-family/programs-support-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
      * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")
      * [Specialty Pharmacy at Moffitt](https://www.moffitt.org/patient-family/programs-support-services/specialty-pharmacy/ "Specialty Pharmacy at Moffitt")
    * [ Patient and Family Centered Care ](https://www.moffitt.org/patient-family/patient-and-family-centered-care/)
      * [Demonstrating Respect at Moffitt](https://www.moffitt.org/patient-family/patient-and-family-centered-care/demonstrating-respect-at-moffitt/ "Demonstrating Respect at Moffitt")
      * [Daisy and Sunflower Awards](https://www.moffitt.org/patient-family/patient-and-family-centered-care/daisy-and-sunflower-awards/ "Daisy and Sunflower Awards")
      * [Patient and Family Advisory Program](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-and-family-advisory-program/ "Patient and Family Advisory Program")
      * [Patient Relations](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-relations/ "Patient Relations")
      * [Patient Researcher Forum](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-researcher-forum/ "Patient Researcher Forum")
      * [Patti K Halula Legacy Award](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patti-k-halula-legacy-award/ "Patti K Halula Legacy Award")
      * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")
    * [ Cancer Survivorship ](https://www.moffitt.org/patient-family/cancer-survivorship/)
      * [Cancer Survivorship Program](https://www.moffitt.org/patient-family/cancer-survivorship/cancer-survivorship-program/ "Cancer Survivorship Program")
    * [ International Patient Services ](https://www.moffitt.org/patient-family/international-patient-services/)
      * [Frequently Asked Questions](https://www.moffitt.org/patient-family/international-patient-services/frequently-asked-questions/ "Frequently Asked Questions")
      * [Online Consult Forms](https://www.moffitt.org/patient-family/international-patient-services/online-consult-forms/ "Online Consult Forms")
      * [Online Consults](https://www.moffitt.org/patient-family/international-patient-services/online-consults/ "Online Consults")
      * [Moffitt Outreach in Puerto Rico](https://www.moffitt.org/patient-family/international-patient-services/puerto-rico/ "Moffitt Outreach in Puerto Rico")
    * [ Moffitt Virtual Care ](https://www.moffitt.org/patient-family/moffitt-virtual-care/)
      * [All About Virtual Care](https://www.moffitt.org/patient-family/moffitt-virtual-care/all-about-virtual-care/ "All About Virtual Care")
      * [Informed Consent for Telemedicine](https://www.moffitt.org/patient-family/moffitt-virtual-care/informed-consent-for-telemedicine/ "Informed Consent for Telemedicine")
      * [New Cancer Patients](https://www.moffitt.org/patient-family/moffitt-virtual-care/new-cancer-patients/ "New Cancer Patients")
      * [Virtual Care Success Checklist](https://www.moffitt.org/patient-family/moffitt-virtual-care/virtual-care-success-checklist/ "Virtual Care Success Checklist")
    * [ Inspiring Stories ](https://www.moffitt.org/inspiring-stories/)
      * [Isabel's Story](https://www.moffitt.org/inspiring-stories/isabels-story/ "Isabel's Story")
      * [Amanda's Story](https://www.moffitt.org/inspiring-stories/amandas-story/ "Amanda's Story")
      * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story-my-prostate-cancer-journey/ "Rick's Story")
      * [Vondalyn's Story: From Adversity to Advocacy](https://www.moffitt.org/inspiring-stories/vondalyns-story-from-adversity-to-advocacy/ "Vondalyn's Story: From Adversity to Advocacy")
      * [Cayla’s Story: Cancer Never Cares About Anything Like That](https://www.moffitt.org/inspiring-stories/caylas-story-cancer-never-cares-about-anything-like-that/ "Cayla’s Story: Cancer Never Cares About Anything Like That")
      * [Rick's Story: Now What?](https://www.moffitt.org/inspiring-stories/ricks-story-now-what/ "Rick's Story: Now What?")
      * [Amy's Story: No Longer Alone](https://www.moffitt.org/inspiring-stories/no-longer-alone/ "Amy's Story: No Longer Alone")
      * [Zoe's Story](https://www.moffitt.org/inspiring-stories/zoeys-story/ "Zoe's Story")
      * [Erma's Story](https://www.moffitt.org/inspiring-stories/ermas-story/ "Erma's Story")
      * [Donna's Story](https://www.moffitt.org/inspiring-stories/donnas-story/ "Donna's Story")
      * [Dr. Vadaparampil's Story](https://www.moffitt.org/inspiring-stories/dr.-vadaparampils-story "Dr. Vadaparampil's Story")
      * [Mark's Story](https://www.moffitt.org/inspiring-stories/marks-story/ "Mark's Story")
      * [Heather's Story](https://www.moffitt.org/inspiring-stories/heathers-story/ "Heather's Story")
      * [Ellen's Story](https://www.moffitt.org/inspiring-stories/ellens-story/ "Ellen's Story")
      * [Dr. Tran's Story](https://www.moffitt.org/inspiring-stories/dr.-trans-story "Dr. Tran's Story")
      * [Dr. Toloza's Story](https://www.moffitt.org/inspiring-stories/dr.-tolozas-story "Dr. Toloza's Story")
      * [Dr. Silva's Story](https://www.moffitt.org/inspiring-stories/dr.-silvas-story "Dr. Silva's Story")
      * [Dr. Fernandez's Story](https://www.moffitt.org/inspiring-stories/dr.-fernandezs-story "Dr. Fernandez's Story")
      * [Dr. Robinson's Story](https://www.moffitt.org/inspiring-stories/dr.-robinsons-story "Dr. Robinson's Story")
      * [Dr. Pow-Sang's Story](https://www.moffitt.org/inspiring-stories/dr.-pow-sangs-story "Dr. Pow-Sang's Story")
      * [Mike's Volunteer Story](https://www.moffitt.org/inspiring-stories/mikes-volunteer-story/ "Mike's Volunteer Story")
      * [Mike's Story](https://www.moffitt.org/inspiring-stories/mikes-story/ "Mike's Story")
      * [Mary Beth's Story](https://www.moffitt.org/inspiring-stories/mary-beths-story/ "Mary Beth's Story")
      * [Malcolm's Story](https://www.moffitt.org/inspiring-stories/malcolms-story/ "Malcolm's Story")
      * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story2/ "Lori's Story")
      * [Miriam's Story](https://www.moffitt.org/inspiring-stories/miriams-story/ "Miriam's Story")
      * [Nick's Story](https://www.moffitt.org/inspiring-stories/nicks-story/ "Nick's Story")
      * [Nadine's Story](https://www.moffitt.org/inspiring-stories/nadines-story/ "Nadine's Story")
      * [Nancy's Story](https://www.moffitt.org/inspiring-stories/nancys-story/ "Nancy's Story")
      * [Madison's Story](https://www.moffitt.org/inspiring-stories/madisons-story/ "Madison's Story")
      * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story/ "Lori's Story")
      * [Lloyd's Story](https://www.moffitt.org/inspiring-stories/lloyds-story/ "Lloyd's Story")
      * [Lanse's Story](https://www.moffitt.org/inspiring-stories/lanses-story/ "Lanse's Story")
      * [Kevin's Story](https://www.moffitt.org/inspiring-stories/kevins-story/ "Kevin's Story")
      * [Dr. Mooney's Story](https://www.moffitt.org/inspiring-stories/dr.-mooneys-story "Dr. Mooney's Story")
      * [Ken's Story](https://www.moffitt.org/inspiring-stories/kens-story/ "Ken's Story")
      * [Dr. Lee's Story](https://www.moffitt.org/inspiring-stories/dr.-lees-story "Dr. Lee's Story")
      * [Dr. Kumar's Story](https://www.moffitt.org/inspiring-stories/dr.-kumars-story "Dr. Kumar's Story")
      * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story2/ "Keith's Story")
      * [Dr. Latifi's Story](https://www.moffitt.org/inspiring-stories/dr.-latifis-story "Dr. Latifi's Story")
      * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story/ "Keith's Story")
      * [Dr. Kubal's Story](https://www.moffitt.org/inspiring-stories/dr.-kubals-story "Dr. Kubal's Story")
      * [Dr. Khakpour's Story](https://www.moffitt.org/inspiring-stories/dr.-khakpours-story "Dr. Khakpour's Story")
      * [Dr. Keenan's Story](https://www.moffitt.org/inspiring-stories/dr.-keenans-story "Dr. Keenan's Story")
      * [Dr. Kanetsky's Story](https://www.moffitt.org/inspiring-stories/dr.-kanetskys-story "Dr. Kanetsky's Story")
      * [Dr. Hoffe's Story](https://www.moffitt.org/inspiring-stories/dr.-hoffes-story "Dr. Hoffe's Story")
      * [Dr. Harrison's Story](https://www.moffitt.org/inspiring-stories/dr.-harrisons-story "Dr. Harrison's Story")
      * [Dr. Gwede's Story](https://www.moffitt.org/inspiring-stories/dr.-gwedes-story "Dr. Gwede's Story")
      * [Dr. Giuliano's Story](https://www.moffitt.org/inspiring-stories/dr.-giulianos-story "Dr. Giuliano's Story")
      * [Juli's Story](https://www.moffitt.org/inspiring-stories/julis-story/ "Juli's Story")
      * [Dr. Gonzalez's Story](https://www.moffitt.org/inspiring-stories/dr.-gonzalezs-story "Dr. Gonzalez's Story")
      * [Dr. Gatenby's Story](https://www.moffitt.org/inspiring-stories/dr.-gatenbys-story "Dr. Gatenby's Story")
      * [Dr. Etame's Story](https://www.moffitt.org/inspiring-stories/dr.-etames-story "Dr. Etame's Story")
      * [Dr. Cleveland's Story](https://www.moffitt.org/inspiring-stories/dr.-clevelands-story "Dr. Cleveland's Story")
      * [John and Whitney's Story](https://www.moffitt.org/inspiring-stories/john-and-whitneys-story/ "John and Whitney's Story")
      * [Liz's Story](https://www.moffitt.org/inspiring-stories/lizs-story/ "Liz's Story")
      * [Meet Lloyd](https://www.moffitt.org/inspiring-stories/meet-lloyd/ "Meet Lloyd")
      * [Paul and Gina's Story](https://www.moffitt.org/inspiring-stories/pauls-and-ginas-story/ "Paul and Gina's Story")
      * [Marvin's Story](https://www.moffitt.org/inspiring-stories/marvins-story/ "Marvin's Story")
      * [Meet Melissa](https://www.moffitt.org/inspiring-stories/meet-melissa/ "Meet Melissa")
      * [Muriel's Story](https://www.moffitt.org/inspiring-stories/muriels-story/ "Muriel's Story")
      * [John's and David's Story](https://www.moffitt.org/inspiring-stories/johns-and-davids-story/ "John's and David's Story")
      * [Melissa's Story](https://www.moffitt.org/inspiring-stories/melissas-story/ "Melissa's Story")
      * [Dr. Alexander Anderson's Story](https://www.moffitt.org/inspiring-stories/dr.-alexander-andersons-story "Dr. Alexander Anderson's Story")
      * [Pam's Story](https://www.moffitt.org/inspiring-stories/pams-story/ "Pam's Story")
      * [Yolanda's Story](https://www.moffitt.org/inspiring-stories/yolandas-story/ "Yolanda's Story")
      * [Wilbur's Story](https://www.moffitt.org/inspiring-stories/wilburs-story/ "Wilbur's Story")
      * [Vikki's Story](https://www.moffitt.org/inspiring-stories/vikkis-story/ "Vikki's Story")
      * [Tiffany's Story](https://www.moffitt.org/inspiring-stories/tiffanys-story/ "Tiffany's Story")
      * [Theresa's Story](https://www.moffitt.org/inspiring-stories/theresas-story/ "Theresa's Story")
      * [Joanna's Story](https://www.moffitt.org/inspiring-stories/joannas-story/ "Joanna's Story")
      * [Jenifer's Story](https://www.moffitt.org/inspiring-stories/jenifers-story/ "Jenifer's Story")
      * [Jeanine's Story](https://www.moffitt.org/inspiring-stories/jeanines-story/ "Jeanine's Story")
      * [Meet Jackie](https://www.moffitt.org/inspiring-stories/meet-jackie/ "Meet Jackie")
      * [Ian's Story](https://www.moffitt.org/inspiring-stories/ians-story/ "Ian's Story")
      * [Howard's Story](https://www.moffitt.org/inspiring-stories/howards-story/ "Howard's Story")
      * [Ryan's Story](https://www.moffitt.org/inspiring-stories/ryans-story/ "Ryan's Story")
      * [Robert's Story](https://www.moffitt.org/inspiring-stories/roberts-story/ "Robert's Story")
      * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story/ "Rick's Story")
      * [Richard's Story](https://www.moffitt.org/inspiring-stories/richards-story/ "Richard's Story")
      * [Rena's Story](https://www.moffitt.org/inspiring-stories/renas-story/ "Rena's Story")
      * [Rebecca's Story](https://www.moffitt.org/inspiring-stories/rebeccas-story/ "Rebecca's Story")
      * [Ray's and Dr. Bui's story](https://www.moffitt.org/inspiring-stories/rays-and-dr.-buis-story "Ray's and Dr. Bui's story")
      * [Patti's Story](https://www.moffitt.org/inspiring-stories/pattis-story/ "Patti's Story")
      * [Pam and Jonathan's story](https://www.moffitt.org/inspiring-stories/pams-and-jonathans-story/ "Pam and Jonathan's story")
      * [Sarah's Story](https://www.moffitt.org/inspiring-stories/sarahs-story/ "Sarah's Story")
      * [Steve and Laura's Story](https://www.moffitt.org/inspiring-stories/steve-and-lauras-story/ "Steve and Laura's Story")
      * [Donna's Story](https://www.moffitt.org/inspiring-stories/donna/ "Donna's Story")
      * [Tommy's Story](https://www.moffitt.org/inspiring-stories/tommys-story/ "Tommy's Story")
      * [Viviana's Story](https://www.moffitt.org/inspiring-stories/vivianas-story/ "Viviana's Story")
      * [Craig's Story](https://www.moffitt.org/inspiring-stories/craigs-story/ "Craig's Story")
      * [William's Story](https://www.moffitt.org/inspiring-stories/williams-story/ "William's Story")
      * [The Wilson - Jones's Family Story](https://www.moffitt.org/inspiring-stories/the-joness-family-story/ "The Wilson - Jones's Family Story")
      * [Woodrow's Story](https://www.moffitt.org/inspiring-stories/woodrows-story/ "Woodrow's Story")
      * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story2/ "Cathy's Story")
      * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story/ "Cathy's Story")
      * [Carolyn's Story](https://www.moffitt.org/inspiring-stories/carolyn/ "Carolyn's Story")
      * [Beth's Story](https://www.moffitt.org/inspiring-stories/beths-story/ "Beth's Story")
      * [Benita's Story](https://www.moffitt.org/inspiring-stories/benitas-story/ "Benita's Story")
      * [Barney's Story](https://www.moffitt.org/inspiring-stories/barneys-story/ "Barney's Story")
      * [Joel's Story](https://www.moffitt.org/inspiring-stories/joels-story/ "Joel's Story")
      * [Jessica's Story](https://www.moffitt.org/inspiring-stories/jessicas-story/ "Jessica's Story")
      * [Jen's Story](https://www.moffitt.org/inspiring-stories/jens-story/ "Jen's Story")
      * [Jay's Story](https://www.moffitt.org/inspiring-stories/jays-story/ "Jay's Story")
      * [Janelle's Story](https://www.moffitt.org/inspiring-stories/janelles-story/ "Janelle's Story")
      * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story2/ "Greg's Story")
      * [Gayle's Story](https://www.moffitt.org/inspiring-stories/gayles-story/ "Gayle's Story")
      * [Francis' Story](https://www.moffitt.org/inspiring-stories/francis-story/ "Francis' Story")
      * [Dr. Lau's Story](https://www.moffitt.org/inspiring-stories/dr.-laus-story "Dr. Lau's Story")
      * [Dr. Roberto Diaz's Story](https://www.moffitt.org/inspiring-stories/dr.-roberto-diazs-story "Dr. Roberto Diaz's Story")
      * [Dimas' Story](https://www.moffitt.org/inspiring-stories/dimas-story/ "Dimas' Story")
      * [David and Vesta's Story](https://www.moffitt.org/inspiring-stories/david-and-vestas-story/ "David and Vesta's Story")
      * [Cydney's Story](https://www.moffitt.org/inspiring-stories/cydneys-story/ "Cydney's Story")
      * [Charles' Story](https://www.moffitt.org/inspiring-stories/charless-story/ "Charles' Story")
      * [Cammie's Story](https://www.moffitt.org/inspiring-stories/cammies-story/ "Cammie's Story")
      * [Joanne's Story](https://www.moffitt.org/inspiring-stories/joannes-story/ "Joanne's Story")
      * [Neisha's Story](https://www.moffitt.org/inspiring-stories/neishas-story/ "Neisha's Story")
      * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story/ "Greg's Story")
      * [Joshua's Story](https://www.moffitt.org/inspiring-stories/joshuas-story/ "Joshua's Story")
      * [Bridget's Story](https://www.moffitt.org/inspiring-stories/bridgets-story/ "Bridget's Story")
      * [Barbara's Story](https://www.moffitt.org/inspiring-stories/barbaras-story/ "Barbara's Story")
      * [Abrianna's Story](https://www.moffitt.org/inspiring-stories/abriannas-story/ "Abrianna's Story")
    * [ ![Friends supporting woman with cancer ](https://www.moffitt.org/globalassets/images/content-images/patient--family/women-cancer-640.jpg) Taking Care of Your Health  Taking Care of Your Health features cancer-related information, health tips, patient stories and more. ](https://www.moffitt.org/taking-care-of-your-health/ "Taking Care of Your Health")
  * [For Healthcare Professionals](https://www.moffitt.org/research-science/researchers/eric-padron)
    * [ For Healthcare Professionals ](https://www.moffitt.org/for-healthcare-professionals/)
    * [ Clinical Programs and Services ](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/)
      * [Adolescent Young Adult (AYA) Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/adolescent-young-adult-aya-program/ "Adolescent Young Adult \(AYA\) Program")
      * [Anesthesiology and Critical Care Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/anesthesiology-program/ "Anesthesiology and Critical Care Program")
      * [BMT and Cellular Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/bmt-and-cellular-immunotherapy-program/ "BMT and Cellular Immunotherapy Program")
      * [Breast Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/breast-oncology-program/ "Breast Oncology Program")
      * [Cardio-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cardio-oncology-program/ "Cardio-Oncology Program")
      * [Cutaneous Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cutaneous-oncology-program/ "Cutaneous Oncology Program")
      * [Diagnostic Imaging and Interventional Radiology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/diagnostic-imaging-and-interventional-radiology-program/ "Diagnostic Imaging and Interventional Radiology Program")
      * [Endocrine Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endocrine-oncology-program/ "Endocrine Oncology Program")
      * [Endoscopic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endoscopic-oncology-program/ "Endoscopic Oncology Program")
      * [Gastrointestinal Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gastrointestinal-oncology-program/ "Gastrointestinal Oncology Program")
      * [Genetic Counseling Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genetic-counseling-program/ "Genetic Counseling Program")
      * [Genitourinary Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genitourinary-oncology-program/ "Genitourinary Oncology Program")
      * [Gynecologic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gynecologic-oncology-program/ "Gynecologic Oncology Program")
      * [Head and Neck Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/head-and-neck-oncology-program/ "Head and Neck Oncology Program")
      * [Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/immunotherapy-program/ "Immunotherapy Program")
      * [Malignant Hematology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/malignant-hematology-program/ "Malignant Hematology Program")
      * [Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/moffitt-malignant-hematology-cellular-therapy-at-memorial-healthcare-system/ "Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System")
      * [Neuro-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/neuro-oncology-program/ "Neuro-Oncology Program")
      * [Pathology](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pathology/ "Pathology")
      * [Pharmacy](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pharmacy/ "Pharmacy")
      * [Radiation Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/radiation-oncology-program/ "Radiation Oncology Program")
      * [Sarcoma Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/sarcoma-program/ "Sarcoma Program")
      * [Screening Prevention](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/screening-prevention/ "Screening Prevention")
      * [Senior Adult Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
      * [Supportive Care Medicine Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/supportive-care-medicine-program/ "Supportive Care Medicine Program")
      * [Thoracic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/thoracic-oncology-program/ "Thoracic Oncology Program")
      * [Translational Pathology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/translational-pathology/ "Translational Pathology Program")
    * [ Physician Relations ](https://www.moffitt.org/for-healthcare-professionals/physician-relations/)
    * [ Continuing Education ](https://www.moffitt.org/for-healthcare-professionals/continuing-education/)
      * [Moffitt Grand Rounds](https://www.moffitt.org/for-healthcare-professionals/continuing-education/moffitt-grand-rounds/ "Moffitt Grand Rounds")
      * [Multidisciplinary Programs](https://www.moffitt.org/for-healthcare-professionals/continuing-education/multidisciplinary-programs/ "Multidisciplinary Programs")
      * [Provider Conferences](https://www.moffitt.org/for-healthcare-professionals/continuing-education/provider-conferences/ "Provider Conferences")
  * [Research](https://www.moffitt.org/research-science/researchers/eric-padron)
    * [ Research Science ](https://www.moffitt.org/research-science/)
    * [ Research Programs ](https://www.moffitt.org/research-science/research-programs/)
      * [Cancer Biology and Evolution](https://www.moffitt.org/research-science/research-programs/cancer-biology-and-evolution/ "Cancer Biology and Evolution")
      * [Cancer Epidemiology](https://www.moffitt.org/research-science/research-programs/cancer-epidemiology/ "Cancer Epidemiology")
      * [Health Outcomes and Behavior](https://www.moffitt.org/research-science/research-programs/health-outcomes-behavior/ "Health Outcomes and Behavior")
      * [Immuno-Oncology](https://www.moffitt.org/research-science/research-programs/immuno-oncology/ "Immuno-Oncology")
      * [Molecular Medicine](https://www.moffitt.org/research-science/research-programs/molecular-medicine/ "Molecular Medicine")
    * [ Divisions and Departments ](https://www.moffitt.org/research-science/divisions-and-departments/)
      * [Basic Science](https://www.moffitt.org/research-science/divisions-and-departments/basic-science/ "Basic Science")
      * [BioEngineering](https://www.moffitt.org/research-science/divisions-and-departments/bioengineering/ "BioEngineering")
      * [Clinical Science](https://www.moffitt.org/research-science/divisions-and-departments/clinical-science/ "Clinical Science")
      * [Population Science](https://www.moffitt.org/research-science/divisions-and-departments/population-science/ "Population Science")
      * [Quantitative Science](https://www.moffitt.org/research-science/divisions-and-departments/quantitative-science/ "Quantitative Science")
    * [ Centers and Institutes ](https://www.moffitt.org/research-science/centers-and-institutes/)
      * [Centers of Excellence](https://www.moffitt.org/research-science/centers-and-institutes/centers-of-excellence/ "Centers of Excellence")
      * [Institutes](https://www.moffitt.org/research-science/centers-and-institutes/institutes/ "Institutes")
    * [ Community Outreach and Engagement ](https://www.moffitt.org/research-science/community-outreach-and-engagement/)
      * [About COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/about-coe/ "About COE")
      * [Advisory Boards](https://www.moffitt.org/research-science/community-outreach-and-engagement/community-advisory-boards/ "Advisory Boards")
      * [Catchment Area](https://www.moffitt.org/research-science/community-outreach-and-engagement/catchment-area/ "Catchment Area")
      * [Data](https://www.moffitt.org/research-science/community-outreach-and-engagement/data/ "Data")
      * [Outreach](https://www.moffitt.org/research-science/community-outreach-and-engagement/outreach/ "Outreach")
      * [Research and Clinical Trials](https://www.moffitt.org/research-science/community-outreach-and-engagement/research-and-clinical-trials/ "Research and Clinical Trials")
      * [Get Involved With COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/get-involved-with-coe/ "Get Involved With COE")
    * [ Shared Resources ](https://www.moffitt.org/research-science/shared-resources/)
      * [Analytic Microscopy](https://www.moffitt.org/research-science/shared-resources/analytic-microscopy/ "Analytic Microscopy")
      * [Biostatistics and Bioinformatics](https://www.moffitt.org/research-science/shared-resources/biostatistics-and-bioinformatics/ "Biostatistics and Bioinformatics")
      * [Cancer Pharmacokinetics and Pharmacodynamics](https://www.moffitt.org/research-science/shared-resources/cancer-pharmacokinetics-and-pharmacodynamics/ "Cancer Pharmacokinetics and Pharmacodynamics")
      * [Chemical Biology](https://www.moffitt.org/research-science/shared-resources/chemical-biology/ "Chemical Biology")
      * [Collaborative Data Services](https://www.moffitt.org/research-science/shared-resources/collaborative-data-services/ "Collaborative Data Services")
      * [Flow Cytometry](https://www.moffitt.org/research-science/shared-resources/flow-cytometry/ "Flow Cytometry")
      * [Gene Targeting](https://www.moffitt.org/research-science/shared-resources/gene-targeting/ "Gene Targeting")
      * [Molecular Genomics](https://www.moffitt.org/research-science/shared-resources/molecular-genomics/ "Molecular Genomics")
      * [Participant Research, Interventions, and Measurement Core (PRISM)](https://www.moffitt.org/research-science/shared-resources/participant-research-interventions-and-measurement-core-prism/ "Participant Research, Interventions, and Measurement Core \(PRISM\)")
      * [Proteomics and Metabolomics](https://www.moffitt.org/research-science/shared-resources/proteomics-and-metabolomics/ "Proteomics and Metabolomics")
      * [Quantitative Imaging Core](https://www.moffitt.org/research-science/shared-resources/quantitative-imaging-core/ "Quantitative Imaging Core")
      * [Small Animal Imaging Lab](https://www.moffitt.org/research-science/shared-resources/small-animal-imaging-lab/ "Small Animal Imaging Lab")
      * [Tissue](https://www.moffitt.org/research-science/shared-resources/tissue/ "Tissue")
    * [ Academic and Industry Partnerships ](https://www.moffitt.org/research-science/academic-and-industry-partnerships/)
      * [Office of Innovation](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/ "Office of Innovation")
      * [Academic Partnerships](https://www.moffitt.org/research-science/academic-and-industry-partnerships/academic-partnerships/ "Academic Partnerships")
    * [ Administration ](https://www.moffitt.org/research-science/administration/)
      * [Non-Therapeutic Research Office](https://www.moffitt.org/research-science/administration/non-therapeutic-research-office/ "Non-Therapeutic Research Office")
    * [ ![Research fellows in a lab](https://www.moffitt.org/contentassets/a7d26515856847ad8ebe488477e34948/research-training.jpg) Research Education and Training  We are interested in recruiting scholars who have a profound interest in preventing, treating and curing cancer. ](https://www.moffitt.org/education/research-education-and-training/ "Research Education and Training")
  * [Training & Education](https://www.moffitt.org/research-science/researchers/eric-padron)
    * [ Education ](https://www.moffitt.org/education/)
    * [ Medical Education ](https://www.moffitt.org/education/medical-education/)
      * [Our Training Programs](https://www.moffitt.org/education/medical-education/our-training-programs/ "Our Training Programs")
      * [Program Staff/Contact Us](https://www.moffitt.org/education/medical-education/program-staffcontact-us/ "Program Staff/Contact Us")
      * [Salary and Benefits](https://www.moffitt.org/education/medical-education/salary-and-benefits/ "Salary and Benefits")
      * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")
    * [ Research Education and Training ](https://www.moffitt.org/education/research-education-and-training/)
      * [Office of Postdoctoral Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-postdoctoral-affairs/ "Office of Postdoctoral Affairs")
      * [Office of Graduate Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-graduate-affairs/ "Office of Graduate Affairs")
      * [Office of Undergraduate and Visiting Scholar Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-undergraduate-and-visiting-scholar-affairs/ "Office of Undergraduate and Visiting Scholar Affairs")
      * [Pre-College Programs](https://www.moffitt.org/education/research-education-and-training/pre-college-programs/ "Pre-College Programs")
      * [What We Provide](https://www.moffitt.org/education/research-education-and-training/what-we-provide/ "What We Provide")
      * [Contact Us](https://www.moffitt.org/education/research-education-and-training/contact-us/ "Contact Us")
      * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")
      * [News](https://www.moffitt.org/education/research-education-and-training/news/ "News")
      * [Where Are They Now](https://www.moffitt.org/education/research-education-and-training/where-are-they-now/ "Where Are They Now")
    * [ Nursing Education ](https://www.moffitt.org/education/nursing-education/)
      * [Ambulatory Care Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/ambulatory-care-oncology-nurse-residency-program/ "Ambulatory Care Oncology Nurse Residency Program")
      * [Nurse Anesthetist](https://www.moffitt.org/education/nursing-education/nurse-anesthetist/ "Nurse Anesthetist")
      * [Nurse Practitioner](https://www.moffitt.org/education/nursing-education/nurse-practitioner/ "Nurse Practitioner")
      * [Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/oncology-nurse-residency-program/ "Oncology Nurse Residency Program")
      * [Registered Nurse](https://www.moffitt.org/education/nursing-education/registered-nurse/ "Registered Nurse")
    * [ Health Professional Education ](https://www.moffitt.org/education/health-professional-education/)
      * [Advanced Pharmacy Practice (APPE)](https://www.moffitt.org/education/health-professional-education/advanced-pharmacy-practice-appe/ "Advanced Pharmacy Practice \(APPE\)")
      * [Anesthesiology Assistant](https://www.moffitt.org/education/health-professional-education/anesthesiology-assistant/ "Anesthesiology Assistant")
      * [Dietetic Technician](https://www.moffitt.org/education/health-professional-education/dietetic-technician/ "Dietetic Technician")
      * [Dietitian](https://www.moffitt.org/education/health-professional-education/dietitian/ "Dietitian")
      * [Genetic Counseling](https://www.moffitt.org/education/health-professional-education/genetic-counseling/ "Genetic Counseling")
      * [Introductory Pharmacy Practice (IPPE)](https://www.moffitt.org/education/health-professional-education/introductory-pharmacy-practice-ippe/ "Introductory Pharmacy Practice \(IPPE\)")
      * [Master of Public Health Field Experience](https://www.moffitt.org/education/health-professional-education/master-of-public-health-field-experience/ "Master of Public Health Field Experience")
      * [Medical Assistants](https://www.moffitt.org/education/health-professional-education/medical-assistants/ "Medical Assistants")
      * [Nuclear Medicine](https://www.moffitt.org/education/health-professional-education/nuclear-medicine/ "Nuclear Medicine")
      * [Occupational Therapy Intern](https://www.moffitt.org/education/health-professional-education/occupational-therapy-intern/ "Occupational Therapy Intern")
      * [PGY1 Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-1-residency/ "PGY1 Pharmacy Residency")
      * [PGY2 Oncology Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-2-oncology-residency/ "PGY2 Oncology Pharmacy Residency")
      * [Oncology Pharmacy Technician Trainee Program](https://www.moffitt.org/education/health-professional-education/pharmacy-technician-extern/ "Oncology Pharmacy Technician Trainee Program")
      * [Physical Therapy](https://www.moffitt.org/education/health-professional-education/physical-therapy/ "Physical Therapy")
      * [Physical Therapy Assistant](https://www.moffitt.org/education/health-professional-education/physical-therapy-assistant/ "Physical Therapy Assistant")
      * [Physician Assistant](https://www.moffitt.org/education/health-professional-education/physician-assistant/ "Physician Assistant")
      * [Psychology](https://www.moffitt.org/education/health-professional-education/psychology/ "Psychology")
      * [Radiation Therapy](https://www.moffitt.org/education/health-professional-education/radiation-therapy/ "Radiation Therapy")
      * [Radiography Therapy](https://www.moffitt.org/education/health-professional-education/radiography-therapy/ "Radiography Therapy")
      * [Respiratory Therapy](https://www.moffitt.org/education/health-professional-education/respiratory-therapy/ "Respiratory Therapy")
      * [Social Work](https://www.moffitt.org/education/health-professional-education/social-work/ "Social Work")
      * [Sonography/Ultrasound Student](https://www.moffitt.org/education/health-professional-education/sonographyultrasound-student/ "Sonography/Ultrasound Student")
      * [Speech Therapy](https://www.moffitt.org/education/health-professional-education/speech-therapy/ "Speech Therapy")
      * [Wound Ostomy](https://www.moffitt.org/education/health-professional-education/wound-ostomy/ "Wound Ostomy")
    * [ Other Educational Programs ](https://www.moffitt.org/education/other-educational-programs/)
  * [Give](https://www.moffitt.org/research-science/researchers/eric-padron)
    * [ Give ](https://www.moffitt.org/give/)
    * [ Why Give? ](https://www.moffitt.org/give/why-give/)
      * [About the Moffitt Foundation](https://www.moffitt.org/give/why-give/about-the-moffitt-foundation/ "About the Moffitt Foundation")
      * [FAQ](https://www.moffitt.org/give/why-give/faq/ "FAQ")
      * [Financials and Stewardship](https://www.moffitt.org/give/why-give/financials-and-stewardship/ "Financials and Stewardship")
      * [Contact the Foundation](https://www.moffitt.org/give/why-give/contact-the-foundation/ "Contact the Foundation")
      * [You Can Make a Difference](https://www.moffitt.org/give/why-give/you-can-make-a-difference/ "You Can Make a Difference")
      * [Impact Report](https://www.moffitt.org/give/your-impact/2022-annual-foundation-impact-report/ "Impact Report")
    * [ Ways to Give ](https://www.moffitt.org/give/ways-to-give/)
      * [Cash, Stock or Other Assets](https://www.moffitt.org/give/ways-to-give/cash-stock-or-other-assets/ "Cash, Stock or Other Assets")
      * [Planned Giving](https://mymoffittlegacy.org/ "Planned Giving")
      * [Philanthropic Foundation Giving](https://www.moffitt.org/give/ways-to-give/philanthropic-foundation-giving/ "Philanthropic Foundation Giving")
      * [Corporate Partnership](https://www.moffitt.org/give/ways-to-give/corporate-partnership/ "Corporate Partnership")
      * [Employer Matching Gifts](https://www.moffitt.org/give/ways-to-give/employer-matching-gifts/ "Employer Matching Gifts")
      * [Endowment Gifts](https://www.moffitt.org/give/ways-to-give/endowment-gifts/ "Endowment Gifts")
      * [Other Ways to Donate](https://www.moffitt.org/give/ways-to-give/other-ways-to-donate/ "Other Ways to Donate")
      * [Breast Cancer Funding Opportunities](https://www.moffitt.org/give/ways-to-give/breast-cancer-funding-opportunities/ "Breast Cancer Funding Opportunities")
      * [Support the Pentecost Family Myeloma Research Center](https://www.moffitt.org/give/ways-to-give/support-the-pentecost-family-myeloma-research-center/ "Support the Pentecost Family Myeloma Research Center")
      * [Partners In Discovery](https://www.moffitt.org/give/ways-to-give/partners-in-discovery/ "Partners In Discovery")
    * [ Get Involved ](https://www.moffitt.org/give/get-involved/)
      * [Become a Member](https://www.moffitt.org/give/get-involved/become-a-member/ "Become a Member")
      * [Volunteer Your Time](https://www.moffitt.org/give/get-involved/volunteer-your-time/ "Volunteer Your Time")
      * [Miles for Moffitt](https://www.moffitt.org/give/get-involved/miles-for-moffitt/ "Miles for Moffitt")
      * [Magnolia](https://www.moffitt.org/give/get-involved/magnolia/ "Magnolia")
      * [Mission Possible Sarasota Luncheon](https://www.moffitt.org/give/get-involved/mission-possible-sarasota-luncheon/ "Mission Possible Sarasota Luncheon")
      * [Discovery Series Webinars](https://www.moffitt.org/give/get-involved/discovery-series-webinars/ "Discovery Series Webinars")
      * [Fundraise for Moffitt](https://www.moffitt.org/give/get-involved/fundraise-for-moffitt/ "Fundraise for Moffitt")
    * [ ![A researcher holds a Moffitt License Plate](https://www.moffitt.org/contentassets/fff003985b6341a8b2d684da79916350/ways-to-give.jpg) Ways to Give  Cancer touches all of us. Our mission - to contribute to the prevention and cure of cancer - depends on your support.  ](https://www.moffitt.org/give/ways-to-give/ "Ways to Give")


# Eric Padron, MD
![Eric  Padron](https://www.moffitt.org/globalassets/images/researchers_bio/PadronEric_7709.jpg)
Eric Padron, MD 
**Specialty:** Internal Medicine 
**Program:** Malignant Hematology 
**Research Program:** Molecular Medicine Program 
[View Lab Page ](http://padronlab.moffitt.org/)
[Google Scholar Profile](https://scholar.google.com/citations?user=B6AkLQ0AAAAJ&hl=en)
[ Contact ](https://eforms.moffitt.org/ContactResearchersForm?PERID=7709)
  * ## Overview
The Padron Lab explores how to combat leukemia by investigating different drugs available for treatment, novel combinations of available drugs, or researching the non-coding genome. Investigating the non-coding part of the human genome is important. Another area of the Padron Lab is looking at what happens to patients before they get leukemia to identify any genetic risk factors. One of these Padron is investigating is an entity called clonal hematopoiesis. Clonal hematopoiesis puts older individuals at much higher risk of getting leukemia, but also puts them at higher risk for cardiovascular disease.
### Associations
    * Malignant Hematology
    * Immunology
    * Molecular Medicine Program
    * Center of Excellence for Evolutionary Therapy
### Education & Training
**Board Certification:**
    * Internal Medicine - Medical Oncology
    * Internal Medicine - Hematology
**Fellowship:**
    * Moffitt Cancer Center - Hematology/Oncology
**Residency:**
    * University of Florida Shands Hospital - 
**Medical School:**
    * University of South Florida - MD
  * ## Research Interest
Chronic myelomonocytic leukemia (CMML) is a rare hematopoeitic malignancy characterized by dysplasia, cytopenias, a propensity to transform to Acute Myeloid Leukemia (AML) and a characteristic monocytosis that defines this entity. In the past, CMML was grouped together with the Myelodysplasitc Syndromes (MDS) but its clinical and genetic behavior is now known to be distinctly different from MDS. As a result, this disease is now grouped in a separate MDS/MPN category by WHO. Our research interests focus on understanding the molecular and genetic pathway of chronic myelomonocytic leukemia to better design targeted agents for study in the clinic. Our previous efforts have identified the GM-CSF signaling cascade as a target for CMML therapeutics and current efforts are underway to test this in the clinic. Future work will focus on uncovering new targets for CMML specific therapies. Dr. Padron has developed an interest in working with existing pharmaceutical compounds to evaluate their effectiveness for bone marrow failure disorders. Other work Dr. Padron is pursuing involves the SRSF2 mutation that can occur in MDS and may be related to progression to other diseases. The research underway examines the ability of an existing compound in development to destroy leukemic cells through targeting the cell's RNA. Positive results from these studies would be a benefit to patients in reducing the symptoms of bone marrow failure diseases, in particular the constitutional symptoms that can distress patients, including enlarged spleen, weight loss and fevers.
  * ## Participating Trials
[ Clinical Trial 22367 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-22367/ "Clinical Trial 22367")   
The Impact Of Inflammation On HSPC Composition And Disease Progression In Chronic Myelomonocytic Leukemia (CMML INTERCEPT STUDY) SUB-TITLE: Intercepting CMML Disease Progression Driven by Acute Inflammation   
Condition: Malignant Hematology   
Status: Open 
[ Clinical Trial 23548 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-23548/ "Clinical Trial 23548")   
A Phase 1, Open-Label, Dose Escalation and Expansion Study of STX-0712 in Patients with Advanced Hematologic Malignancies   
Condition: Malignant Hematology   
Intervention: STX-0712 ()   
Status: Open 
**If you believe you are eligible for one of these trials or studies, please call  
[813-745-6100](tel:+813-745-6100) or toll-free [1-800-679-0775](tel:+1-800-679-0775). **
  * ## Publications
    * Aguirre LE, Ball S, Jain A, Ali NA, Sallman DA, Kuykendall A, Sweet K, Lancet JE, Padron E, Komrokji RS. Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression. Clin Lymphoma Myeloma Leuk. 2025 Sep.25(9):661-671. Pubmedid: [40254502](https://www.ncbi.nlm.nih.gov/pubmed/40254502). 
    * Komrokji RS, Supina D, Navada S, Potluri R, Tyagi R, Werwath T, Xie Z, Padron E, Sallman DA. Transfusion Independence Corresponds With Survival in Patients With Lower-Risk Myelodysplastic Syndrome: Real-World Evidence From United States Insurance Claims. Clin Lymphoma Myeloma Leuk. 2025 Oct.25(10):e740-e749. Pubmedid: [40410022](https://www.ncbi.nlm.nih.gov/pubmed/40410022). 
    * Neupane N, Padron E. The Role of Inflammation in CMML Pathobiology and Progression. Curr Hematol Malig Rep. 2025 Oct.20(1):14. Pubmedid: [41062769](https://www.ncbi.nlm.nih.gov/pubmed/41062769). 
    * Ball S, Jain AG, Al Ali N, Aguirre LE, Bewersdorf JP, Kent A, Rose A, Hayden A, Siddon A, Lykon J, Madarang E, Swoboda DM, Padron E, Sweet K, Sallman DA, Lancet J, Carraway HE, Watts J, Zeidan A, Pollyea DA, Komrokji RS. Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia. Am J Hematol. 2025 Oct.100(10):1920-1923. Pubmedid: [40772639](https://www.ncbi.nlm.nih.gov/pubmed/40772639). 
    * Xie Z, Al Ali N, Zhang L, Papenhausen P, Volpe VO, Chan O, Kuykendall A, Yun S, Walker A, Sweet K, Lancet JE, Padron E, Sallman DA, Komrokji RS. Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm. Blood Neoplasia. 2025 May.2(2):100062. Pubmedid: [40453136](https://www.ncbi.nlm.nih.gov/pubmed/40453136). Pmcid: PMC12067887. 
    * Polverelli N, Hernandez-Boluda JC, Onida F, Gurnari C, Raj K, Czerw T, Kenyon M, Robin M, Sockel K, Ruggeri A, Sánchez-Ortega I, Arber DA, Arcaini L, Duarte FB, Battipaglia G, Chalandon Y, Ciceri F, Cross NCP, Drozd-Sokolowska J, Funke VAM, Gagelmann N, Gangat N, Gotlib J, Guglielmelli P, Harrison CN, Hobbs GS, Jain T, Khoury JD, Kiladjian JJ, Kröger N, Malcovati L, Martino M, Mesa R, Orazi A, Padron E, Palandri F, Passamonti F, Patnaik MM, Pemmaraju N, Radia DH, Reiter A, Russo D, Scheid C, Tefferi A, Vannucchi AM, Wiseman DH, Yakoub-Agha I, McLornan DP. Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT. Blood. 2025 May.145(22):2561-2573. Pubmedid: [40106773](https://www.ncbi.nlm.nih.gov/pubmed/40106773). 
    * Komrokji Z, Ali NA, Xie Z, Chan O, Yun S, Walker A, Lancet J, Kuykendall A, Sallman D, Padron E, Komrokji RS. Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML). Leuk Res. 2025 Mar.150:107662. Pubmedid: [39921921](https://www.ncbi.nlm.nih.gov/pubmed/39921921). 
    * Borate U, Pugh K, Waller A, Welkie RL, Huang Y, Bewersdorf JP, Stahl M, DeZern AE, Platzbecker U, Sekeres MA, Wei AH, Buckstein RJ, Roboz GJ, Savona MR, Loghavi S, Hasserjian RP, Fenaux P, Sallman DA, Hourigan CS, Della Porta MG, Nimer S, Little RF, Santini V, Efficace F, Taylor J, Garcia-Manero G, Odenike O, Kim TK, Halene S, Komrokji RS, Griffiths EA, Greenberg PL, Xu ML, Xie Z, Bejar R, Sanz GF, Patnaik MM, Figueroa M, Carraway HE, Abdel-Wahab O, Starczynowski D, Padron E, Boultwood J, Gore S, Daver NG, Churpek JE, Majeti R, Bennett JM, List AF, Brunner AM, Zeidan AM. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood. 2025 Mar.145(13):1369-1381. Pubmedid: [40146152](https://www.ncbi.nlm.nih.gov/pubmed/40146152). Pmcid: PMC11969261. 
    * Takaoka K, Komrokji R, Chien K, Montalban-Bravo G, Salman JB, Urrutia S, Bataller A, Bazinet A, Kekedjian J, Al Ali NH, Sallman D, Padron E, Xie Z, Kanagal-Shamanna R, Tang G, Yang H, Rodriguez-Sevilla JJ, Garcia-Manero G, Sasaki K. Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion. Leuk Res. 2025 Mar.150:107661. Pubmedid: [39938357](https://www.ncbi.nlm.nih.gov/pubmed/39938357). 
    * Sallman DA, Komrokji RS, Dezern AE, Sebert M, Garcia-Manero G, Rahmé R, Winer ES, Lehmann-Che J, Roboz GJ, Madelaine I, Sekeres MA, Peterlin P, Chan O, Beyne-Rauzy O, Kuykendall A, Recher C, McLemore A, Stamatoullas A, Zhang L, Willems L, Mo Q, Raffoux E, Nardelli L, Berthon C, Al Ali NH, Quesnel B, Padron E, Kantarjian HM, List AF, Ades L, Lancet JE, Fenaux P, Cluzeau T. Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML. Hemasphere. 2025 Jul.9(7):e70164. Pubmedid: [40657305](https://www.ncbi.nlm.nih.gov/pubmed/40657305). Pmcid: PMC12255903. 
    * Komrokji RS, Ammad-Ud-Din M, Ali NHA, Xie Z, Chan O, Kuykendall AT, Yun S, Walker AR, Lancet J, Padron E, Sallman DA. Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival. Clin Lymphoma Myeloma Leuk. 2025 Jul.25(7):e487-e490. Pubmedid: [40113545](https://www.ncbi.nlm.nih.gov/pubmed/40113545). 
    * Kruer TL, Quintana-Gonzalez A, Newman HL, Ferrall-Fairbanks MC, Zhang L, McLemore AF, Neupane S, Yang Q, Ben-Crentsil NA, Balasis ME, Letson CT, Komrokji RS, Chaudhry S, Totiger TM, Traina JA, Figueroa ME, Ryder CB, Cluzeau T, Taylor J, Sallman DA, Padron E. XPO1 Drives Resistance to Eprenetapopt and Azacitidine and Can Be Targeted in TP53-Mutated Myeloid Malignancies. Blood. 2025 Jul. Pubmedid: [40737597](https://www.ncbi.nlm.nih.gov/pubmed/40737597). 
    * Jain AG, Volpe VO, Wang C, Ball S, Tobon K, Chan O, Padron E, Kuykendall A, Lancet JE, Komrokji R, Sallman DA, Sweet KL. Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia. Ann Hematol. 2025 Jan.104(1):307-315. Pubmedid: [39243312](https://www.ncbi.nlm.nih.gov/pubmed/39243312). 
    * Tremblay D, Csizmar C, DiNardo CD, Ball S, Rippel N, Hammond D, Kadia TM, Ravandi F, Chien K, Van Hyfte G, Mazumdar M, Saliba A, Mangaonkar A, Lasho T, Al-Kali A, Kremyanskaya M, Feld J, Silverman LR, Komrokji R, Mascarenhas J, Padron E, Garcia-Manero G, Sallman DA, Patnaik MM, Montalban-Bravo G. Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study. Leukemia. 2025 Jan.39(1):257-260. Pubmedid: [39533069](https://www.ncbi.nlm.nih.gov/pubmed/39533069). 
    * Consagra A, Lanino L, Al Ali NH, Aguirre L, Xie Z, Chan O, Andreossi G, Raddi MG, Rigodanza L, Sanna A, Mattiuz G, Tofacchi E, Amato C, Tanturli M, De Pourcq S, Walker A, Kuykendall A, Lancet J, Padron E, Sallman DA, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Maggioni G, Campagna A, Della Porta MG, Santini V, Komrokji RS. Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS. Hemasphere. 2025 Feb.9(2):e70086. Pubmedid: [39944234](https://www.ncbi.nlm.nih.gov/pubmed/39944234). Pmcid: PMC11814532. 
    * Csizmar CM, Natu A, Gurney M, Fathima S, Alsugair AKA, Kanagal-Shamanna R, Loghavi S, Bazinet A, Chien K, Hammond D, DiNardo C, Kadia T, Ravandi-Kashani F, Pemmaraju N, Sasaki K, Lasho TL, Finke CM, Al-Kali A, Alkhateeb H, Begna K, Gangat N, Hefazi Torghabeh M, Matin A, Mangaonkar AA, Saliba AN, Tefferi A, Garcia-Manero G, Kantarjian HM, Komrokji RS, Xie Z, Ali NA, Sallman D, Padron E, Montalban-Bravo G, Patnaik MM. Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes. Leukemia. 2025 Aug.39(8):2030-2034. Pubmedid: [40555734](https://www.ncbi.nlm.nih.gov/pubmed/40555734). 
    * Sekeres MA, Venugopal S, Chandhok NS, Watts JM, Bradley T, Taylor J, Sallman DA, Xie Z, Padron E, Zyborowicz E, Anderson Chadha C, Carter J, Heggen C, Sullivan S, Gurska L, Komrokji RS. Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings. Leuk Lymphoma. 2025 Aug.1-5. Pubmedid: [40853277](https://www.ncbi.nlm.nih.gov/pubmed/40853277). 
    * Gharaee N, Wegrzyn-Woltosz J, Jiang J, Akhade VS, Bridgers J, Stubbins RJ, Hiwase D, Kutyna MM, Chan O, Komrokji R, Padron E, Deng Y, Cole G, Umlandt P, Fuller M, Kim A, Karsan A. Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm. Leukemia. 2025 Apr.39(4):917-928. Pubmedid: [40000845](https://www.ncbi.nlm.nih.gov/pubmed/40000845). Pmcid: PMC11976265. 
    * Gutmann DH, Boehm JS, Karlsson EK, Padron E, Seshadri M, Wallis D, Snyder JC. Precision preclinical modeling to advance cancer treatment. J Natl Cancer Inst. 2025 Apr.117(4):586-594. Pubmedid: [39383197](https://www.ncbi.nlm.nih.gov/pubmed/39383197). Pmcid: PMC11972679. 
    * Ben-Crentsil NA, Padron E. If You Build It, Patients with Rare Cancers Will Come: A Successful Clinical Trial in Relapsed and Refractory JMML. Cancer Discov. 2024 Sep.14(9):1574-1576. Pubmedid: [39228296](https://www.ncbi.nlm.nih.gov/pubmed/39228296). 
    * Csizmar CM, Gurney M, Kanagal-Shamanna R, Chien K, Hammond D, Lasho TL, Finke CM, Dean C, Natu A, Mangaonkar AA, Al-Kali A, Gangat N, Tefferi A, Alkhateeb H, Garcia-Manero G, Komrokji RS, Ali NA, Padron E, Montalban-Bravo G, Patnaik MM. ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. Haematologica. 2024 Oct.109(10):3419-3425. Pubmedid: [38899337](https://www.ncbi.nlm.nih.gov/pubmed/38899337). Pmcid: PMC11443373. 
    * Xie Z, Komrokji RS, Al-Ali N, Regelson A, Geyer S, Patel AA, Saygin C, Zeidan AM, Bewersdorf JP, Mendez LM, Kishtagari A, Zeidner JF, Coombs CC, Madanat YF, Chung SS, Badar T, Foran JM, Desai P, Tsai C, Griffiths EA, Al Malki MM, Amanam I, Lai C, Deeg HJ, Ades L, Arana-Yi C, Osman AE, Dinner SN, Abaza Y, Taylor J, Chandhok NS, Soong D, Brunner AM, Carraway HE, Singh A, Elena C, Ferrari J, Galli A, Pozzi S, Padron E, Patnaik MM, Malcovati L, Savona MR, Al-Kali A. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood. 2024 Nov.144(19):2033-2044. Pubmedid: [38996210](https://www.ncbi.nlm.nih.gov/pubmed/38996210). Pmcid: PMC11561536. 
    * Komrokji RS, Lanino L, Ball S, Bewersdorf JP, Marchetti M, Maggioni G, Travaglino E, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain AG, Aguirre LE, Tinsley-Vance SM, Schwabkey ZI, Chan O, Xie Z, Brunner AM, Kuykendall AT, Bennett JM, Buckstein R, Bejar R, Carraway HE, DeZern AE, Griffiths EA, Halene S, Hasserjian RP, Lancet J, List AF, Loghavi S, Odenike O, Padron E, Patnaik MM, Roboz GJ, Stahl M, Sekeres MA, Steensma DP, Savona MR, Taylor J, Xu ML, Sweet K, Sallman DA, Nimer SD, Hourigan CS, Wei AH, Sauta E, D'Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate UM, Sanz G, Efficace F, Gore SD, Kim TK, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang SA, Foucar MK, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht AA, Ades L, Zeidan AM, Della Porta MG. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. Lancet Haematol. 2024 Nov.11(11):e862-e872. Pubmedid: [39393368](https://www.ncbi.nlm.nih.gov/pubmed/39393368). 
    * Hunter AM, Patnaik MM, Itzykson R, Mesa R, Karanes C, Li Y, de Claro RA, Norsworthy KJ, Theoret M, Pulte E, Padron E. Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm. Blood. 2024 Nov.144(19):1987-1992. Pubmedid: [39509115](https://www.ncbi.nlm.nih.gov/pubmed/39509115). 
    * Tentori CA, Zhao LP, Tinterri B, Strange KE, Zoldan K, Dimopoulos K, Feng X, Riva E, Lim B, Simoni Y, Murthy V, Hayes MJ, Poloni A, Padron E, Cardoso BA, Cross M, Winter S, Santaolalla A, Patel BA, Groarke EM, Wiseman DH, Jones K, Jamieson L, Manogaran C, Daver N, Gallur L, Ingram W, Ferrell PB, Sockel K, Dulphy N, Chapuis N, Kubasch AS, Olsnes AM, Kulasekararaj A, De Lavellade H, Kern W, Van Hemelrijck M, Bonnet D, Westers TM, Freeman S, Oelschlaegel U, Valcarcel D, Raddi MG, Grønbæk K, Fontenay M, Loghavi S, Santini V, Almeida AM, Irish JM, Sallman DA, Young NS, van de Loosdrecht AA, Adès L, Della Porta MG, Cargo C, Platzbecker U, Kordasti S. Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium. Hemasphere. 2024 May.8(5):e64. Pubmedid: [38756352](https://www.ncbi.nlm.nih.gov/pubmed/38756352). Pmcid: PMC11096644. 
    * Chan O, Al Ali NH, Tashkandi H, Ellis A, Ball S, Grenet J, Hana C, Deutsch Y, Zhang L, Hussaini MO, Song J, Yun S, Talati C, Kuykendall AT, Padron E, Walker AR, Roboz GJ, Desai P, Sallman DA, Sweet KL, Komrokji RS, Lancet JE. Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML. Blood Adv. 2024 Mar.8(5):1075-1083. Pubmedid: [38170740](https://www.ncbi.nlm.nih.gov/pubmed/38170740). Pmcid: PMC10907389. 
    * Jain AG, Gesiotto Q, Ball S, Nodzon L, Rodriguez A, Chan O, Padron E, Kuykendall A, Komrokji R, Sallman DA, Lancet JE, Pinilla-Ibarz J, Sweet K. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML. Ann Hematol. 2024 Jun.103(6):1941-1945. Pubmedid: [38634915](https://www.ncbi.nlm.nih.gov/pubmed/38634915). Pmcid: PMC11090947. 
    * Ionescu F, David JC, Ravichandran A, Sallman DA, Sweet K, Komrokji RS, Chan O, Kuykendall A, Padron E, Faramand R, Bejanyan N, Khimani F, Elmariah H, Pidala J, Mishra A, Perez L, Nishihori T, Lancet JE. Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk. 2024 Jun.24(6):400-406. Pubmedid: [38429222](https://www.ncbi.nlm.nih.gov/pubmed/38429222). 
    * Jain AG, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, Kuykendall A, Chan O, Sweet K, Lancet JE, Padron E, Sallman DA, Komrokji R. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia. Haematologica. 2024 Jul.109(7):2157-2164. Pubmedid: [38299605](https://www.ncbi.nlm.nih.gov/pubmed/38299605). Pmcid: PMC11215361. 
    * Aguirre LE, Jain A, Ball S, Ali NA, Volpe VO, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Yun S, Kuykendall A, Komrokji R. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Clin Lymphoma Myeloma Leuk. 2024 Jul.24(7):459-467. Pubmedid: [38548563](https://www.ncbi.nlm.nih.gov/pubmed/38548563). 
    * Horvat NP, Abdallah EF, Xie Z, Al Ali N, Yun S, Walker A, Padron E, Sallman D, Chan O, Lancet J, Komrokji R, Kuykendall AT. Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities. Ann Hematol. 2024 Jan.103(1):117-123. Pubmedid: [38030891](https://www.ncbi.nlm.nih.gov/pubmed/38030891). 
    * Aakash F, Gisriel SD, Zeidan AM, Bennett JM, Bejar R, Bewersdorf JP, Borate UM, Boultwood J, Brunner AM, Buckstein R, Carraway H, Churpek JE, Daver NG, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Garcia-Manero G, Gore SD, Greenberg PL, Griffiths EA, Halene S, Hourigan CS, Kim TK, Kim N, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Platzbecker U, Della Porta MG, Roboz GJ, Sallman DA, Santini V, Sanz G, Savona MR, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Wei AH, Zhuoer X, Xu ML, Hasserjian RP, Loghavi S. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]). Mod Pathol. 2024 Dec.37(12):100615. Pubmedid: [39322118](https://www.ncbi.nlm.nih.gov/pubmed/39322118). 
    * Ben-Crentsil NA, Mohammed Ismail W, Balasis ME, Newman H, Quintana A, Binder M, Kruer T, Neupane S, Ferrall-Fairbanks MC, Fernandez J, Lasho TL, Finke CM, Ibrahim ML, McGraw KL, Wysota M, Aldrich AL, Ryder CB, Letson CT, Traina J, McLemore AF, Droin N, Shastri A, Yun S, Solary E, Sallman DA, Beg AA, Ma L, Gaspar-Maia A, Patnaik MM, Padron E. RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal Hematopoiesis. Cancer Discov. 2024 Dec.14(12):2509-2531. Pubmedid: [39189614](https://www.ncbi.nlm.nih.gov/pubmed/39189614). Pmcid: PMC11611684. 
    * Berry DK, Gillis N, Padron E, Moore C, Barton LV, Gewandter KR, Haskins CG, Knepper TC. Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance. J Genet Couns. 2024 Aug.33(4):916-926. Pubmedid: [37715966](https://www.ncbi.nlm.nih.gov/pubmed/37715966). 
    * Tefferi A, Fleti F, Chan O, Al Ali NH, Al-Kali A, Begna KH, Foran JM, Badar T, Khera N, Shah M, Hiwase D, Padron E, Sallman DA, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q). Brit J Haematol. 2024 Apr.204(4):1243-1248. Pubmedid: [38083865](https://www.ncbi.nlm.nih.gov/pubmed/38083865). 
    * Gillis N, Padron E, Wang T, Chen K, DeVos JD, Spellman SR, Lee SJ, Kitko CL, MacMillan ML, West J, Tang YH, Teng M, McNulty S, Druley TE, Pidala JA, Lazaryan A. Pilot Study of Donor-Engrafted Clonal Hematopoiesis Evolution and Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation Recipients Using a National Registry. Transplant Cell Ther. 2023 Oct.29(10):640.e1-640.e8. Pubmedid: [37517612](https://www.ncbi.nlm.nih.gov/pubmed/37517612). Pmcid: PMC10592088. 
    * Jain AG, Ball S, Aguirre LE, Tobon KA, Chan O, Padron E, Kuykendall A, Komrokji R, Sallman D, Lancet JE, Sweet K. Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2023 Oct.23(10):e315-e322. Pubmedid: [37558530](https://www.ncbi.nlm.nih.gov/pubmed/37558530). 
    * Gorak E, Otterstatter M, Al Baghdadi T, Gillis N, Foran JM, Liu JJ, Bejar R, Gore SD, Kroft SH, Harrington AM, Saber W, Starczynowski DT, Rollison DE, Zhang L, Moscinski LC, Wilson SH, Thompson J, Borchert C, Sherman S, Hebert D, Walker ME, Padron E, DeZern A, Sekeres MA. Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies. Blood Adv. 2023 Oct.7(20):6120-6129. Pubmedid: [37552083](https://www.ncbi.nlm.nih.gov/pubmed/37552083). Pmcid: PMC10582385. 
    * Stahl M, Bewersdorf JP, Xie Z, Porta MGD, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, Sekeres MA, Sanz G, Sallman DA, Roboz GJ, Platzbecker U, Patnaik MM, Padron E, Odenike O, Nimer SD, Nazha A, Majeti R, Loghavi S, Little RF, List AF, Kim TK, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Gore SD, Greenberg P, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Daver NG, Churpek JE, Carraway HE, Buckstein R, Brunner AM, Boultwood J, Borate U, Bejar R, Bennett JM, Wei AH, Santini V, Savona MR, Zeidan AM. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev. 2023 Nov.62:101128. Pubmedid: [37704469](https://www.ncbi.nlm.nih.gov/pubmed/37704469). 
    * Tinsley-Vance SM, Ali NA, Ball S, Aguirre LE, Jain AG, Hussaini MO, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman DA, Komrokji RS. Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes. Clin Lymphoma Myeloma Leuk. 2023 May.23(5):355-359. Pubmedid: [36813626](https://www.ncbi.nlm.nih.gov/pubmed/36813626). Pmcid: PMC10121764. 
    * Mo Q, Yun S, Sallman DA, Vincelette ND, Peng G, Zhang L, Lancet JE, Padron E. Integrative molecular subtypes of acute myeloid leukemia. Blood Cancer J. 2023 May.13(1):71. Pubmedid: [37156780](https://www.ncbi.nlm.nih.gov/pubmed/37156780). Pmcid: PMC10167212. 
    * Zhang Y, Nguyen L, Lu CM, Wang E, Lauw MIS, Ball S, Dong N, Moscinski L, Chan O, Yun S, Sallman D, Sokol L, Shah B, Knepper T, Lancet J, Komrokji R, Padron E, Kuykendall A, Zhang L. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion. Clin Lymphoma Myeloma Leuk. 2023 Mar.23(3):e150-e163. Pubmedid: [36624015](https://www.ncbi.nlm.nih.gov/pubmed/36624015). 
    * Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski DT, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore SD, List AF, Kuchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood Adv. 2023 Jun.7(12):2709-2714. Pubmedid: [36260702](https://www.ncbi.nlm.nih.gov/pubmed/36260702). Pmcid: PMC10333740. 
    * Komrokji RS, Aguirre LE, Al-Ali N, Chan O, Xie Z, Kuykendall AT, Sweet KL, Lancet JE, Padron E, Sallman DA. Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes. Blood Adv. 2023 Jul.7(14):3677-3679. Pubmedid: [37058483](https://www.ncbi.nlm.nih.gov/pubmed/37058483). Pmcid: PMC10365940. 
    * Aguirre LE, Al Ali N, Sallman DA, Ball S, Jain AG, Chan O, Tinsley-Vance SM, Kuykendall A, Sweet K, Lancet JE, Padron E, Komrokji RS. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes. Leukemia. 2023 Jul.37(7):1530-1539. Pubmedid: [37147425](https://www.ncbi.nlm.nih.gov/pubmed/37147425). 
    * DeZern AE, Goll JB, Lindsley RC, Bejar R, Wilson SH, Hebert D, Deeg HJ, Zhang L, Gore SD, Al Baghdadi T, Maciejewski JP, Liu JJ, Padron E, Komrokji RS, Saber W, Abel GA, Kroft SH, Harrington AM, Grimes T, Reed HHV, Fulton RS, DiFronzo NL, Gillis N, Sekeres MA, Walter MJ. Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions. Blood Adv. 2023 Jul.7(14):3749-3759. Pubmedid: [36947201](https://www.ncbi.nlm.nih.gov/pubmed/36947201). Pmcid: PMC10368770. 
    * Abel GA, Hebert D, Lee C, Rollison DE, Gillis N, Komrokji RS, Foran JM, Liu JJ, Al Baghdadi T, Deeg HJ, Gore SD, Saber W, Wilson SH, Otterstatter M, Thompson J, Borchert C, Padron E, DeZern A, Cella D, Sekeres MA. Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study. Blood Adv. 2023 Jul.7(14):3506-3515. Pubmedid: [37146263](https://www.ncbi.nlm.nih.gov/pubmed/37146263). Pmcid: PMC10362255. 
    * Ball S, Aguirre LE, Jain AG, Ali NA, Tinsley SM, Chan O, Kuykendall AT, Sweet K, Lancet JE, Sallman DA, Hussaini MO, Padron E, Komrokji RS. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients. Leuk Res. 2023 Jan.124:106999. Pubmedid: [36542963](https://www.ncbi.nlm.nih.gov/pubmed/36542963). 
    * Komrokji RS, Aguirre LE, Al-Ali N, Hussaini MO, Sallman DA, Rollison DE, Padron E. U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes. Blood Adv. 2023 Jan.7(1):1-8. Pubmedid: [36129843](https://www.ncbi.nlm.nih.gov/pubmed/36129843). Pmcid: PMC9813529. 
    * Ward GA, Dalton RP, Meyer BS, McLemore AF, Aldrich AL, Lam NB, Onimus AH, Vincelette ND, Trinh TL, Chen X, Calescibetta AR, Christiansen SM, Hou HA, Johnson JO, Wright KL, Padron E, Eksioglu EA, List AF. Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes. Int J Mol Sci. 2023 Feb.24(4). Pubmedid: [36835307](https://www.ncbi.nlm.nih.gov/pubmed/36835307). Pmcid: PMC9966808. 
    * Patel PC, Ball S, Jain AG, Wang C, Hussaini MO, Aguirre LE, Chan O, Yun S, Kuykendall A, Padron E, Sweet K, Lancet JE, Komrokji RS, Sallman DA. Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia. Am J Hematol. 2023 Dec.98(12):E360-E363. Pubmedid: [37705256](https://www.ncbi.nlm.nih.gov/pubmed/37705256). 
    * Rajagopalan A, Feng Y, Gayatri MB, Ranheim EA, Klungness T, Matson DR, Lee MH, Jung MM, Zhou Y, Gao X, Nadiminti KV, Yang DT, Tran VL, Padron E, Miyamoto S, Bresnick EH, Zhang J. A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice. J Clin Invest. 2023 Dec.133(24). Pubmedid: [37847561](https://www.ncbi.nlm.nih.gov/pubmed/37847561). Pmcid: PMC10721149. 
    * Letson CT, Balasis ME, Newman H, Binder M, Vedder A, Kinose F, Ball M, Kruer T, Quintana A, Lasho TL, Finke CM, Almada LL, Grants JM, Zhang G, Fernandez-Zapico ME, Gaspar-Maia A, Lancet J, Komrokji R, Haura E, Sallman DA, Reuther GW, Karsan A, Rix U, Patnaik MM, Padron E. Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML. Clin Cancer Res. 2023 Aug.29(15):2919-2932. Pubmedid: [37223910](https://www.ncbi.nlm.nih.gov/pubmed/37223910). Pmcid: PMC10524644. 
    * Mangaonkar AA, Swoboda DM, Lasho TL, Finke C, Ketterling RP, Reichard KK, Komrokji R, Padron E, Patnaik MM. Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS). Leuk Res. 2023 Aug.131:107340. Pubmedid: [37356165](https://www.ncbi.nlm.nih.gov/pubmed/37356165). 
    * Gurney M, Mangaonkar AA, Lasho T, Finke C, Al-Kali A, Gangat N, Shah MV, Alkhateeb HB, Tefferi A, Sallman D, Xie Z, Viswanatha D, Reichard K, Al Ali N, Komrokji R, Padron E, Patnaik MM. Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML). Leukemia. 2023 Aug.37(8):1753-1756. Pubmedid: [37422593](https://www.ncbi.nlm.nih.gov/pubmed/37422593). 
    * Komrokji R, Al Ali N, Chan O, Sweet K, Kuykendall A, Lancet J, Padron E, Sallman DA. IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy. Haematologica. 2023 Apr.108(4):1168-1172. Pubmedid: [36420802](https://www.ncbi.nlm.nih.gov/pubmed/36420802). Pmcid: PMC10071110. 
    * Fleti F, Chan O, Singh A, Abdelmagid MG, Al-Kali A, Elliott MA, Begna KH, Foran JM, Badar T, Khera N, Al Ali NH, Padron E, Sallman DA, Shah M, Hiwase D, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R, Tefferi A. TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. Am J Hematol. 2023 Apr.98(4):E76-E79. Pubmedid: [36655582](https://www.ncbi.nlm.nih.gov/pubmed/36655582). 
    * Robin M, de Wreede LC, Padron E, Bakunina K, Fenaux P, Koster L, Nazha A, Beelen DW, Rampal RK, Sockel K, Komrokji RS, Gagelmann N, Eikema DJ, Radujkovic A, Finke J, Potter V, Killick S, Legrand-Izadifar F, Solary E, Broom A, Garcia-Manero G, Rizzoli V, Hayden P, Patnaik MM, Onida F, Yakoub-Agha I, Itzykson RA. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood. 2022 Sep.140(12):1408-1418. Pubmedid: [35667047](https://www.ncbi.nlm.nih.gov/pubmed/35667047). 
    * Moyo TK, Mendler JH, Itzykson R, Kishtagari A, Solary E, Seegmiller AC, Gerds AT, Ayers GD, Dezern AE, Nazha A, Valent P, van de Loosdrecht AA, Onida F, Pleyer L, Cirici BX, Tibes R, Geissler K, Komrokji RS, Zhang J, Germing U, Steensma DP, Wiseman DH, Pfeilstöecker M, Elena C, Cross NCP, Kiladjian JJ, Luebbert M, Mesa RA, Montalban-Bravo G, Sanz GF, Platzbecker U, Patnaik MM, Padron E, Santini V, Fenaux P, Savona MR. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes. BMC Cancer. 2022 Sep.22(1):1013. Pubmedid: [36153475](https://www.ncbi.nlm.nih.gov/pubmed/36153475). Pmcid: PMC9509596. 
    * Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov. 2022 Sep.3(5):385-393. Pubmedid: [35533245](https://www.ncbi.nlm.nih.gov/pubmed/35533245). Pmcid: PMC9445749. 
    * Kuykendall AT, Mo Q, Sallman DA, Ali NA, Chan O, Yun S, Sweet KL, Padron E, Lancet JE, Komrokji RS. Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates. Cancer. 2022 Oct.128(19):3495-3501. Pubmedid: [35942592](https://www.ncbi.nlm.nih.gov/pubmed/35942592). 
    * Lee D, Jain AG, Deutsch Y, Eatrides J, Chan O, Padron E, Kuykendall A, Komrokji R, Lancet J, Sallman D, Talati C, Sweet K. CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2022 Oct.22(10):774-779. Pubmedid: [35760672](https://www.ncbi.nlm.nih.gov/pubmed/35760672). 
    * Komrokji RS, Singh AM, Ali NA, Chan O, Padron E, Sweet K, Kuykendall A, Lancet JE, Sallman DA. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome. Blood Cancer J. 2022 Nov.12(11):148. Pubmedid: [36329025](https://www.ncbi.nlm.nih.gov/pubmed/36329025). Pmcid: PMC9633639. 
    * Ball S, Knepper TC, Deutsch YE, Samra W, Watts JM, Bradley TJ, Chan O, Hussaini MO, Zhang L, Sweet KL, Kuykendall AT, Talati C, Padron E, Komrokji RS, Lancet JE, Sallman DA. Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations. Cancer. 2022 Nov.128(21):3880-3887. Pubmedid: [36107670](https://www.ncbi.nlm.nih.gov/pubmed/36107670). 
    * Bradley T, Kwon D, Monge J, Sekeres M, Chandhok N, Thomassen A, Swords R, Padron E, Lancet J, Talati C, Watts J. Molecular characteristics and outcomes in Hispanic and non-Hispanic patients with acute myeloid leukemia. EJHaem. 2022 Nov.3(4):1231-1240. Pubmedid: [36467830](https://www.ncbi.nlm.nih.gov/pubmed/36467830). Pmcid: PMC9713060. 
    * Ferrall-Fairbanks MC, Dhawan A, Johnson B, Newman H, Volpe V, Letson C, Ball M, Hunter AM, Balasis ME, Kruer T, Ben-Crentsil NA, Kroeger JL, Balderas R, Komrokji RS, Sallman DA, Zhang J, Bejar R, Altrock PM, Padron E. Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse Outcomes. Blood Cancer Discov. 2022 Nov.3(6):536-553. Pubmedid: [36053528](https://www.ncbi.nlm.nih.gov/pubmed/36053528). Pmcid: PMC9627238. 
    * Gao X, You X, Droin N, Banaszak LG, Churpek J, Padron E, Geissler K, Solary E, Patnaik MM, Zhang J. Role of ASXL1 in hematopoiesis and myeloid diseases. Exp Hematol. 2022 Nov.115:14-19. Pubmedid: [36183966](https://www.ncbi.nlm.nih.gov/pubmed/36183966). 
    * Ball S, Jain AG, Aguirre LE, Al Ali N, Zhang Y, Chan O, Kuykendall AT, Sweet KL, Lancet JE, Swoboda DM, Padron E, Komrokji RS, Sallman DA. Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?. Am J Hematol. 2022 May.97(5):E185-E188. Pubmedid: [35179241](https://www.ncbi.nlm.nih.gov/pubmed/35179241). 
    * Mangaonkar AA, Lasho TL, Finke C, Ketterling RP, Reichard KK, McCullough K, Gangat N, Al-Kali A, Begna KH, Hogan WH, Litzow MR, Alkhateeb H, Shah M, Pardanani A, Tefferi A, Ali NHA, Talati C, Sallman D, Padron E, Komrokji R, Patnaik MM. SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica. 2022 May.107(5):1189-1192. Pubmedid: [35142154](https://www.ncbi.nlm.nih.gov/pubmed/35142154). Pmcid: PMC9052897. 
    * Wang C, McGraw KL, McLemore AF, Komrokji R, Basiorka AA, Al Ali N, Lancet JE, Padron E, Kosmider O, Fontenay M, Fenaux P, List AF, Sallman DA. Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin. Haematologica. 2022 Mar.107(3):737-739. Pubmedid: [34320786](https://www.ncbi.nlm.nih.gov/pubmed/34320786). Pmcid: PMC8883562. 
    * Walsh C, Hunter A, Lasho T, Finke C, Ketterling R, Komrokji R, Tefferi A, Mangaonkar A, Howard M, Gangat N, Al-Kali A, Ali NA, Padron E, Patnaik MM. Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia. Leukemia. 2022 Jun.36(6):1693-1696. Pubmedid: [35351982](https://www.ncbi.nlm.nih.gov/pubmed/35351982). 
    * Castillo Tokumori F, Al Ali N, Chan O, Sallman D, Yun S, Sweet K, Padron E, Lancet J, Komrokji R, Kuykendall AT. Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2022 Jul.22(7):e521-e525. Pubmedid: [35241387](https://www.ncbi.nlm.nih.gov/pubmed/35241387). 
    * Chan O, Ali NA, Sallman D, Padron E, Lancet J, Komrokji R. Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS). Clin Lymphoma Myeloma Leuk. 2022 Jul.22(7):e467-e476. Pubmedid: [35101379](https://www.ncbi.nlm.nih.gov/pubmed/35101379). 
    * Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul.36(7):1703-1719. Pubmedid: [35732831](https://www.ncbi.nlm.nih.gov/pubmed/35732831). Pmcid: PMC9252913. 
    * Komrokji R, Melody M, Al Ali N, Chan O, Klimek V, Ball BJ, Sekeres MA, Lucas G, Maciejewski JP, Sallman DA, Padron E, Kuykendall A, Lasho T, Al-Kali A, Naqvi K, Steensma DP, Garcia-Manero G, Patnaik MM. Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leuk Lymphoma. 2022 Jan.63(1):199-204. Pubmedid: [34448437](https://www.ncbi.nlm.nih.gov/pubmed/34448437). 
    * Dhawan A, Padron E. Abnormal monocyte differentiation and function in chronic myelomonocytic leukemia. Curr Opin Hematol. 2022 Jan.29(1):20-26. Pubmedid: [34854831](https://www.ncbi.nlm.nih.gov/pubmed/34854831). 
    * Mangaonkar AA, Lasho TL, Ketterling RP, Reichard KK, Gangat N, Al-Kali A, Begna KH, Pardanani A, Al Ali NH, Talati C, Sallman D, Padron E, Patnaik MM, Tefferi A, Komrokji R. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer J. 2022 Feb.12(2):26. Pubmedid: [35105856](https://www.ncbi.nlm.nih.gov/pubmed/35105856). Pmcid: PMC8807827. 
    * You X, Liu F, Binder M, Vedder A, Lasho TL, Wen Z, Gao X, Flietner E, Rajagopalan A, Zhou Y, Finke CM, Mangaonkar AA, Liao R, Kong G, Ranheim EA, Droin NM, Hunter AM, Nikolaev S, Balasis ME, Abdel-Wahab O, Levine RL, Will B, Nadiminti KVG, Yang DT, Geissler K, Solary E, Xu W, Padron E, Patnaik MM, Zhang J. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood. 2022 Feb.139(7):1066-1079. Pubmedid: [34699595](https://www.ncbi.nlm.nih.gov/pubmed/34699595). Pmcid: PMC8854684. 
    * Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia. 2022 Dec.36(12):2939-2946. Pubmedid: [36266326](https://www.ncbi.nlm.nih.gov/pubmed/36266326). 
    * Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia. 2022 Dec.36(12):2934-2938. Pubmedid: [36335264](https://www.ncbi.nlm.nih.gov/pubmed/36335264). 
    * Volpe VO, Al Ali N, Chan O, Padron E, Sallman DA, Kuykendall A, Sweet K, Lancet JE, Komrokji RS. Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes. Brit J Haematol. 2022 Aug.198(4):713-720. Pubmedid: [35751140](https://www.ncbi.nlm.nih.gov/pubmed/35751140). 
    * McLemore AF, Hou HA, Meyer BS, Lam NB, Ward GA, Aldrich AL, Rodrigues MA, Vedder A, Zhang L, Padron E, Vincelette ND, Sallman DA, Abdel-Wahab O, List AF, McGraw KL. Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes. JCI Insight. 2022 Aug.7(15). Pubmedid: [35788117](https://www.ncbi.nlm.nih.gov/pubmed/35788117). Pmcid: PMC9462508. 
    * Swoboda DM, Kanagal-Shamanna R, Brunner AM, Cluzeau T, Chan O, Al Ali N, Montalban-Bravo G, Gesiotto QJ, Gavralidis A, Hunter AM, Lee JH, Kuykendall AT, Talati C, Sweet KL, Lancet JE, Padron E, Hussaini M, Song J, Garcia-Manero G, Komrokji RS, Sallman DA. Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia. 2022 Apr.36(4):1189-1192. Pubmedid: [34975158](https://www.ncbi.nlm.nih.gov/pubmed/34975158). 
    * Komrokji RS, Volpe VO, Chan O, Al Ali NH, Swoboda DM, Kuykendall AT, Padron E, Sallman DA. Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes. Blood. 2021 Sep.138(11):989-992. Pubmedid: [34036300](https://www.ncbi.nlm.nih.gov/pubmed/34036300). 
    * Hunter AM, Al Ali N, Mai A, Shah S, Swoboda DM, Kuykendall A, Talati C, Sweet KL, Sallman DA, Lancet JE, Komrokji RS, Padron E. Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy. Leuk Res. 2021 Oct.109:106640. Pubmedid: [34144312](https://www.ncbi.nlm.nih.gov/pubmed/34144312). 
    * Renneville A, Patnaik MM, Chan O, Padron E, Solary E. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia. Leukemia. 2021 Oct.35(10):2739-2751. Pubmedid: [34175902](https://www.ncbi.nlm.nih.gov/pubmed/34175902). 
    * Komrokji R, Al Ali N, Padron E, Lancet J, Nazha A, Steensma D, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, Sallman D. What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?. Leuk Lymphoma. 2021 Nov.62(11):2762-2767. Pubmedid: [34114922](https://www.ncbi.nlm.nih.gov/pubmed/34114922). 
    * Hunter AM, Newman H, DeZern AE, Steensma DP, Niyongere S, Roboz GJ, Mo Q, Chan O, Gerds A, Sallman DA, Dominguez-Viqueira W, Letson C, Balasis ME, Ball M, Kruer T, Zhang H, Lancet JE, List AF, Sekeres MA, Komrokji RS, Padron E. Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. Clin Cancer Res. 2021 Nov.27(22):6095-6105. Pubmedid: [34253584](https://www.ncbi.nlm.nih.gov/pubmed/34253584). Pmcid: PMC8595542. 
    * Nazha A, Komrokji R, Meggendorfer M, Jia X, Radakovich N, Shreve J, Hilton CB, Nagata Y, Hamilton BK, Mukherjee S, Al Ali N, Walter W, Hutter S, Padron E, Sallman D, Kuzmanovic T, Kerr C, Adema V, Steensma DP, Dezern A, Roboz G, Garcia-Manero G, Erba H, Haferlach C, Maciejewski JP, Haferlach T, Sekeres MA. Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. J Clin Oncol. 2021 Nov.39(33):3737-3746. Pubmedid: [34406850](https://www.ncbi.nlm.nih.gov/pubmed/34406850). Pmcid: PMC8601291. 
    * Radakovich N, Meggendorfer M, Malcovati L, Hilton CB, Sekeres MA, Shreve J, Rouphail Y, Walter W, Hutter S, Galli A, Pozzi S, Elena C, Padron E, Savona MR, Gerds AT, Mukherjee S, Nagata Y, Komrokji RS, Jha BK, Haferlach C, Maciejewski JP, Haferlach T, Nazha A. A geno-clinical decision model for the diagnosis of myelodysplastic syndromes. Blood Adv. 2021 Nov.5(21):4361-4369. Pubmedid: [34592765](https://www.ncbi.nlm.nih.gov/pubmed/34592765). Pmcid: PMC8579270. 
    * Mangaonkar AA, Swoboda DM, Lasho TL, Finke C, Ketterling RP, Reichard KK, Padron E, Talati C, Patnaik MM. Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. Leukemia. 2021 Nov.35(11):3329-3333. Pubmedid: [33931725](https://www.ncbi.nlm.nih.gov/pubmed/33931725). 
    * Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021 May.39(14):1584-1594. Pubmedid: [33449813](https://www.ncbi.nlm.nih.gov/pubmed/33449813). Pmcid: PMC8099410. 
    * Carr RM, Vorobyev D, Lasho T, Marks DL, Tolosa EJ, Vedder A, Almada LL, Yurcheko A, Padioleau I, Alver B, Coltro G, Binder M, Safgren SL, Horn I, You X, Solary E, Balasis ME, Berger K, Hiebert J, Witzig T, Buradkar A, Graf T, Valent P, Mangaonkar AA, Robertson KD, Howard MT, Kaufmann SH, Pin C, Fernandez-Zapico ME, Geissler K, Droin N, Padron E, Zhang J, Nikolaev S, Patnaik MM. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun. 2021 May.12(1):2901. Pubmedid: [34006870](https://www.ncbi.nlm.nih.gov/pubmed/34006870). Pmcid: PMC8131698. 
    * Gesiotto QJ, Swoboda DM, Shallis RM, Al Ali N, Padron E, Kuykendall AT, Song J, Talati C, Sweet K, Lancet JE, Zeidan AM, Komrokji RS, Sallman DA. Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies. Clin Lymphoma Myeloma Leuk. 2021 Jun.21(6):421-424.e2. Pubmedid: [33583730](https://www.ncbi.nlm.nih.gov/pubmed/33583730). 
    * Hunter A, Padron E. Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia. Curr Hematol Malig Rep. 2021 Jun.16(3):247-255. Pubmedid: [33660195](https://www.ncbi.nlm.nih.gov/pubmed/33660195). 
    * Chan O, Renneville A, Padron E. Chronic myelomonocytic leukemia diagnosis and management. Leukemia. 2021 Jun.35(6):1552-1562. Pubmedid: [33714974](https://www.ncbi.nlm.nih.gov/pubmed/33714974). 
    * Sevin M, Debeurme F, Laplane L, Badel S, Morabito M, Newman HL, Torres-Martin M, Yang Q, Badaoui B, Wagner-Ballon O, Saada V, Selimoglu-Buet D, Kraus-Berthier L, Banquet S, Derreal A, Fenaux P, Itzykson RA, Braun T, Etienne G, Berthon C, Thepot S, Kepp O, Kroemer G, Padron E, Figueroa ME, Droin NM, Solary E. Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML. Blood. 2021 Jun.137(24):3390-3402. Pubmedid: [33690800](https://www.ncbi.nlm.nih.gov/pubmed/33690800). Pmcid: PMC8233685. 
    * Swoboda DM, Ali NA, Chan O, Padron E, Kuykendall AT, Song J, Hussaini M, Talati C, Sweet K, Lancet JE, Sallman DA, Komrokji RS. PTPN11 mutations are associated with poor outcomes across myeloid malignancies. Leukemia. 2021 Jan.35(1):286-288. Pubmedid: [33132383](https://www.ncbi.nlm.nih.gov/pubmed/33132383). 
    * Schwabkey ZI, Al Ali N, Chan O, Sallman DA, Padron E, Kuykendall AT, Talati C, Sweet K, Lancet JE, Komrokji RS. Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype. Clin Lymphoma Myeloma Leuk. 2021 Jan.21(1):e52-e56. Pubmedid: [33093008](https://www.ncbi.nlm.nih.gov/pubmed/33093008). 
    * Komrokji RS, Al Ali NH, Sallman D, Padron E, DeZern AE, Barnard J, Roboz GJ, Garcia-Manero G, List A, Steensma DP, Sekeres MA. Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium. Cancer Med. 2021 Jan.10(2):447-453. Pubmedid: [33350168](https://www.ncbi.nlm.nih.gov/pubmed/33350168). Pmcid: PMC7877342. 
    * Hunter AM, Komrokji RS, Yun S, Al Ali N, Chan O, Song J, Hussaini M, Talati C, Sweet KL, Lancet JE, Padron E, List AF, Sallman DA. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021 Feb.5(4):1017-1028. Pubmedid: [33591325](https://www.ncbi.nlm.nih.gov/pubmed/33591325). Pmcid: PMC7903224. 
    * Pleyer L, Leisch M, Kourakli A, Padron E, Maciejewski JP, Xicoy Cirici B, Kaivers J, Ungerstedt J, Heibl S, Patiou P, Hunter AM, Mora E, Geissler K, Dimou M, Jimenez Lorenzo MJ, Melchardt T, Egle A, Viniou AN, Patel BJ, Arnan M, Valent P, Roubakis C, Bernal Del Castillo T, Galanopoulos A, Calabuig Muñoz M, Bonadies N, Medina de Almeida A, Cermak J, Jerez A, Montoro MJ, Cortés A, Avendaño Pita A, Lopez Andrade B, Hellstroem-Lindberg E, Germing U, Sekeres MA, List AF, Symeonidis A, Sanz GF, Larcher-Senn J, Greil R. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematol. 2021 Feb.8(2):e135-e148. Pubmedid: [33513373](https://www.ncbi.nlm.nih.gov/pubmed/33513373). 
    * Gajzer D, Logothetis CN, Sallman DA, Calon G, Babu A, Chan O, Vincelette ND, Volpe VO, Al Ali NH, Basra P, Talati C, Kuykendall AT, Mo Q, Padron E, Sweet K, Komrokji RS, Lancet JE, Yun S, Zhang L. MYC overexpression is associated with an early disease progression from MDS to AML. Leuk Res. 2021 Dec.111:106733. Pubmedid: [34749168](https://www.ncbi.nlm.nih.gov/pubmed/34749168). Pmcid: PMC8643343. 
    * Schwabkey Z, Al Ali N, Sallman D, Kuykendall A, Talati C, Sweet K, Lancet J, Padron E, Komrokji R. Impact of obesity on survival of patients with myelodysplastic syndromes. Hematology. 2021 Dec.26(1):393-397. Pubmedid: [34029507](https://www.ncbi.nlm.nih.gov/pubmed/34029507). 
    * Song A, Altabbakh O, Sallman DA, Padron E, Talati C, Hussaini MO. Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes. Eur J Haematol. 2021 Dec.107(6):609-616. Pubmedid: [34407254](https://www.ncbi.nlm.nih.gov/pubmed/34407254). 
    * Aguirre LE, Komrokji R, Padron E. It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS. Best Pract Res Clin Haematol. 2021 Dec.34(4):101325. Pubmedid: [34865697](https://www.ncbi.nlm.nih.gov/pubmed/34865697). 
    * Yun S, Geyer SM, Komrokji RS, Al Ali NH, Song J, Hussaini M, Sweet KL, Lancet JE, List AF, Padron E, Sallman DA. Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Leukemia. 2021 Apr.35(4):1145-1155. Pubmedid: [32728186](https://www.ncbi.nlm.nih.gov/pubmed/32728186). Pmcid: PMC7854836. 
    * Ward GA, McGraw KL, Abbas-Aghababazadeh F, Meyer BS, McLemore AF, Vincelette ND, Lam NB, Aldrich AL, Al Ali NH, Padron E, Pinilla-Ibarz J, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Johnson J, Fridley BL, List AF. Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. Blood Adv. 2021 Apr.5(8):2216-2228. Pubmedid: [33890980](https://www.ncbi.nlm.nih.gov/pubmed/33890980). Pmcid: PMC8095151. 
    * Belizaire R, Koochaki SHJ, Udeshi ND, Vedder A, Sun L, Svinkina T, Hartigan C, McConkey ME, Kovalcik V, Bizuayehu A, Stanclift C, Schenone M, Carr SA, Padron E, Ebert BL. CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1. Blood. 2021 Apr.137(16):2209-2220. Pubmedid: [33512474](https://www.ncbi.nlm.nih.gov/pubmed/33512474). Pmcid: PMC8063090. 
    * Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. Clin Lymphoma Myeloma Leuk. 2020 Sep.20(9):e597-e605. Pubmedid: [32303488](https://www.ncbi.nlm.nih.gov/pubmed/32303488). 
    * Hunter AM, Padron E. Molecular genetics of MDS/MPN overlap syndromes. Best Pract Res Clin Haematol. 2020 Sep.33(3):101195. Pubmedid: [33038984](https://www.ncbi.nlm.nih.gov/pubmed/33038984). 
    * Padron E. Toward classifying the unclassifiable. Blood. 2020 Oct.136(16):1800-1801. Pubmedid: [33057699](https://www.ncbi.nlm.nih.gov/pubmed/33057699). 
    * Komrokji RS, Ali NA, Sallman D, Padron E, Lancet J, Sokol L, Varnadoe C, Burnette PK, List A. Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL). Leukemia. 2020 Nov.34(11):3097-3099. Pubmedid: [32565544](https://www.ncbi.nlm.nih.gov/pubmed/32565544). 
    * Wudhikarn K, Loghavi S, Mangaonkar AA, Al-Kali A, Binder M, Carr R, Reichard K, Finke C, Howard M, Gangat N, Tefferi A, Komrokji R, Ali N, Lasho T, Ketterling R, Padron E, Patnaik MM. SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Adv. 2020 Nov.4(22):5716-5721. Pubmedid: [33216886](https://www.ncbi.nlm.nih.gov/pubmed/33216886). Pmcid: PMC7686903. 
    * Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, Patel M, Berthon A, Syed A, Yabe M, Coombs CC, Caltabellotta NM, Walsh M, Offit K, Stadler Z, Mandelker D, Schulman J, Patel A, Philip J, Bernard E, Gundem G, Ossa JEA, Levine M, Martinez JSM, Farnoud N, Glodzik D, Li S, Robson ME, Lee C, Pharoah PDP, Stopsack KH, Spitzer B, Mantha S, Fagin J, Boucai L, Gibson CJ, Ebert BL, Young AL, Druley T, Takahashi K, Gillis N, Ball M, Padron E, Hyman DM, Baselga J, Norton L, Gardos S, Klimek VM, Scher H, Bajorin D, Paraiso E, Benayed R, Arcila ME, Ladanyi M, Solit DB, Berger MF, Tallman M, Garcia-Closas M, Chatterjee N, Diaz LA, Levine RL, Morton LM, Zehir A, Papaemmanuil E. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genetics. 2020 Nov.52(11):1219-1226. Pubmedid: [33106634](https://www.ncbi.nlm.nih.gov/pubmed/33106634). Pmcid: PMC7891089. 
    * Melody M, Al Ali N, Zhang L, Ramadan H, Padron E, Sallman D, Sweet K, Lancet J, List A, Bennett JM, Komrokji R. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2020 May.20(5):324-328. Pubmedid: [32044274](https://www.ncbi.nlm.nih.gov/pubmed/32044274). 
    * Melody M, Kuykendall A, Sallman D, Al Ali N, Zhang L, Talati C, Padron E, Sweet K, Extermann M, List A, Lancet J, Komrokji R. Defining Acute Myeloid Leukemia Ontogeny in Older Patients. Clin Lymphoma Myeloma Leuk. 2020 May.20(5):312-315. Pubmedid: [32139296](https://www.ncbi.nlm.nih.gov/pubmed/32139296). 
    * Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, Gangat N, Binder M, Pardanani A, Fernandez-Zapico M, Robertson KD, Bosi A, Droin N, Vannucchi AM, Tefferi A, Hunter A, Padron E, Solary E, Patnaik MM. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Leukemia. 2020 May.34(5):1407-1421. Pubmedid: [31836856](https://www.ncbi.nlm.nih.gov/pubmed/31836856). 
    * Nguyen L, Zhang X, Roberts E, Yun S, McGraw K, Abraham I, Song J, Braswell D, Qin D, Sallman DA, Lancet JE, List AF, Moscinski LC, Padron E, Zhang L. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1. Leuk Lymphoma. 2020 Jun.61(6):1395-1405. Pubmedid: [32091281](https://www.ncbi.nlm.nih.gov/pubmed/32091281). Pmcid: PMC7269833. 
    * Talati C, Goldberg AD, Przespolewski A, Chan O, Ali NA, Kim J, Famulare C, Sallman D, Padron E, Kuykendall A, Lancet JE, Wang E, Tallman MS, Komrokji R, Sweet K. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leuk Res. 2020 Jun.93:106367. Pubmedid: [32408060](https://www.ncbi.nlm.nih.gov/pubmed/32408060). Pmcid: PMC7771257. 
    * Badar T, Szabo A, Sallman D, Komrokji R, Lancet J, Padron E, Song J, Hussaini MO. Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. Leuk Lymphoma. 2020 Jun.61(6):1418-1427. Pubmedid: [32013644](https://www.ncbi.nlm.nih.gov/pubmed/32013644). 
    * Zhang Q, Haider M, Al Ali NH, Lancet JE, Epling-Burnette PK, List AF, Padron E, Komrokji RS. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2020 Jun.20(6):400-406.e2. Pubmedid: [32179032](https://www.ncbi.nlm.nih.gov/pubmed/32179032). Pmcid: PMC7771378. 
    * Chan O, Padron E. Moving towards a uniform risk stratification system in CMML - How far are we?. Best Pract Res Clin Haematol. 2020 Jun.33(2):101131. Pubmedid: [32460982](https://www.ncbi.nlm.nih.gov/pubmed/32460982). 
    * Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M, Gill SI, Manning BM, Koprivnikar J, McCloskey J, Testi R, Prebet T, Al Ali NH, Padron E, Sallman DA, Komrokji RS, Goldberg AD. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020 Jul.4(13):2866-2870. Pubmedid: [32589727](https://www.ncbi.nlm.nih.gov/pubmed/32589727). Pmcid: PMC7362378. 
    * Sweet K, Komrokji RS, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. Clin Cancer Res. 2020 Jan.26(1):54-60. Pubmedid: [31636097](https://www.ncbi.nlm.nih.gov/pubmed/31636097). Pmcid: PMC7787346. 
    * Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, Carr RM, Binder M, Finke CM, Gangat N, Al-Kali A, Begna KH, Reichard KK, Ketterling RP, Al Ali NH, Vafaii P, Zhang L, Padron E, Talati C, Patnaik MM. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia. 2020 Feb.34(2):656-661. Pubmedid: [31511613](https://www.ncbi.nlm.nih.gov/pubmed/31511613). 
    * Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, Ebert BL, Al-Ali N, Lancet JE, Cleveland JL, Padron E, List AF. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020 Dec.136(24):2812-2823. Pubmedid: [32730593](https://www.ncbi.nlm.nih.gov/pubmed/32730593). Pmcid: PMC7731792. 
    * Castillo-Tokumori F, Talati C, Al Ali N, Sallman D, Yun S, Sweet K, Padron E, Lancet J, Komrokji R, Kuykendall AT. Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2020 Dec.20(12):e956-e960. Pubmedid: [32778513](https://www.ncbi.nlm.nih.gov/pubmed/32778513). 
    * Duong VH, Al Ali N, Zhang L, Padron E, Sallman D, Lancet JE, List AF, Komrokji RS. A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure. Leuk Lymphoma. 2020 Aug.61(8):1901-1907. Pubmedid: [32306798](https://www.ncbi.nlm.nih.gov/pubmed/32306798). 
    * Patnaik MM, Sallman DA, Mangaonkar A, Heuer R, Hirvela J, Zblewski D, Al-Kali A, Binder M, Balasis ME, Newman H, Letson C, Kruer TL, Gangat N, Komrokji RS, Tefferi A, Lo A, Shih T, Durrant C, List AF, Padron E. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 2020 Aug.136(7):909-913. Pubmedid: [32294158](https://www.ncbi.nlm.nih.gov/pubmed/32294158). Pmcid: PMC7531999. 
    * Patnaik MM, Lasho T, Padron E, McCullough K, Al-Kali A, Tefferi A, Zeidan AM, Gangat N, Savona M, Steensma DP, Solary E. Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic. Am J Hematol. 2020 Aug.95(8):E203-E208. Pubmedid: [32356322](https://www.ncbi.nlm.nih.gov/pubmed/32356322). Pmcid: PMC7267346. 
    * Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematol. 2020 Aug.7(8):e601-e612. Pubmedid: [32563283](https://www.ncbi.nlm.nih.gov/pubmed/32563283). Pmcid: PMC7302757. 
    * Badaat I, Mirza S, Padron E, Sallman D, Komrokji R, Song J, Hussaini MO. Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome. J Clin Pathol. 2020 Apr.73(4):209-212. Pubmedid: [31771970](https://www.ncbi.nlm.nih.gov/pubmed/31771970). 
    * Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leuk Res. 2019 Sep.84:106194. Pubmedid: [31357093](https://www.ncbi.nlm.nih.gov/pubmed/31357093). Pmcid: PMC7375354. 
    * Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lubbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstocker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica. 2019 Oct.104(10):1935-1949. Pubmedid: [31048353](https://www.ncbi.nlm.nih.gov/pubmed/31048353). Pmcid: PMC6886439. 
    * Lucas N, Duchmann M, Rameau P, Noël F, Michea P, Saada V, Kosmider O, Pierron G, Fernandez-Zapico ME, Howard MT, King RL, Niyongere S, Diop MK, Fenaux P, Itzykson R, Willekens C, Ribrag V, Fontenay M, Padron E, Soumelis V, Droin N, Patnaik MM, Solary E. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia. 2019 Oct.33(10):2466-2480. Pubmedid: [30894665](https://www.ncbi.nlm.nih.gov/pubmed/30894665). 
    * McGraw KL, Cheng CH, Chen YA, Hou HA, Nilsson B, Genovese G, Cluzeau T, Pellagatti A, Przychodzen BP, Mallo M, Arenillas L, Mohamedali A, Adès L, Sallman DA, Padron E, Sokol L, Moreilhon C, Raynaud S, Tien HF, Boultwood J, Ebert BL, Sole F, Fenaux P, Mufti GJ, Maciejewski JP, Kanetsky PA, List AF. Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. Blood Adv. 2019 Nov.3(22):3579-3589. Pubmedid: [31738830](https://www.ncbi.nlm.nih.gov/pubmed/31738830). Pmcid: PMC6880887. 
    * Rose A, Slone S, Padron E. Relapsed Acute Lymphoblastic Leukemia Presenting as Acute Renal Failure. Case Rep Nephrol. 2019 May.2019:7913027. Pubmedid: [31214367](https://www.ncbi.nlm.nih.gov/pubmed/31214367). Pmcid: PMC6535833. 
    * Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF. A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2019 Mar.19(3):157-161. Pubmedid: [30713125](https://www.ncbi.nlm.nih.gov/pubmed/30713125). 
    * Badar T, Johnson L, Trifilo K, Wang H, Kudlow BA, Padron E, Pappenhausen PR, Hussaini MO. Detection of Novel t(12;17)(p12;p13) in Relapsed Refractory Acute Myeloid Leukemia by Anchored Multiplex PCR(AMP)-based Next-Generation Sequencing. Appl Immunohistochem Mol Morphol. 2019 Mar.27(3):e28-e31. Pubmedid: [28187034](https://www.ncbi.nlm.nih.gov/pubmed/28187034). 
    * Kong G, You X, Wen Z, Chang YI, Qian S, Ranheim EA, Letson C, Zhang X, Zhou Y, Liu Y, Rajagopalan A, Zhang J, Stieglitz E, Loh M, Hofmann I, Yang D, Zhong X, Padron E, Zhou L, Pear WS, Zhang J. Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm. Leukemia. 2019 Mar.33(3):671-685. Pubmedid: [30206308](https://www.ncbi.nlm.nih.gov/pubmed/30206308). Pmcid: PMC6405304. 
    * Chung J, Sallman DA, Padron E. TP53 and therapy-related myeloid neoplasms. Best Pract Res Clin Haematol. 2019 Mar.32(1):98-103. Pubmedid: [30927980](https://www.ncbi.nlm.nih.gov/pubmed/30927980). 
    * Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE. A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leuk Res. 2019 Jun.81:56-61. Pubmedid: [31030089](https://www.ncbi.nlm.nih.gov/pubmed/31030089). Pmcid: PMC7787349. 
    * Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019 Jul.33(7):1747-1758. Pubmedid: [30635634](https://www.ncbi.nlm.nih.gov/pubmed/30635634). Pmcid: PMC6609480. 
    * Andrew K, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. Am J Hematol. 2019 Jan.94(1):87-92. Pubmedid: [30390311](https://www.ncbi.nlm.nih.gov/pubmed/30390311). 
    * Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E. Managing Clonal Hematopoiesis in Patients With Solid Tumors. J Clin Oncol. 2019 Jan.37(1):7-11. Pubmedid: [30403571](https://www.ncbi.nlm.nih.gov/pubmed/30403571). Pmcid: PMC6354773. 
    * Kuenzi BM, Remsing Rix LL, Kinose F, Kroeger JL, Lancet JE, Padron E, Rix U. Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia. Sci Rep. 2019 Jan.9(1):606. Pubmedid: [30679640](https://www.ncbi.nlm.nih.gov/pubmed/30679640). Pmcid: PMC6345777. 
    * Niyongere S, Lucas N, Zhou JM, Sansil S, Pomicter AD, Balasis ME, Robinson J, Kroeger J, Zhang Q, Zhao YL, Ball M, Komrokji R, List A, Deininger MW, Fridley BL, Santini V, Solary E, Padron E. Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia. 2019 Jan.33(1):205-216. Pubmedid: [30026572](https://www.ncbi.nlm.nih.gov/pubmed/30026572). Pmcid: PMC7787307. 
    * McGraw KL, Nguyen J, Al Ali NH, Komrokji RS, Sallman D, Zhang X, Song J, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes. Brit J Haematol. 2019 Feb.184(3):450-455. Pubmedid: [29359794](https://www.ncbi.nlm.nih.gov/pubmed/29359794). Pmcid: PMC7771337. 
    * Kuykendall AT, Talati C, Padron E, Sweet K, Lancet JE, List AF, Sallman D, Komrokji RS. Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis. Am J Hematol. 2019 Dec.94(12):E314-E317. Pubmedid: [31444809](https://www.ncbi.nlm.nih.gov/pubmed/31444809). 
    * Kuykendall AT, Padron E. Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO. Curr Hematol Malig Rep. 2019 Dec.14(6):543-549. Pubmedid: [31776774](https://www.ncbi.nlm.nih.gov/pubmed/31776774). 
    * Letson C, Padron E. Non-canonical transcriptional consequences of BET inhibition in cancer. Pharmacol Res. 2019 Dec.150:104508. Pubmedid: [31698067](https://www.ncbi.nlm.nih.gov/pubmed/31698067). 
    * Vedder AR, Miedel EL, Ragland NH, Balasis ME, Letson CT, Engelman RW, Padron E. Effects of Corynebacterium bovis on Engraftment of Patient-derived Chronic-Myelomonocytic Leukemia Cells in NSGS Mice. Comp Med. 2019 Aug.69(4):276-282. Pubmedid: [31349880](https://www.ncbi.nlm.nih.gov/pubmed/31349880). Pmcid: PMC6733163. 
    * Komrokji RS, Al Ali NH, Padron E, Cogle C, Tinsley S, Sallman D, Lancet JE, List AF. Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. Clin Lymphoma Myeloma Leuk. 2019 Apr.19(4):251-254. Pubmedid: [30852241](https://www.ncbi.nlm.nih.gov/pubmed/30852241). 
    * Ferrall-Fairbanks MC, Ball M, Padron E, Altrock PM. Leveraging Single-Cell RNA Sequencing Experiments to Model Intratumor Heterogeneity. JCO Clin Cancer Inform. 2019 Apr.3:1-10. Pubmedid: [30995123](https://www.ncbi.nlm.nih.gov/pubmed/30995123). Pmcid: PMC6873939. 
    * Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore AF, Vincelette ND, Ward GA, Eksioglu EA, Sallman DA, Ali NA, Padron E, Pinilla-Ibarz J, Komrokji R, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Sokol L, Wei S, Fridley B, List AF. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. Lancet Haematol. 2018 Sep.5(9):e393-e402. Pubmedid: [30072146](https://www.ncbi.nlm.nih.gov/pubmed/30072146). Pmcid: PMC6505461. 
    * Zhu G, Brayer J, Padron E, Mulé JJ, Mailloux AW. OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms. Cytometry A. 2018 Oct.93(10):982-986. Pubmedid: [30347519](https://www.ncbi.nlm.nih.gov/pubmed/30347519). Pmcid: PMC6484443. 
    * Hunter AM, Zhang L, Padron E. Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia. CURR TREAT OPTION ON. 2018 Oct.19(12):67. Pubmedid: [30367269](https://www.ncbi.nlm.nih.gov/pubmed/30367269). 
    * Vela CM, Van den Bergh M, Gillis NK, Ball M, Hussaini MO, Walko CM, Hicks JK, Perez L, Padron E, Komrokji RS. Somatic Sequencing Identifies Trametinib-Responsive Myelodysplastic Syndrome and Finds Acquired Clonal Hematopoiesis of Indeterminate Potential. JCO Precis Oncol. 2018 Nov.2. Pubmedid: [35135101](https://www.ncbi.nlm.nih.gov/pubmed/35135101). Pmcid: PMC9797240. 
    * Itzykson R, Fenaux P, Bowen D, Cross NCP, Cortes J, De Witte T, Germing U, Onida F, Padron E, Platzbecker U, Santini V, Sanz GF, Solary E, Van de Loosdrecht A, Malcovati L. Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. Hemasphere. 2018 Nov.2(6):e150. Pubmedid: [31723789](https://www.ncbi.nlm.nih.gov/pubmed/31723789). Pmcid: PMC6745959. 
    * Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, Zhang L, Moscinski LC, Rollison DE, Gore SD, Bejar R, Walter MJ, Sekeres MA, Komrokji RS, Epling-Burnette PK. Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood. 2018 May.131(21):2402-2405. Pubmedid: [29661788](https://www.ncbi.nlm.nih.gov/pubmed/29661788). Pmcid: PMC5969383. 
    * Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine. 2018 May.31:174-181. Pubmedid: [29728305](https://www.ncbi.nlm.nih.gov/pubmed/29728305). Pmcid: PMC6013781. 
    * Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, Agrawal AA, Caleb B, Csibi A, Sean E, Fekkes P, Karr C, Klimek V, Lai G, Lee L, Kumar P, Lee SC, Liu X, Mackenzie C, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Peng S, Prajapati S, Taylor J, Teng T, Wang J, Warmuth M, Yao H, Yu L, Zhu P, Abdel-Wahab O, Smith PG, Buonamici S. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018 May.24(4):497-504. Pubmedid: [29457796](https://www.ncbi.nlm.nih.gov/pubmed/29457796). Pmcid: PMC6730556. 
    * Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018 Mar.97(3):435-441. Pubmedid: [29189896](https://www.ncbi.nlm.nih.gov/pubmed/29189896). 
    * Hussaini MO, Mirza AS, Komrokji R, Lancet J, Padron E, Song J. Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience. Cancer Genomics Proteomics. 2018 Mar.15(2):121-126. Pubmedid: [29496691](https://www.ncbi.nlm.nih.gov/pubmed/29496691). Pmcid: PMC5892606. 
    * Duong VH, Padron E, Al Ali NH, Lancet JE, Hall J, Kwok B, Zhang L, Epling-Burnette PK, List AF, Komrokji RS. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes. Ann Hematol. 2018 Feb.97(2):247-254. Pubmedid: [29167940](https://www.ncbi.nlm.nih.gov/pubmed/29167940). 
    * Zhang Q, Ball MC, Zhao Y, Balasis M, Letson C, Vedder A, List AF, Epling-Burnette PK, Komrokji RS, Padron E. Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia. Leukemia. 2018 Feb.32(2):532-538. Pubmedid: [28694526](https://www.ncbi.nlm.nih.gov/pubmed/28694526). Pmcid: PMC7771351. 
    * Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2018 Dec.16(12):1500-1537. Pubmedid: [30545997](https://www.ncbi.nlm.nih.gov/pubmed/30545997). 
    * Coombs CC, Gillis NK, Tan X, Berg JS, Ball MC, Balasis ME, Montgomery ND, Bolton K, Parker JS, Mesa TE, Yoder SJ, Hayward MC, Patel NM, Richards KL, Walko CM, Knepper TC, Soper JT, Weiss J, Grilley-Olson JE, Kim WY, Earp S, Levine R, Papaemmanuil E, Zehir A, Hayes DN, Padron E. Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays. Clin Cancer Res. 2018 Dec.24(23):5918-5924. Pubmedid: [29866652](https://www.ncbi.nlm.nih.gov/pubmed/29866652). Pmcid: PMC6812550. 
    * Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Canc Ne. 2017 Oct.15(10):1193-1207. Pubmedid: [28982745](https://www.ncbi.nlm.nih.gov/pubmed/28982745). 
    * Gillis NK, Padron E. Chipping in on clonal hematopoiesis. Oncotarget. 2017 Oct.8(49):84637-84638. Pubmedid: [29156670](https://www.ncbi.nlm.nih.gov/pubmed/29156670). Pmcid: PMC5689560. 
    * Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A, Anasetti C, Padron E. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Nov.17(11):753-758. Pubmedid: [28687222](https://www.ncbi.nlm.nih.gov/pubmed/28687222). Pmcid: PMC5675815. 
    * Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. Am J Hematol. 2017 Mar.92(3):232-237. Pubmedid: [28006850](https://www.ncbi.nlm.nih.gov/pubmed/28006850). 
    * Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji R, Moscinski L, Padron E. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood. 2017 Mar.129(13):1881-1883. Pubmedid: [28159734](https://www.ncbi.nlm.nih.gov/pubmed/28159734). 
    * Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia. 2017 Jun.31(6):1391-1397. Pubmedid: [28111463](https://www.ncbi.nlm.nih.gov/pubmed/28111463). 
    * Yoshimi A, Balasis ME, Vedder A, Feldman K, Ma Y, Zhang H, Lee SC, Letson C, Niyongere S, Lu SX, Ball M, Taylor J, Zhang Q, Zhao Y, Youssef S, Chung YR, Zhang XJ, Durham BH, Yang W, List AF, Loh ML, Klimek V, Berger MF, Stieglitz E, Padron E, Abdel-Wahab O. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood. 2017 Jul.130(4):397-407. Pubmedid: [28576879](https://www.ncbi.nlm.nih.gov/pubmed/28576879). Pmcid: PMC5533204. 
    * Nassereddine S, Nishihori T, Padron E, Mahfouz R, Bazarbachi A, Komrokji RS, Kharfan-Dabaja MA. Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2017 Jan.17(1):7-13. Pubmedid: [27771290](https://www.ncbi.nlm.nih.gov/pubmed/27771290). 
    * Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017 Jan.18(1):112-121. Pubmedid: [27927582](https://www.ncbi.nlm.nih.gov/pubmed/27927582). Pmcid: PMC7771361. 
    * Zhang J, Kong G, Rajagopalan A, Lu L, Song J, Hussaini M, Zhang X, Ranheim EA, Liu Y, Wang J, Gao X, Chang YI, Johnson K, Zhou Y, Yang D, Bhatnagar B, Lucas DM, Bresnick E, Zhong X, Padron E, Zhang J. p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia. Blood. 2017 Jan.129(3):358-370. Pubmedid: [27815262](https://www.ncbi.nlm.nih.gov/pubmed/27815262). Pmcid: PMC5248933. 
    * Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. Oncologist. 2017 Feb.22(2):144-151. Pubmedid: [28179575](https://www.ncbi.nlm.nih.gov/pubmed/28179575). Pmcid: PMC5330702. 
    * Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. Clin Lymphoma Myeloma Leuk. 2017 Dec.17(12):e45-e53. Pubmedid: [28869184](https://www.ncbi.nlm.nih.gov/pubmed/28869184). 
    * Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec.17(12):902-907. Pubmedid: [29030092](https://www.ncbi.nlm.nih.gov/pubmed/29030092). 
    * Apuri S, Al Ali N, Padron E, Lancet JE, List AF, Komrokji RS. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Apr.17(4):211-214. Pubmedid: [28185797](https://www.ncbi.nlm.nih.gov/pubmed/28185797). 
    * Sallman DA, Komrokji R, Cluzeau T, Vaupel C, Al Ali NH, Lancet J, Hall J, List A, Padron E, Song J. ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS. Blood Cancer J. 2017 11.7(12):633. Pubmedid: [29176559](https://www.ncbi.nlm.nih.gov/pubmed/29176559). Pmcid: PMC5802523. 
    * Sallman DA, Padron E. Myelodysplasia in younger adults: outlier or unique molecular entity?. Haematologica. 2017 06.102(6):967-968. Pubmedid: [28566339](https://www.ncbi.nlm.nih.gov/pubmed/28566339). Pmcid: PMC5451326. 
    * Sallman DA, Komrokji R, List A, Padron E. Reply to Goel et al. 'TP53 mutation allele-burden and disease outcome in MDS/AML'. Leukemia. 2017 03.31(3):767-768. Pubmedid: [27740632](https://www.ncbi.nlm.nih.gov/pubmed/27740632). 
    * Sallman DA, Padron E. Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. Hematol Oncol Stem Cell Ther. 2016 Sep.9(3):89-95. Pubmedid: [27187622](https://www.ncbi.nlm.nih.gov/pubmed/27187622). 
    * Clara JA, Sallman DA, Padron E. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Cancer Biol Med. 2016 Sep.13(3):360-372. Pubmedid: [27807503](https://www.ncbi.nlm.nih.gov/pubmed/27807503). Pmcid: PMC5069836. 
    * Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, Levine RL, Rampal RK, Rapaport F. Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. 2016 Nov.101(11):e457-e460. Pubmedid: [27418649](https://www.ncbi.nlm.nih.gov/pubmed/27418649). Pmcid: PMC5394875. 
    * Ball M, List AF, Padron E. When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia. Blood. 2016 Nov.128(20):2381-2387. Pubmedid: [27707735](https://www.ncbi.nlm.nih.gov/pubmed/27707735). 
    * Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016 May.91(5):E280-E283. Pubmedid: [26875020](https://www.ncbi.nlm.nih.gov/pubmed/26875020). 
    * Suleiman Y, Dalia S, Liu JJ, Bowers JW, Padron E, Lancet JE, Fulp W, Moscinski LC, Komrokji RS, Zuckerman KS, Zhang L. Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia. Leuk Res. 2016 Mar.42:52-58. Pubmedid: [26894965](https://www.ncbi.nlm.nih.gov/pubmed/26894965). 
    * Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016 Mar.30(3):666-673. Pubmedid: [26514544](https://www.ncbi.nlm.nih.gov/pubmed/26514544). Pmcid: PMC7864381. 
    * Rollison DE, Shain KH, Lee JH, Hampras SS, Fulp W, Fisher K, Al Ali NH, Padron E, Lancet J, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Dalton W, List A, Komrokji RS. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. Cancer Med. 2016 Jul.5(7):1694-1701. Pubmedid: [27098006](https://www.ncbi.nlm.nih.gov/pubmed/27098006). Pmcid: PMC4944897. 
    * Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M, Chautard E, Auboeuf D, Fenaux P, Braun T, Itzykson R, de Botton S, Quesnel B, Commes T, Jourdan E, Vainchenker W, Bernard O, Pata-Merci N, Solier S, Gayevskiy V, Dinger ME, Cowley MJ, Selimoglu-Buet D, Meyer V, Artiguenave F, Deleuze JF, Preudhomme C, Stratton MR, Alexandrov LB, Padron E, Ogawa S, Koscielny S, Figueroa M, Solary E. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016 Feb.7:10767. Pubmedid: [26908133](https://www.ncbi.nlm.nih.gov/pubmed/26908133). Pmcid: PMC4770084. 
    * Talati C, Padron E. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T. Curr Hematol Malig Rep. 2016 Dec.11(6):425-433. Pubmedid: [27664113](https://www.ncbi.nlm.nih.gov/pubmed/27664113). 
    * Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2016 Dec.14(12):1572-1611. Pubmedid: [27956542](https://www.ncbi.nlm.nih.gov/pubmed/27956542). 
    * Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016 Dec.128(25):2960-2975. Pubmedid: [27737891](https://www.ncbi.nlm.nih.gov/pubmed/27737891). Pmcid: PMC5179338. 
    * McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2016 Aug.101(8):e320-e323. Pubmedid: [27081179](https://www.ncbi.nlm.nih.gov/pubmed/27081179). Pmcid: PMC4967580. 
    * Ramadan H, Duong VH, Al Ali N, Padron E, Zhang L, Lancet JE, List AF, Komrokji RS. Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S64-S66. Pubmedid: [27521328](https://www.ncbi.nlm.nih.gov/pubmed/27521328). 
    * Grabska J, Shah B, Reed D, Al Ali N, Padron E, Ramadan H, Lancet J, List A, Komrokji R. Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S53-S56. Pubmedid: [27521325](https://www.ncbi.nlm.nih.gov/pubmed/27521325). 
    * Haider M, Al Ali N, Padron E, Epling-Burnette P, Lancet J, List A, Komrokji R. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S44-S48. Pubmedid: [27521323](https://www.ncbi.nlm.nih.gov/pubmed/27521323). 
    * Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, Ma Y, Balasis ME, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GJ, Lancet JE, List AF, Sekeres MA, Komrokji RS. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clin Cancer Res. 2016 Aug.22(15):3746-3754. Pubmedid: [26858309](https://www.ncbi.nlm.nih.gov/pubmed/26858309). Pmcid: PMC5278764. 
    * Bell GC, Padron E. Detection of a PDGFRB fusion in refractory CMML without eosinophilia: A case for broad spectrum tumor profiling. Leuk Res Rep. 2015 Sep.4(2):70-71. Pubmedid: [26716078](https://www.ncbi.nlm.nih.gov/pubmed/26716078). Pmcid: PMC4672079. 
    * Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, Mufti G, Solary E, List AF. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica. 2015 Sep.100(9):1117-1130. Pubmedid: [26341525](https://www.ncbi.nlm.nih.gov/pubmed/26341525). Pmcid: PMC4800699. 
    * Zeidan AM, Al Ali NH, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Clin Lymphoma Myeloma Leuk. 2015 Nov.15(11):705-710. Pubmedid: [26440749](https://www.ncbi.nlm.nih.gov/pubmed/26440749). 
    * Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?. Am J Hematol. 2015 Nov.90(11):1036-1040. Pubmedid: [26284571](https://www.ncbi.nlm.nih.gov/pubmed/26284571). 
    * Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar.121(6):876-882. Pubmedid: [25410759](https://www.ncbi.nlm.nih.gov/pubmed/25410759). Pmcid: PMC4378905. 
    * Padron E, Steensma DP. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies. Curr Opin Hematol. 2015 Mar.22(2):163-170. Pubmedid: [25575034](https://www.ncbi.nlm.nih.gov/pubmed/25575034). 
    * Zeidan AM, Gore SD, Padron E, Komrokji RS. Current state of prognostication and risk stratification in myelodysplastic syndromes. Curr Opin Hematol. 2015 Mar.22(2):146-154. Pubmedid: [25575032](https://www.ncbi.nlm.nih.gov/pubmed/25575032). 
    * Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, Maciejewski J, Fenaux P, Garcia-Manero G, Gerds A, Sanz G, Niemeyer CM, Cervantes F, Germing U, Cross NC, List AF. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015 Mar.125(12):1857-1865. Pubmedid: [25624319](https://www.ncbi.nlm.nih.gov/pubmed/25624319). Pmcid: PMC4915792. 
    * Komrokji R, Ramadan H, Al Ali N, Corrales-Yepez M, Zhang L, Padron E, Lancet J, List A. Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2015 Jun.15 Suppl:S60-S63. Pubmedid: [26297280](https://www.ncbi.nlm.nih.gov/pubmed/26297280). 
    * Chavez JC, Dalia S, Sandoval-Sus J, Kharfan-Dabaja MA, Al-Ali N, Komrokji R, Padron E, Corrales-Yepez G, Rock-Klotz J, Pinilla-Ibarz J. Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience. Clin Lymphoma Myeloma Leuk. 2015 Jun.15 Suppl:S14-S18. Pubmedid: [26297266](https://www.ncbi.nlm.nih.gov/pubmed/26297266). 
    * Sallman DA, Padron E. Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization. Clin Lymphoma Myeloma Leuk. 2015 Jun.15 Suppl:S50-S55. Pubmedid: [26297278](https://www.ncbi.nlm.nih.gov/pubmed/26297278). 
    * Mishra A, Rollison DE, Brandon TH, Al Ali NH, Corrales-Yepez M, Padron E, Epling-Burnette PK, Lancet JE, List AF, Komrokji RS. Impact of tobacco usage on disease outcome in myelodysplastic syndromes. Leuk Res. 2015 Jul.39(7):673-678. Pubmedid: [25934048](https://www.ncbi.nlm.nih.gov/pubmed/25934048). Pmcid: PMC5992898. 
    * Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015 Jul.5:e333. Pubmedid: [26230957](https://www.ncbi.nlm.nih.gov/pubmed/26230957). Pmcid: PMC4526779. 
    * Zhang L, Padron E, Lancet J. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes. Leuk Res. 2015 Jan.39(1):6-17. Pubmedid: [25465125](https://www.ncbi.nlm.nih.gov/pubmed/25465125). 
    * Patnaik MM, Wassie EA, Padron E, Onida F, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Ketterling RP, Komrokji R, Tefferi A, Solary E. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J. 2015 Jan.5:e270. Pubmedid: [25555161](https://www.ncbi.nlm.nih.gov/pubmed/25555161). Pmcid: PMC5404217. 
    * Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS. Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better?. Am J Hematol. 2015 Aug. Pubmedid: [26260295](https://www.ncbi.nlm.nih.gov/pubmed/26260295). Pmcid: PMC4751065. 
    * Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, Lancet JE, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol. 2015 Apr.133(2):249-256. Pubmedid: [25413011](https://www.ncbi.nlm.nih.gov/pubmed/25413011). 
    * Padron E. Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?. Hematology Am Soc Hematol Educ Program. 2015.2015:349-354. Pubmedid: [26637742](https://www.ncbi.nlm.nih.gov/pubmed/26637742). 
    * Padron E, Komrokji R, List AF. The clinical management of chronic myelomonocytic leukemia. Clin Adv Hematol Oncol. 2014 Mar.12(3):172-178. Pubmedid: [24927265](https://www.ncbi.nlm.nih.gov/pubmed/24927265). 
    * Padron E, Yoder S, Kunigal S, Mesa T, Teer JK, Al Ali N, Sekeres MA, Painter JS, Zhang L, Lancet J, Maciejewski JP, Epling-Burnette PK, Sotomayor E, Komrokji RS, List AF. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood. 2014 Jun.123(23):3675-3677. Pubmedid: [24904105](https://www.ncbi.nlm.nih.gov/pubmed/24904105). Pmcid: PMC4047502. 
    * McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, Heaton R, Ozawa Y, Wei S, Sokol L, List AF. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. PLoS One. 2014 Dec.9(12):e114249. Pubmedid: [25469886](https://www.ncbi.nlm.nih.gov/pubmed/25469886). Pmcid: PMC4254997. 
    * Komrokji RS, Padron E, Yu D, Fulp WJ, Rodriguez Y, Tinsley S, List AF, Lancet JE. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am J Hematol. 2014 Aug.89(8):809-812. Pubmedid: [24764152](https://www.ncbi.nlm.nih.gov/pubmed/24764152). Pmcid: PMC4561860. 
    * Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014 Apr.38(4):443-446. Pubmedid: [24439565](https://www.ncbi.nlm.nih.gov/pubmed/24439565). 
    * Komrokji RS, Padron E, Lancet JE, List AF. Prognostic factors and risk models in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013 Sep.13 Suppl 2:S295-S299. Pubmedid: [24290214](https://www.ncbi.nlm.nih.gov/pubmed/24290214). 
    * Duong VH, Padron E, List AF, Komrokji RS. Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?. Expert Rev Hematol. 2013 Oct.6(5):485-487. Pubmedid: [24083503](https://www.ncbi.nlm.nih.gov/pubmed/24083503). 
    * Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013 Jun.121(25):5068-5077. Pubmedid: [23632888](https://www.ncbi.nlm.nih.gov/pubmed/23632888). Pmcid: PMC4347259. 
    * Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol. 2013 Jul.88(7):566-570. Pubmedid: [23605934](https://www.ncbi.nlm.nih.gov/pubmed/23605934). Pmcid: PMC4685468. 
    * Padron E, Abdel-Wahab O. Importance of genetics in the clinical management of chronic myelomonocytic leukemia. J Clin Oncol. 2013 Jul.31(19):2374-2376. Pubmedid: [23690427](https://www.ncbi.nlm.nih.gov/pubmed/23690427). 
    * Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Al-kali A, Pardanani A, Ali NA, Komrokji RS, Komroji RS, Tefferi A. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013 Jul.27(7):1504-1510. Pubmedid: [23531518](https://www.ncbi.nlm.nih.gov/pubmed/23531518). 
    * Komrokji RS, Padron E, Ebert BL, List AF. Deletion 5q MDS: molecular and therapeutic implications. Best Pract Res Clin Haematol. 2013 Dec.26(4):365-375. Pubmedid: [24507813](https://www.ncbi.nlm.nih.gov/pubmed/24507813). 
    * Komrokji RS, Verstovsek S, Padron E, List AF. Advances in the management of myelofibrosis. Cancer Control. 2012 Oct.19(4 Suppl):4-15. Pubmedid: [23042420](https://www.ncbi.nlm.nih.gov/pubmed/23042420). 
    * Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012 Nov.87(11):1006-1009. Pubmedid: [23090887](https://www.ncbi.nlm.nih.gov/pubmed/23090887). 
    * Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 2012 May.118(10):2659-2664. Pubmedid: [21956402](https://www.ncbi.nlm.nih.gov/pubmed/21956402). 
    * Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012 Mar.2(3):e63. Pubmedid: [22829258](https://www.ncbi.nlm.nih.gov/pubmed/22829258). Pmcid: PMC3317526. 
    * Padron E, Fernandez H. Anthracycline dose intensification in young adults with acute myeloid leukemia. Ther Adv Hematol. 2012 Feb.3(1):17-27. Pubmedid: [23556109](https://www.ncbi.nlm.nih.gov/pubmed/23556109). Pmcid: PMC3573430. 
    * Padron E, Hazlehurst LE, Pinilla-Ibarz J. Molecular Pathogenesis of BCR-ABL in CML. Adv Malig Hematol. 2011 Mar.(62):71. 
    * Padron E, Komrokji R, List AF. Biology and treatment of the 5q- syndrome. Expert Rev Hematol. 2011 Feb.4(1):61-69. Pubmedid: [21322779](https://www.ncbi.nlm.nih.gov/pubmed/21322779). 
    * Padron E, Komrokji R, List AF. The 5q- syndrome: biology and treatment. CURR TREAT OPTION ON. 2011 Dec.12(4):354-368. Pubmedid: [21964863](https://www.ncbi.nlm.nih.gov/pubmed/21964863). 
    * Lane MD, Nam HJ, Padron E, Gurda-Whitaker B, Kohlbrenner E, Aslanidi G, Byrne B, McKenna R, Muzyczka N, Zolotukhin S, Agbandje-McKenna M. Production, purification, crystallization and preliminary X-ray analysis of adeno-associated virus serotype 8. Acta Crytstallogr F. 2005 Jun.61(Pt 6):558-561. Pubmedid: [16511095](https://www.ncbi.nlm.nih.gov/pubmed/16511095). Pmcid: PMC1952340. 
    * Kaludov N, Padron E, Govindasamy L, McKenna R, Chiorini JA, Agbandje-McKenna M. Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 4. Virology. 2003 Feb.306(1):1-6. Pubmedid: [12620791](https://www.ncbi.nlm.nih.gov/pubmed/12620791). 
  * ## Grants
    * Title: Advancing the Therapeutic Landscape for Chronic Myelomonocytic Leukemia (CMML)  
Award Number:   
Sponsor: Blood Cancer United  
Padron, E. (PD/PI)
    * Title: CLL-1 CAR-T cells and trametinib for the treatment of Ras-mutated CMML and JMML  
Award Number: 8047-24  
Sponsor: Blood Cancer United  
Padron, E. (PD/PI)
    * Title: Developing and Credentialing Patient-derived Xenograft Models to Advance Therapeutic Approaches for Chronic Myelomonocytic Leukemia  
Award Number: 5R37CA234021  
Sponsor: National Cancer Institute (NCI)  
Padron, E. (PD/PI)
    * Title: The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia.  
Award Number: 1R01CA278300-03  
Sponsor: National Cancer Institute (NCI)  
Padron, E. (PD/PI)
    * Title: Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia  
Award Number: 4R37CA234021-07  
Sponsor: National Cancer Institute (NCI)  
Padron, E. (PD/PI)
    * Title: The National Myelodysplastic Syndromes Natural History Study (The National MDS Study)  
Award Number: HHSN2682014000031/P00008  
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)  
Johnson, N. (PD/PI), Padron, E. (PD/PI)


## Find a Researcher Search
Program Select Cancer Biology and Evolution Program Cancer Epidemiology Program Molecular Medicine Program Health Outcomes & Behavior Program Immuno-Oncology Non-Programmatically Aligned
Department Select BioEngineering Biostatistics and Bioinformatics Cancer Epidemiology Metabolism and Physiology Drug Discovery Health Outcomes & Behavior Immunology Integrated Mathematical Oncology Machine Learning Molecular Oncology Tumor Microenvironment and Metastasis
Center of Excellence Select Center for Infection Research in Cancer DeBartolo Family Personalized Medicine Institute Evolutionary Therapy Lung Cancer Center of Excellence Melanoma Research Center of Excellence
Work Group Select Cancer Chemoprevention Research Interest Group Myeloma Systems Medicine Working Group Tobacco Research & Intervention Program
Keyword
Search
[ ![Moffitt Cancer Center](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-full-white.svg) ](https://www.moffitt.org/ "Logo for Moffitt Cancer Center") [ ![](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-mobile-white.svg) ](https://www.moffitt.org/ "Logo for Moffitt Cancer Center")
Our Mission
To contribute to the prevention and cure of cancer.
[Connect with a Cancer Expert](https://www.moffitt.org/eforms/patientregistrationform/)
[ ![Designated Comprehensive Cancer Center](https://www.moffitt.org/globalassets/images/logos/nci.png) ](https://www.moffitt.org/about-moffitt/nci-designation/?source=footer "Designated Comprehensive Cancer Center") [ ![Florida Health Cancer Center of Excellence](https://www.moffitt.org/globalassets/global-blocks/navigation/footer/moffitt-cancer-center-of-excellence-2.png) ](https://www.floridahealth.gov/provider-and-partner-resources/research/cancer-center-of-excellence-award.html "Florida Health Cancer Center of Excellence") [ ![Magnet Recognized](https://www.moffitt.org/globalassets/images/logos/magnet.png) ](https://www.moffitt.org/about-moffitt/medical/nursing/?source=footer "Magnet Recognized") [ ![National Comprehensive Cancer Network](https://www.moffitt.org/globalassets/global-blocks/navigation/footer/nccn.png) ](https://www.nccn.org/patients/ "National Comprehensive Cancer Network")
Careers
    * [Careers at Moffitt](https://www.moffitt.org/careers/)
    * [Search Jobs](https://moffitt-cancer-center-careers.hctsportals.com/)
    * [Training & Education](https://www.moffitt.org/education/)


Emerging Cancer Therapies
    * [CAR T Therapy](https://www.moffitt.org/treatments/immunotherapy/car-t-therapy/)
    * [Immunotherapy](https://www.moffitt.org/treatments/immunotherapy/)
    * [TIL Therapy](https://www.moffitt.org/treatments/immunotherapy/til-therapy/)


Cancers & Treatments
    * [Cancers We Treat](https://www.moffitt.org/cancers/)
    * [Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/)
    * [Diagnostic Services](https://www.moffitt.org/diagnostic-services/)
    * [Treatments We Offer](https://www.moffitt.org/treatments/)


Get Involved
    * [Donate](https://fundraise.moffitt.org/give/563959/#!/donation/checkout)
    * [Volunteer](https://www.moffitt.org/give/get-involved/volunteer-your-time/)
    * [Ways to Give](https://www.moffitt.org/give/ways-to-give/)


Cancer Screening
    * [Head and Neck Cancer Screening](https://www.moffitt.org/diagnostic-services/cancer-screenings/head-and-neck-cancer-screening/)
    * [Lung CT Screening](https://www.moffitt.org/cancers/lung-cancer/lung-cancer-screening-and-surveillance-program/)
    * [Mammogram](https://www.moffitt.org/cancers/breast-cancer/diagnosis/screening/mammogram/)
    * [Skin Cancer Mole Patrol](https://www.moffitt.org/diagnostic-services/cancer-screenings/mole-patrol/)


Patients & Family
    * [Appointments](https://www.moffitt.org/eforms/patientregistrationform/)
    * [Find a Doctor](https://www.moffitt.org/find-a-doctor/)
    * [Insurance & Financial Info](https://www.moffitt.org/patient-family/insurance-financial-information/)
    * [Moffitt Blog for Patients](https://www.moffitt.org/taking-care-of-your-health/)
    * [Patient & Family Resources](https://www.moffitt.org/patient-family/)


About Moffitt
    * [About](https://www.moffitt.org/about-moffitt/)
    * [Community Benefit](https://www.moffitt.org/publications/community-benefit/)
    * [Patient Outcomes](https://www.moffitt.org/about-moffitt/outcomes/)
    * [Research](https://www.moffitt.org/research-science/)


Industry Partnerships
    * [Available Emerging Technologies](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/available-technologies/)
    * [Business of Biotech](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/business-of-biotech/)
    * [Cell Therapy Facility](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/cell-therapy-gene-engineering/)
    * [Office of Innovation](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/)


Resources
    * [Calendar of Events](https://www.moffitt.org/calendar/)
    * [Endeavor](https://www.moffitt.org/endeavor/)
    * [Newsroom](https://www.moffitt.org/newsroom/)
    * [Partnerships](https://www.moffitt.org/about-moffitt/strategic-alliances-and-partnerships/)
    * [Publications](https://www.moffitt.org/publications/)


Call Today
[1-888-663-3488](tel:1-888-663-3488 "Call Today")
[ ](https://www.facebook.com/MoffittCancerCenter "Facebook") [ ](https://twitter.com/MoffittNews "Twitter") [ ](https://www.instagram.com/moffittcancercenter/ "Instagram") [ ](https://www.youtube.com/user/MoffittNews "YouTube")
[ Getting Here ](https://www.moffitt.org/locations-directions/) [ Patient Portal ](https://my.moffitt.org/?source=footer&_ga=2.263078223.2128654650.1660063894-1522311918.1659049215) [ Refer a Patient ](https://www.moffitt.org/eforms/referapatient/) [ Provider Portal ](https://rpp.moffitt.org/) [ Staff Login ](https://hlmconnect.moffitt.org/dana-na/auth/url_default/welcome.cgi?source=footer&_ga=2.192849257.2128654650.1660063894-1522311918.1659049215)
  * [Privacy Policy](https://www.moffitt.org/legal-statements-and-policies/privacy-policy/)
  * [Terms & Conditions](https://www.moffitt.org/terms-conditions/ "Terms & Condition")
  * [Unsubscribe](https://www.moffitt.org/eforms/unsubscribe/ "Unsubscribe")
  * [State Nonprofit Disclosures](https://www.moffitt.org/globalassets/pdfs/footer/state-registration-for-web.pdf "State Nonprofit Disclosures")
  * [Donor Privacy](https://www.moffitt.org/give/donor-privacy/ "Donor Privacy")
  * [Notice of Privacy Practices](https://www.moffitt.org/legal-statements-and-policies/notice-of-privacy-practices/ "Notice of Privacy Practices")
  * [Visitor Policy](https://www.moffitt.org/globalassets/pdfs/patient--family/preparing-for-your-appointment/visitation-and-family-presence-policy.pdf "Visitor Policy")
  * [Moffitt Masking Policy](https://www.moffitt.org/globalassets/pdfs/footer/ic-085-moffitt-masking-policy.pdf)
  * [Price Transparency](https://eforms.moffitt.org/Moffittcancercenter_standardcharges/593238634_H.-Lee-Moffitt-Cancer-Center-and-Research-Institute-Hospital,-Inc._standardcharges.json)
  * [Sitemap](https://www.moffitt.org/sitemap.xml)


©Copyright 2025 Moffitt Cancer Center
Discover More
  * [Individualized Cancer Treatment in Florida](https://moffitt.org/patient-family/)
  * [Cancer Second Opinion Appointment in Florida](https://moffitt.org/diagnostic-services/second-opinion/)
  * [Cancer Healthcare Professionals in Florida](https://moffitt.org/for-healthcare-professionals/)


### Cambiar el idioma
Si no encuentra la información que busca o si desea programar una cita, llámenos gratis al [1-888-663-3488](tel:1-888-663-3488).
Gracias.
[Cancel | Cancelar](https://www.moffitt.org/research-science/researchers/eric-padron) [OK](https://www.moffitt.org/research-science/researchers/eric-padron)
[ ![Moffitt Cancer Center](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-full-white.svg) ](https://www.moffitt.org/ "Moffitt Cancer Center")
Search
Menu
  * [Cancer Types & Treatments](https://www.moffitt.org/research-science/researchers/eric-padron) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-3)
  * [Patients & Families](https://www.moffitt.org/research-science/researchers/eric-padron) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)
  * [For Healthcare Professionals](https://www.moffitt.org/research-science/researchers/eric-padron) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-31)
  * [Research](https://www.moffitt.org/research-science/researchers/eric-padron) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-37)
  * [Training & Education](https://www.moffitt.org/research-science/researchers/eric-padron) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-53)
  * [Give](https://www.moffitt.org/research-science/researchers/eric-padron) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-63)


Schedule
[New Patients](https://www.moffitt.org/eforms/patientregistrationform/ "New Patients") [Referring Physicians](https://www.moffitt.org/eforms/referapatient/ "Referring Physicians")
[ Find a Doctor ](https://www.moffitt.org/find-a-doctor/ "Find a Doctor")
Patient Portal
[Log In](https://mymoffitt.iqhealth.com/ "Log In") [Enroll](https://mymoffitt.iqhealth.com/self-enroll/)
[ Careers ](https://www.moffitt.org/careers/ "Careers")
[ Locations ](https://www.moffitt.org/locations-directions/ "Locations")
[ 1-888-663-3488 ](tel:1-888-663-3488 "Call 1-888-663-3488")
English
[English](https://www.moffitt.org/research-science/researchers/eric-padron/ "English") [Spanish](https://www.moffitt.org/es/research-science/researchers/eric-padron/ "Spanish")
[ ](https://www.moffitt.org/research-science/researchers/?campaign=567103 "Donate")
[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-1)[Cancer Types & Treatments](https://www.moffitt.org/research-science/researchers/eric-padron#mm-1)
  * [ Cancers ](https://www.moffitt.org/cancers/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-5)
  * [ Treatments ](https://www.moffitt.org/treatments/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-7)
  * [ Clinical Trials ](https://www.moffitt.org/clinical-trials-research/clinical-trials/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-9)
  * [ Diagnostic Services ](https://www.moffitt.org/diagnostic-services/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-11)


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-3)[Cancers](https://www.moffitt.org/research-science/researchers/eric-padron#mm-3)
  * [Acute Lymphocytic Leukemia (ALL)](https://www.moffitt.org/cancers/acute-lymphocytic-leukemia-all/ "Acute Lymphocytic Leukemia \(ALL\)")
  * [Acute Myelogenous Leukemia (AML)](https://www.moffitt.org/cancers/acute-myelogenous-leukemia/ "Acute Myelogenous Leukemia \(AML\)")
  * [Acute Promyelocytic Leukemia (APL)](https://www.moffitt.org/cancers/acute-promyelocytic-leukemia-apl/ "Acute Promyelocytic Leukemia \(APL\)")
  * [Adrenal Cancer](https://www.moffitt.org/cancers/adrenal-cancer/ "Adrenal Cancer")
  * [Anal Cancer](https://www.moffitt.org/cancers/anal-cancer/ "Anal Cancer")
  * [Appendiceal (Appendix) Cancer](https://www.moffitt.org/cancers/appendiceal-appendix-cancer/ "Appendiceal \(Appendix\) Cancer")
  * [Astrocytoma](https://www.moffitt.org/cancers/astrocytoma/ "Astrocytoma")
  * [Basal Cell Carcinoma](https://www.moffitt.org/cancers/basal-cell-carcinoma/ "Basal Cell Carcinoma")
  * [Bladder Cancer](https://www.moffitt.org/cancers/bladder-cancer/ "Bladder Cancer")
  * [Bone Metastasis](https://www.moffitt.org/cancers/bone-metastasis/ "Bone Metastasis")
  * [Brain Cancer](https://www.moffitt.org/cancers/brain-cancer/ "Brain Cancer")
  * [Brain Tumor](https://www.moffitt.org/cancers/brain-tumor/ "Brain Tumor")
  * [Brain Metastases](https://www.moffitt.org/cancers/brain-metastases/ "Brain Metastases")
  * [Breast Cancer](https://www.moffitt.org/cancers/breast-cancer/ "Breast Cancer")
  * [Cervical Cancer](https://www.moffitt.org/cancers/cervical-cancer/ "Cervical Cancer")
  * [Cholangiocarcinoma (Bile Duct Cancer)](https://www.moffitt.org/cancers/cholangiocarcinoma-bile-duct-cancer/ "Cholangiocarcinoma \(Bile Duct Cancer\)")
  * [Chronic Lymphocytic Leukemia (CLL)](https://www.moffitt.org/cancers/chronic-lymphocytic-leukemia/ "Chronic Lymphocytic Leukemia \(CLL\)")
  * [Colon Cancer](https://www.moffitt.org/cancers/colon-cancer/ "Colon Cancer")
  * [Colorectal Cancer](https://www.moffitt.org/cancers/colorectal-cancer/ "Colorectal Cancer")
  * [Chronic Myelogenous Leukemia (CML)](https://www.moffitt.org/cancers/chronic-myelogenous-leukemia-cml/ "Chronic Myelogenous Leukemia \(CML\)")
  * [Cutaneous Lymphoma (CTCL)](https://www.moffitt.org/cancers/cutaneous-t-cell-lymphoma/ "Cutaneous Lymphoma \(CTCL\)")
  * [Diffuse Large B-Cell Lymphoma](https://www.moffitt.org/cancers/diffuse-large-b-cell-lymphoma/ "Diffuse Large B-Cell Lymphoma")
  * [Ductal Carcinoma In Situ](https://www.moffitt.org/cancers/ductal-carcinoma-in-situ/ "Ductal Carcinoma In Situ")
  * [Endometrial (Uterine) Cancer](https://www.moffitt.org/cancers/endometrial-uterine-cancer/ "Endometrial \(Uterine\) Cancer")
  * [Esophageal Cancer](https://www.moffitt.org/cancers/esophageal-cancer/ "Esophageal Cancer")
  * [Follicular Lymphoma](https://www.moffitt.org/cancers/follicular-lymphoma/ "Follicular Lymphoma")
  * [Gallbladder Cancer](https://www.moffitt.org/cancers/gallbladder-cancer/ "Gallbladder Cancer")
  * [Gastrointestinal Carcinoid Tumor](https://www.moffitt.org/cancers/gastrointestinal-carcinoid-tumor/ "Gastrointestinal Carcinoid Tumor")
  * [GIST (Gastrointestinal Stromal Tumor)](https://www.moffitt.org/cancers/gist-gastrointestinal-stromal-tumor/ "GIST \(Gastrointestinal Stromal Tumor\)")
  * [Glioblastoma](https://www.moffitt.org/cancers/glioblastoma/ "Glioblastoma")
  * [Head and Neck Cancer](https://www.moffitt.org/cancers/head-and-neck-cancer/ "Head and Neck Cancer")
  * [HER2 Positive Breast Cancer](https://www.moffitt.org/cancers/her2-positive-breast-cancer/ "HER2 Positive Breast Cancer")
  * [Hodgkin Lymphoma](https://www.moffitt.org/cancers/hodgkin-lymphoma/ "Hodgkin Lymphoma")
  * [Inflammatory Breast Cancer](https://www.moffitt.org/cancers/inflammatory-breast-cancer/ "Inflammatory Breast Cancer")
  * [Invasive Ductal Carcinoma](https://www.moffitt.org/cancers/invasive-ductal-carcinoma/ "Invasive Ductal Carcinoma")
  * [Kidney (Renal Cell) Cancer](https://www.moffitt.org/cancers/kidney-renal-cell-cancer/ "Kidney \(Renal Cell\) Cancer")
  * [Leukemia](https://www.moffitt.org/cancers/leukemia/ "Leukemia")
  * [Liver (Hepatocellular) Cancer](https://www.moffitt.org/cancers/liver-hepatocellular-cancer/ "Liver \(Hepatocellular\) Cancer")
  * [Low-Grade Glioma](https://www.moffitt.org/cancers/low-grade-glioma/ "Low-Grade Glioma")
  * [Lung Cancer](https://www.moffitt.org/cancers/lung-cancer/ "Lung Cancer")
  * [Lymphomas (Hodgkin and Non-Hodgkin)](https://www.moffitt.org/cancers/lymphomas-hodgkin-and-non-hodgkin/ "Lymphomas \(Hodgkin and Non-Hodgkin\)")
  * [Mantle Cell Lymphoma](https://www.moffitt.org/cancers/mantle-cell-lymphoma/ "Mantle Cell Lymphoma")
  * [Melanoma](https://www.moffitt.org/cancers/melanoma/ "Melanoma")
  * [Meningioma](https://www.moffitt.org/cancers/meningioma/ "Meningioma")
  * [Merkel Cell Carcinoma](https://www.moffitt.org/cancers/merkel-cell-carcinoma/ "Merkel Cell Carcinoma")
  * [Mesothelioma](https://www.moffitt.org/cancers/mesothelioma/ "Mesothelioma")
  * [Metastatic Breast Cancer](https://www.moffitt.org/cancers/metastatic-breast-cancer/ "Metastatic Breast Cancer")
  * [Monoclonal Gammopathy of Undetermined Significance (MGUS)](https://www.moffitt.org/cancers/monoclonal-gammopathy-of-undetermined-significance-mgus/ "Monoclonal Gammopathy of Undetermined Significance \(MGUS\)")
  * [Multiple Myeloma-Plasma Cell Tumor](https://www.moffitt.org/cancers/multiple-myeloma-plasma-cell-tumor/ "Multiple Myeloma-Plasma Cell Tumor")
  * [Myelodysplastic Syndromes (MDS)](https://www.moffitt.org/cancers/myelodysplastic-syndromes-mds/ "Myelodysplastic Syndromes \(MDS\)")
  * [Neuroendocrine Tumor](https://www.moffitt.org/cancers/neuroendocrine-tumor/ "Neuroendocrine Tumor")
  * [Neurofibromatosis](https://www.moffitt.org/cancers/neurofibromatosis/ "Neurofibromatosis")
  * [Non-Hodgkin Lymphoma](https://www.moffitt.org/cancers/non-hodgkin-lymphoma/ "Non-Hodgkin Lymphoma")
  * [Oral Cavity (Mouth) Cancer](https://www.moffitt.org/cancers/oral-cavity-mouth-cancer/ "Oral Cavity \(Mouth\) Cancer")
  * [Insurance and Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/ "Insurance and Financial Information")
  * [Oral Cavity or Throat Cancer](https://www.moffitt.org/cancers/oral-cavity-or-throat-cancer/ "Oral Cavity or Throat Cancer")
  * [Osteosarcoma](https://www.moffitt.org/cancers/osteosarcoma/ "Osteosarcoma")
  * [Ovarian Cancer](https://www.moffitt.org/cancers/ovarian-cancer/ "Ovarian Cancer")
  * [Pancoast Tumor](https://www.moffitt.org/cancers/pancoast-tumor/ "Pancoast Tumor")
  * [Pancreatic Cancer](https://www.moffitt.org/cancers/pancreatic-cancer/ "Pancreatic Cancer")
  * [Penile Cancer](https://www.moffitt.org/cancers/penile-cancer/ "Penile Cancer")
  * [Pituitary Adenoma](https://www.moffitt.org/cancers/pituitary-adenoma/ "Pituitary Adenoma")
  * [Prostate Cancer](https://www.moffitt.org/cancers/prostate-cancer/ "Prostate Cancer")
  * [Rectal Cancer](https://www.moffitt.org/cancers/rectal-cancer/ "Rectal Cancer")
  * [Sarcoma](https://www.moffitt.org/cancers/sarcoma/ "Sarcoma")
  * [Skin Cancer (Nonmelanoma)](https://www.moffitt.org/cancers/skin-cancer-nonmelanoma/ "Skin Cancer \(Nonmelanoma\)")
  * [Skull Base Tumors](https://www.moffitt.org/cancers/skull-base-tumors/ "Skull Base Tumors")
  * [Small Intestine Cancer](https://www.moffitt.org/cancers/small-intestine-cancer/ "Small Intestine Cancer")
  * [Spinal Tumor](https://www.moffitt.org/cancers/spinal-tumor/ "Spinal Tumor")
  * [Squamous Cell Carcinoma](https://www.moffitt.org/cancers/squamous-cell-carcinoma/ "Squamous Cell Carcinoma")
  * [Smoldering Multiple Myeloma](https://www.moffitt.org/cancers/smoldering-multiple-myeloma-smm/ "Smoldering Multiple Myeloma")
  * [Stomach (Gastric) Cancer](https://www.moffitt.org/cancers/stomach-gastric-cancer/ "Stomach \(Gastric\) Cancer")
  * [Testicular Cancer](https://www.moffitt.org/cancers/testicular-cancer/ "Testicular Cancer")
  * [Throat Cancer](https://www.moffitt.org/cancers/throat-cancer/ "Throat Cancer")
  * [Thymoma](https://www.moffitt.org/cancers/thymoma/ "Thymoma")
  * [Thyroid Cancer](https://www.moffitt.org/cancers/thyroid-cancer/ "Thyroid Cancer")
  * [Tongue Cancer](https://www.moffitt.org/cancers/tongue-cancer/ "Tongue Cancer")
  * [Tracheal Cancer](https://www.moffitt.org/cancers/tracheal-cancer/ "Tracheal Cancer")
  * [Triple Negative Breast Cancer](https://www.moffitt.org/cancers/triple-negative-breast-cancer/ "Triple Negative Breast Cancer")
  * [Vaginal Cancer](https://www.moffitt.org/cancers/vaginal-cancer/ "Vaginal Cancer")
  * [Vulvar Cancer](https://www.moffitt.org/cancers/vulvar-cancer/ "Vulvar Cancer")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-3)[Treatments](https://www.moffitt.org/research-science/researchers/eric-padron#mm-3)
  * [Blood Bone Marrow Transplant](https://www.moffitt.org/treatments/blood-bone-marrow-transplant/ "Blood Bone Marrow Transplant")
  * [Bloodless Medicine and Surgery](https://www.moffitt.org/treatments/bloodless-medicine-and-surgery/ "Bloodless Medicine and Surgery")
  * [Cardio-Oncology](https://www.moffitt.org/treatments/cardio-oncology/ "Cardio-Oncology")
  * [Chemotherapy](https://www.moffitt.org/treatments/chemotherapy/ "Chemotherapy")
  * [Clinical Pathways](https://www.moffitt.org/treatments/clinical-pathways/ "Clinical Pathways")
  * [Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/ "Clinical Trials")
  * [Diagnostic Services](https://www.moffitt.org/diagnostic-services/ "Diagnostic Services")
  * [Endoscopic Procedures](https://www.moffitt.org/treatments/endoscopic-procedures/ "Endoscopic Procedures")
  * [Fertility Preservation](https://www.moffitt.org/treatments/fertility-preservation/ "Fertility Preservation")
  * [Gynecologic Oncology](https://www.moffitt.org/treatments/gynecologic-oncology/ "Gynecologic Oncology")
  * [Immunotherapy](https://www.moffitt.org/treatments/immunotherapy/ "Immunotherapy")
  * [Interventional Pain Management](https://www.moffitt.org/treatments/interventional-pain-management/ "Interventional Pain Management")
  * [Interventional Radiology](https://www.moffitt.org/treatments/interventional-radiology/ "Interventional Radiology")
  * [Precision Medicine](https://www.moffitt.org/treatments/precision-medicine/ "Precision Medicine")
  * [Pharmacy](https://www.moffitt.org/treatments/pharmacy/ "Pharmacy")
  * [Radiation Therapy](https://www.moffitt.org/treatments/radiation-therapy/ "Radiation Therapy")
  * [Rehabilitation Services](https://www.moffitt.org/treatments/rehabilitation-services/ "Rehabilitation Services")
  * [Supportive Care Medicine](https://www.moffitt.org/treatments/supportive-care-medicine/ "Supportive Care Medicine")
  * [Surgical Care](https://www.moffitt.org/treatments/surgical-care/ "Surgical Care")
  * [Systemic Therapy](https://www.moffitt.org/treatments/systemic-therapy/ "Systemic Therapy")
  * [Targeted Therapy](https://www.moffitt.org/treatments/targeted-therapy/ "Targeted Therapy")
  * [Tumor Board](https://www.moffitt.org/treatments/tumor-board/ "Tumor Board")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-3)[Clinical Trials](https://www.moffitt.org/research-science/researchers/eric-padron#mm-3)
  * [Am I A Candidate?](https://www.moffitt.org/clinical-trials-research/clinical-trials/am-i-a-candidate/ "Am I A Candidate?")
  * [Clinical Research Unit](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-research-unit/ "Clinical Research Unit")
  * [Clinical Trials Administration](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-administration/ "Clinical Trials Administration")
  * [Clinical Trials: Are They Right for You?](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-are-they-right-for-you/ "Clinical Trials: Are They Right for You?")
  * [Patient Protection](https://www.moffitt.org/clinical-trials-research/clinical-trials/patient-protection/ "Patient Protection")
  * [Phase 1 Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/phase-1-clinical-trials/ "Phase 1 Clinical Trials")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-3)[Diagnostic Services](https://www.moffitt.org/research-science/researchers/eric-padron#mm-3)
  * [Cancer Screenings](https://www.moffitt.org/diagnostic-services/cancer-screenings/ "Cancer Screenings")
  * [Genetic Counseling and Genetic Testing](https://www.moffitt.org/diagnostic-services/genetic-counseling-and-genetic-testing/ "Genetic Counseling and Genetic Testing")
  * [Labwork and Bloodwork](https://www.moffitt.org/diagnostic-services/labwork-and-bloodwork/ "Labwork and Bloodwork")
  * [Pathology](https://www.moffitt.org/diagnostic-services/pathology/ "Pathology")
  * [Radiology – Diagnostic Imaging and Interventional Radiology](https://www.moffitt.org/diagnostic-services/radiology-diagnostic-imaging-and-interventional-radiology/ "Radiology – Diagnostic Imaging and Interventional Radiology")
  * [Cancer Treatments](https://www.moffitt.org/treatments/ "Cancer Treatments")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-1)[Patients & Families](https://www.moffitt.org/research-science/researchers/eric-padron#mm-1)
  * [ Patient & Family ](https://www.moffitt.org/patient-family/)
  * [ Preparing For Your Appointment ](https://www.moffitt.org/patient-family/preparing-for-your-appointment/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-15)
  * [ Insurance & Financial Information ](https://www.moffitt.org/patient-family/insurance-financial-information/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-17)
  * [ Programs & Support Services ](https://www.moffitt.org/patient-family/programs-support-services/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-19)
  * [ Patient and Family Centered Care ](https://www.moffitt.org/patient-family/patient-and-family-centered-care/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-21)
  * [ Cancer Survivorship ](https://www.moffitt.org/patient-family/cancer-survivorship/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-23)
  * [ International Patient Services ](https://www.moffitt.org/patient-family/international-patient-services/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-25)
  * [ Moffitt Virtual Care ](https://www.moffitt.org/patient-family/moffitt-virtual-care/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-27)
  * [ Inspiring Stories ](https://www.moffitt.org/inspiring-stories/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-29)


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)[Preparing For Your Appointment](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)
  * [Patient and Family Orientation](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-and-family-orientation/ "Patient and Family Orientation")
  * [Medical Records](https://www.moffitt.org/patient-family/preparing-for-your-appointment/medical-records/ "Medical Records")
  * [Appointment Reminder Service](https://www.moffitt.org/patient-family/preparing-for-your-appointment/appointment-reminder-service/ "Appointment Reminder Service")
  * [MyMoffitt Patient Portal](https://www.moffitt.org/patient-family/preparing-for-your-appointment/mymoffitt-patient-portal/ "MyMoffitt Patient Portal")
  * [New Cancer Diagnosis](https://www.moffitt.org/patient-family/preparing-for-your-appointment/new-cancer-diagnosis/ "New Cancer Diagnosis")
  * [Online Registration Frequently Asked Questions](https://www.moffitt.org/patient-family/preparing-for-your-appointment/online-registration-frequently-asked-questions/ "Online Registration Frequently Asked Questions")
  * [Scheduling Your Appointment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/scheduling-your-appointment/ "Scheduling Your Appointment")
  * [Traveling for Cancer Treatment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/traveling-for-cancer-treatment/ "Traveling for Cancer Treatment")
  * [Preparing For Your Hospitalization](https://www.moffitt.org/patient-family/preparing-for-your-hospitalization/ "Preparing For Your Hospitalization")
  * [Preparing For Your Surgery](https://www.moffitt.org/patient-family/preparing-for-your-surgery/ "Preparing For Your Surgery")
  * [Visitor Policy](https://www.moffitt.org/patient-family/preparing-for-your-appointment/visitor-policy/ "Visitor Policy")
  * [Patient Rights and Responsibilities](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-rights-and-responsibilities/ "Patient Rights and Responsibilities")
  * [What to Know About Your Appointments During Hurricane Season](https://www.moffitt.org/patient-family/hurricane/appointments-during-hurricane-season/ "What to Know About Your Appointments During Hurricane Season")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)[Insurance & Financial Information](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)
  * [Copay Assistance Program](https://www.moffitt.org/patient-family/insurance-financial-information/copay-assistance-program/ "Copay Assistance Program")
  * [Financial Assistance](https://www.moffitt.org/patient-family/insurance-financial-information/financial-assistance/ "Financial Assistance")
  * [Glossary of Terms](https://www.moffitt.org/patient-family/insurance-financial-information/glossary-of-terms/ "Glossary of Terms")
  * [Health Exchange](https://www.moffitt.org/patient-family/insurance-financial-information/health-exchange/ "Health Exchange")
  * [Insurance Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/insurance-coverage/ "Insurance Coverage")
  * [Medicare Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/medicare-coverage/ "Medicare Coverage")
  * [Obtain a Cost Estimate](https://www.moffitt.org/patient-family/insurance-financial-information/obtain-a-cost-estimate/ "Obtain a Cost Estimate")
  * [Questions to Ask Your Insurance Company](https://www.moffitt.org/patient-family/insurance-financial-information/questions-to-ask-your-insurance-company/ "Questions to Ask Your Insurance Company")
  * [Understanding Your Bill](https://www.moffitt.org/patient-family/insurance-financial-information/understanding-your-bill/ "Understanding Your Bill")
  * [Frequently Asked Questions](https://www.moffitt.org/patient-family/insurance-financial-information/frequently-asked-questions/ "Frequently Asked Questions")
  * [Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/financial-information/ "Financial Information")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)[Programs & Support Services](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)
  * [Advance Care Planning](https://www.moffitt.org/patient-family/programs-support-services/advance-care-planning/ "Advance Care Planning")
  * [AYA: Adolescent Young Adult Program](https://www.moffitt.org/patient-family/programs-support-services/aya-adolescent-young-adult-program/ "AYA: Adolescent Young Adult Program")
  * [Chaplaincy Spiritual Care](https://www.moffitt.org/patient-family/programs-support-services/chaplaincy-spiritual-care/ "Chaplaincy Spiritual Care")
  * [Community Resources](https://www.moffitt.org/patient-family/programs-support-services/online-resources/ "Community Resources")
  * [Counseling and Support](https://www.moffitt.org/patient-family/programs-support-services/counseling-and-support/ "Counseling and Support")
  * [Language Services](https://www.moffitt.org/patient-family/programs-support-services/language-services/ "Language Services")
  * [Nutrition](https://www.moffitt.org/patient-family/programs-support-services/nutrition/ "Nutrition")
  * [Senior Adult Oncology Program](https://www.moffitt.org/patient-family/programs-support-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
  * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")
  * [Specialty Pharmacy at Moffitt](https://www.moffitt.org/patient-family/programs-support-services/specialty-pharmacy/ "Specialty Pharmacy at Moffitt")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)[Patient and Family Centered Care](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)
  * [Demonstrating Respect at Moffitt](https://www.moffitt.org/patient-family/patient-and-family-centered-care/demonstrating-respect-at-moffitt/ "Demonstrating Respect at Moffitt")
  * [Daisy and Sunflower Awards](https://www.moffitt.org/patient-family/patient-and-family-centered-care/daisy-and-sunflower-awards/ "Daisy and Sunflower Awards")
  * [Patient and Family Advisory Program](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-and-family-advisory-program/ "Patient and Family Advisory Program")
  * [Patient Relations](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-relations/ "Patient Relations")
  * [Patient Researcher Forum](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-researcher-forum/ "Patient Researcher Forum")
  * [Patti K Halula Legacy Award](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patti-k-halula-legacy-award/ "Patti K Halula Legacy Award")
  * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)[Cancer Survivorship](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)
  * [Cancer Survivorship Program](https://www.moffitt.org/patient-family/cancer-survivorship/cancer-survivorship-program/ "Cancer Survivorship Program")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)[International Patient Services](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)
  * [Frequently Asked Questions](https://www.moffitt.org/patient-family/international-patient-services/frequently-asked-questions/ "Frequently Asked Questions")
  * [Online Consult Forms](https://www.moffitt.org/patient-family/international-patient-services/online-consult-forms/ "Online Consult Forms")
  * [Online Consults](https://www.moffitt.org/patient-family/international-patient-services/online-consults/ "Online Consults")
  * [Moffitt Outreach in Puerto Rico](https://www.moffitt.org/patient-family/international-patient-services/puerto-rico/ "Moffitt Outreach in Puerto Rico")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)[Moffitt Virtual Care](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)
  * [All About Virtual Care](https://www.moffitt.org/patient-family/moffitt-virtual-care/all-about-virtual-care/ "All About Virtual Care")
  * [Informed Consent for Telemedicine](https://www.moffitt.org/patient-family/moffitt-virtual-care/informed-consent-for-telemedicine/ "Informed Consent for Telemedicine")
  * [New Cancer Patients](https://www.moffitt.org/patient-family/moffitt-virtual-care/new-cancer-patients/ "New Cancer Patients")
  * [Virtual Care Success Checklist](https://www.moffitt.org/patient-family/moffitt-virtual-care/virtual-care-success-checklist/ "Virtual Care Success Checklist")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)[Inspiring Stories](https://www.moffitt.org/research-science/researchers/eric-padron#mm-13)
  * [Isabel's Story](https://www.moffitt.org/inspiring-stories/isabels-story/ "Isabel's Story")
  * [Amanda's Story](https://www.moffitt.org/inspiring-stories/amandas-story/ "Amanda's Story")
  * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story-my-prostate-cancer-journey/ "Rick's Story")
  * [Vondalyn's Story: From Adversity to Advocacy](https://www.moffitt.org/inspiring-stories/vondalyns-story-from-adversity-to-advocacy/ "Vondalyn's Story: From Adversity to Advocacy")
  * [Cayla’s Story: Cancer Never Cares About Anything Like That](https://www.moffitt.org/inspiring-stories/caylas-story-cancer-never-cares-about-anything-like-that/ "Cayla’s Story: Cancer Never Cares About Anything Like That")
  * [Rick's Story: Now What?](https://www.moffitt.org/inspiring-stories/ricks-story-now-what/ "Rick's Story: Now What?")
  * [Amy's Story: No Longer Alone](https://www.moffitt.org/inspiring-stories/no-longer-alone/ "Amy's Story: No Longer Alone")
  * [Zoe's Story](https://www.moffitt.org/inspiring-stories/zoeys-story/ "Zoe's Story")
  * [Erma's Story](https://www.moffitt.org/inspiring-stories/ermas-story/ "Erma's Story")
  * [Donna's Story](https://www.moffitt.org/inspiring-stories/donnas-story/ "Donna's Story")
  * [Dr. Vadaparampil's Story](https://www.moffitt.org/inspiring-stories/dr.-vadaparampils-story "Dr. Vadaparampil's Story")
  * [Mark's Story](https://www.moffitt.org/inspiring-stories/marks-story/ "Mark's Story")
  * [Heather's Story](https://www.moffitt.org/inspiring-stories/heathers-story/ "Heather's Story")
  * [Ellen's Story](https://www.moffitt.org/inspiring-stories/ellens-story/ "Ellen's Story")
  * [Dr. Tran's Story](https://www.moffitt.org/inspiring-stories/dr.-trans-story "Dr. Tran's Story")
  * [Dr. Toloza's Story](https://www.moffitt.org/inspiring-stories/dr.-tolozas-story "Dr. Toloza's Story")
  * [Dr. Silva's Story](https://www.moffitt.org/inspiring-stories/dr.-silvas-story "Dr. Silva's Story")
  * [Dr. Fernandez's Story](https://www.moffitt.org/inspiring-stories/dr.-fernandezs-story "Dr. Fernandez's Story")
  * [Dr. Robinson's Story](https://www.moffitt.org/inspiring-stories/dr.-robinsons-story "Dr. Robinson's Story")
  * [Dr. Pow-Sang's Story](https://www.moffitt.org/inspiring-stories/dr.-pow-sangs-story "Dr. Pow-Sang's Story")
  * [Mike's Volunteer Story](https://www.moffitt.org/inspiring-stories/mikes-volunteer-story/ "Mike's Volunteer Story")
  * [Mike's Story](https://www.moffitt.org/inspiring-stories/mikes-story/ "Mike's Story")
  * [Mary Beth's Story](https://www.moffitt.org/inspiring-stories/mary-beths-story/ "Mary Beth's Story")
  * [Malcolm's Story](https://www.moffitt.org/inspiring-stories/malcolms-story/ "Malcolm's Story")
  * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story2/ "Lori's Story")
  * [Miriam's Story](https://www.moffitt.org/inspiring-stories/miriams-story/ "Miriam's Story")
  * [Nick's Story](https://www.moffitt.org/inspiring-stories/nicks-story/ "Nick's Story")
  * [Nadine's Story](https://www.moffitt.org/inspiring-stories/nadines-story/ "Nadine's Story")
  * [Nancy's Story](https://www.moffitt.org/inspiring-stories/nancys-story/ "Nancy's Story")
  * [Madison's Story](https://www.moffitt.org/inspiring-stories/madisons-story/ "Madison's Story")
  * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story/ "Lori's Story")
  * [Lloyd's Story](https://www.moffitt.org/inspiring-stories/lloyds-story/ "Lloyd's Story")
  * [Lanse's Story](https://www.moffitt.org/inspiring-stories/lanses-story/ "Lanse's Story")
  * [Kevin's Story](https://www.moffitt.org/inspiring-stories/kevins-story/ "Kevin's Story")
  * [Dr. Mooney's Story](https://www.moffitt.org/inspiring-stories/dr.-mooneys-story "Dr. Mooney's Story")
  * [Ken's Story](https://www.moffitt.org/inspiring-stories/kens-story/ "Ken's Story")
  * [Dr. Lee's Story](https://www.moffitt.org/inspiring-stories/dr.-lees-story "Dr. Lee's Story")
  * [Dr. Kumar's Story](https://www.moffitt.org/inspiring-stories/dr.-kumars-story "Dr. Kumar's Story")
  * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story2/ "Keith's Story")
  * [Dr. Latifi's Story](https://www.moffitt.org/inspiring-stories/dr.-latifis-story "Dr. Latifi's Story")
  * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story/ "Keith's Story")
  * [Dr. Kubal's Story](https://www.moffitt.org/inspiring-stories/dr.-kubals-story "Dr. Kubal's Story")
  * [Dr. Khakpour's Story](https://www.moffitt.org/inspiring-stories/dr.-khakpours-story "Dr. Khakpour's Story")
  * [Dr. Keenan's Story](https://www.moffitt.org/inspiring-stories/dr.-keenans-story "Dr. Keenan's Story")
  * [Dr. Kanetsky's Story](https://www.moffitt.org/inspiring-stories/dr.-kanetskys-story "Dr. Kanetsky's Story")
  * [Dr. Hoffe's Story](https://www.moffitt.org/inspiring-stories/dr.-hoffes-story "Dr. Hoffe's Story")
  * [Dr. Harrison's Story](https://www.moffitt.org/inspiring-stories/dr.-harrisons-story "Dr. Harrison's Story")
  * [Dr. Gwede's Story](https://www.moffitt.org/inspiring-stories/dr.-gwedes-story "Dr. Gwede's Story")
  * [Dr. Giuliano's Story](https://www.moffitt.org/inspiring-stories/dr.-giulianos-story "Dr. Giuliano's Story")
  * [Juli's Story](https://www.moffitt.org/inspiring-stories/julis-story/ "Juli's Story")
  * [Dr. Gonzalez's Story](https://www.moffitt.org/inspiring-stories/dr.-gonzalezs-story "Dr. Gonzalez's Story")
  * [Dr. Gatenby's Story](https://www.moffitt.org/inspiring-stories/dr.-gatenbys-story "Dr. Gatenby's Story")
  * [Dr. Etame's Story](https://www.moffitt.org/inspiring-stories/dr.-etames-story "Dr. Etame's Story")
  * [Dr. Cleveland's Story](https://www.moffitt.org/inspiring-stories/dr.-clevelands-story "Dr. Cleveland's Story")
  * [John and Whitney's Story](https://www.moffitt.org/inspiring-stories/john-and-whitneys-story/ "John and Whitney's Story")
  * [Liz's Story](https://www.moffitt.org/inspiring-stories/lizs-story/ "Liz's Story")
  * [Meet Lloyd](https://www.moffitt.org/inspiring-stories/meet-lloyd/ "Meet Lloyd")
  * [Paul and Gina's Story](https://www.moffitt.org/inspiring-stories/pauls-and-ginas-story/ "Paul and Gina's Story")
  * [Marvin's Story](https://www.moffitt.org/inspiring-stories/marvins-story/ "Marvin's Story")
  * [Meet Melissa](https://www.moffitt.org/inspiring-stories/meet-melissa/ "Meet Melissa")
  * [Muriel's Story](https://www.moffitt.org/inspiring-stories/muriels-story/ "Muriel's Story")
  * [John's and David's Story](https://www.moffitt.org/inspiring-stories/johns-and-davids-story/ "John's and David's Story")
  * [Melissa's Story](https://www.moffitt.org/inspiring-stories/melissas-story/ "Melissa's Story")
  * [Dr. Alexander Anderson's Story](https://www.moffitt.org/inspiring-stories/dr.-alexander-andersons-story "Dr. Alexander Anderson's Story")
  * [Pam's Story](https://www.moffitt.org/inspiring-stories/pams-story/ "Pam's Story")
  * [Yolanda's Story](https://www.moffitt.org/inspiring-stories/yolandas-story/ "Yolanda's Story")
  * [Wilbur's Story](https://www.moffitt.org/inspiring-stories/wilburs-story/ "Wilbur's Story")
  * [Vikki's Story](https://www.moffitt.org/inspiring-stories/vikkis-story/ "Vikki's Story")
  * [Tiffany's Story](https://www.moffitt.org/inspiring-stories/tiffanys-story/ "Tiffany's Story")
  * [Theresa's Story](https://www.moffitt.org/inspiring-stories/theresas-story/ "Theresa's Story")
  * [Joanna's Story](https://www.moffitt.org/inspiring-stories/joannas-story/ "Joanna's Story")
  * [Jenifer's Story](https://www.moffitt.org/inspiring-stories/jenifers-story/ "Jenifer's Story")
  * [Jeanine's Story](https://www.moffitt.org/inspiring-stories/jeanines-story/ "Jeanine's Story")
  * [Meet Jackie](https://www.moffitt.org/inspiring-stories/meet-jackie/ "Meet Jackie")
  * [Ian's Story](https://www.moffitt.org/inspiring-stories/ians-story/ "Ian's Story")
  * [Howard's Story](https://www.moffitt.org/inspiring-stories/howards-story/ "Howard's Story")
  * [Ryan's Story](https://www.moffitt.org/inspiring-stories/ryans-story/ "Ryan's Story")
  * [Robert's Story](https://www.moffitt.org/inspiring-stories/roberts-story/ "Robert's Story")
  * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story/ "Rick's Story")
  * [Richard's Story](https://www.moffitt.org/inspiring-stories/richards-story/ "Richard's Story")
  * [Rena's Story](https://www.moffitt.org/inspiring-stories/renas-story/ "Rena's Story")
  * [Rebecca's Story](https://www.moffitt.org/inspiring-stories/rebeccas-story/ "Rebecca's Story")
  * [Ray's and Dr. Bui's story](https://www.moffitt.org/inspiring-stories/rays-and-dr.-buis-story "Ray's and Dr. Bui's story")
  * [Patti's Story](https://www.moffitt.org/inspiring-stories/pattis-story/ "Patti's Story")
  * [Pam and Jonathan's story](https://www.moffitt.org/inspiring-stories/pams-and-jonathans-story/ "Pam and Jonathan's story")
  * [Sarah's Story](https://www.moffitt.org/inspiring-stories/sarahs-story/ "Sarah's Story")
  * [Steve and Laura's Story](https://www.moffitt.org/inspiring-stories/steve-and-lauras-story/ "Steve and Laura's Story")
  * [Donna's Story](https://www.moffitt.org/inspiring-stories/donna/ "Donna's Story")
  * [Tommy's Story](https://www.moffitt.org/inspiring-stories/tommys-story/ "Tommy's Story")
  * [Viviana's Story](https://www.moffitt.org/inspiring-stories/vivianas-story/ "Viviana's Story")
  * [Craig's Story](https://www.moffitt.org/inspiring-stories/craigs-story/ "Craig's Story")
  * [William's Story](https://www.moffitt.org/inspiring-stories/williams-story/ "William's Story")
  * [The Wilson - Jones's Family Story](https://www.moffitt.org/inspiring-stories/the-joness-family-story/ "The Wilson - Jones's Family Story")
  * [Woodrow's Story](https://www.moffitt.org/inspiring-stories/woodrows-story/ "Woodrow's Story")
  * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story2/ "Cathy's Story")
  * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story/ "Cathy's Story")
  * [Carolyn's Story](https://www.moffitt.org/inspiring-stories/carolyn/ "Carolyn's Story")
  * [Beth's Story](https://www.moffitt.org/inspiring-stories/beths-story/ "Beth's Story")
  * [Benita's Story](https://www.moffitt.org/inspiring-stories/benitas-story/ "Benita's Story")
  * [Barney's Story](https://www.moffitt.org/inspiring-stories/barneys-story/ "Barney's Story")
  * [Joel's Story](https://www.moffitt.org/inspiring-stories/joels-story/ "Joel's Story")
  * [Jessica's Story](https://www.moffitt.org/inspiring-stories/jessicas-story/ "Jessica's Story")
  * [Jen's Story](https://www.moffitt.org/inspiring-stories/jens-story/ "Jen's Story")
  * [Jay's Story](https://www.moffitt.org/inspiring-stories/jays-story/ "Jay's Story")
  * [Janelle's Story](https://www.moffitt.org/inspiring-stories/janelles-story/ "Janelle's Story")
  * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story2/ "Greg's Story")
  * [Gayle's Story](https://www.moffitt.org/inspiring-stories/gayles-story/ "Gayle's Story")
  * [Francis' Story](https://www.moffitt.org/inspiring-stories/francis-story/ "Francis' Story")
  * [Dr. Lau's Story](https://www.moffitt.org/inspiring-stories/dr.-laus-story "Dr. Lau's Story")
  * [Dr. Roberto Diaz's Story](https://www.moffitt.org/inspiring-stories/dr.-roberto-diazs-story "Dr. Roberto Diaz's Story")
  * [Dimas' Story](https://www.moffitt.org/inspiring-stories/dimas-story/ "Dimas' Story")
  * [David and Vesta's Story](https://www.moffitt.org/inspiring-stories/david-and-vestas-story/ "David and Vesta's Story")
  * [Cydney's Story](https://www.moffitt.org/inspiring-stories/cydneys-story/ "Cydney's Story")
  * [Charles' Story](https://www.moffitt.org/inspiring-stories/charless-story/ "Charles' Story")
  * [Cammie's Story](https://www.moffitt.org/inspiring-stories/cammies-story/ "Cammie's Story")
  * [Joanne's Story](https://www.moffitt.org/inspiring-stories/joannes-story/ "Joanne's Story")
  * [Neisha's Story](https://www.moffitt.org/inspiring-stories/neishas-story/ "Neisha's Story")
  * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story/ "Greg's Story")
  * [Joshua's Story](https://www.moffitt.org/inspiring-stories/joshuas-story/ "Joshua's Story")
  * [Bridget's Story](https://www.moffitt.org/inspiring-stories/bridgets-story/ "Bridget's Story")
  * [Barbara's Story](https://www.moffitt.org/inspiring-stories/barbaras-story/ "Barbara's Story")
  * [Abrianna's Story](https://www.moffitt.org/inspiring-stories/abriannas-story/ "Abrianna's Story")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-1)[For Healthcare Professionals](https://www.moffitt.org/research-science/researchers/eric-padron#mm-1)
  * [ For Healthcare Professionals ](https://www.moffitt.org/for-healthcare-professionals/)
  * [ Clinical Programs and Services ](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-33)
  * [ Physician Relations ](https://www.moffitt.org/for-healthcare-professionals/physician-relations/)
  * [ Continuing Education ](https://www.moffitt.org/for-healthcare-professionals/continuing-education/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-35)


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-31)[Clinical Programs and Services](https://www.moffitt.org/research-science/researchers/eric-padron#mm-31)
  * [Adolescent Young Adult (AYA) Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/adolescent-young-adult-aya-program/ "Adolescent Young Adult \(AYA\) Program")
  * [Anesthesiology and Critical Care Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/anesthesiology-program/ "Anesthesiology and Critical Care Program")
  * [BMT and Cellular Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/bmt-and-cellular-immunotherapy-program/ "BMT and Cellular Immunotherapy Program")
  * [Breast Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/breast-oncology-program/ "Breast Oncology Program")
  * [Cardio-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cardio-oncology-program/ "Cardio-Oncology Program")
  * [Cutaneous Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cutaneous-oncology-program/ "Cutaneous Oncology Program")
  * [Diagnostic Imaging and Interventional Radiology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/diagnostic-imaging-and-interventional-radiology-program/ "Diagnostic Imaging and Interventional Radiology Program")
  * [Endocrine Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endocrine-oncology-program/ "Endocrine Oncology Program")
  * [Endoscopic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endoscopic-oncology-program/ "Endoscopic Oncology Program")
  * [Gastrointestinal Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gastrointestinal-oncology-program/ "Gastrointestinal Oncology Program")
  * [Genetic Counseling Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genetic-counseling-program/ "Genetic Counseling Program")
  * [Genitourinary Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genitourinary-oncology-program/ "Genitourinary Oncology Program")
  * [Gynecologic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gynecologic-oncology-program/ "Gynecologic Oncology Program")
  * [Head and Neck Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/head-and-neck-oncology-program/ "Head and Neck Oncology Program")
  * [Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/immunotherapy-program/ "Immunotherapy Program")
  * [Malignant Hematology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/malignant-hematology-program/ "Malignant Hematology Program")
  * [Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/moffitt-malignant-hematology-cellular-therapy-at-memorial-healthcare-system/ "Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System")
  * [Neuro-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/neuro-oncology-program/ "Neuro-Oncology Program")
  * [Pathology](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pathology/ "Pathology")
  * [Pharmacy](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pharmacy/ "Pharmacy")
  * [Radiation Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/radiation-oncology-program/ "Radiation Oncology Program")
  * [Sarcoma Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/sarcoma-program/ "Sarcoma Program")
  * [Screening Prevention](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/screening-prevention/ "Screening Prevention")
  * [Senior Adult Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
  * [Supportive Care Medicine Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/supportive-care-medicine-program/ "Supportive Care Medicine Program")
  * [Thoracic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/thoracic-oncology-program/ "Thoracic Oncology Program")
  * [Translational Pathology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/translational-pathology/ "Translational Pathology Program")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-31)[Continuing Education](https://www.moffitt.org/research-science/researchers/eric-padron#mm-31)
  * [Moffitt Grand Rounds](https://www.moffitt.org/for-healthcare-professionals/continuing-education/moffitt-grand-rounds/ "Moffitt Grand Rounds")
  * [Multidisciplinary Programs](https://www.moffitt.org/for-healthcare-professionals/continuing-education/multidisciplinary-programs/ "Multidisciplinary Programs")
  * [Provider Conferences](https://www.moffitt.org/for-healthcare-professionals/continuing-education/provider-conferences/ "Provider Conferences")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-1)[Research](https://www.moffitt.org/research-science/researchers/eric-padron#mm-1)
  * [ Research Science ](https://www.moffitt.org/research-science/)
  * [ Research Programs ](https://www.moffitt.org/research-science/research-programs/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-39)
  * [ Divisions and Departments ](https://www.moffitt.org/research-science/divisions-and-departments/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-41)
  * [ Centers and Institutes ](https://www.moffitt.org/research-science/centers-and-institutes/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-43)
  * [ Community Outreach and Engagement ](https://www.moffitt.org/research-science/community-outreach-and-engagement/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-45)
  * [ Shared Resources ](https://www.moffitt.org/research-science/shared-resources/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-47)
  * [ Academic and Industry Partnerships ](https://www.moffitt.org/research-science/academic-and-industry-partnerships/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-49)
  * [ Administration ](https://www.moffitt.org/research-science/administration/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-51)


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-37)[Research Programs](https://www.moffitt.org/research-science/researchers/eric-padron#mm-37)
  * [Cancer Biology and Evolution](https://www.moffitt.org/research-science/research-programs/cancer-biology-and-evolution/ "Cancer Biology and Evolution")
  * [Cancer Epidemiology](https://www.moffitt.org/research-science/research-programs/cancer-epidemiology/ "Cancer Epidemiology")
  * [Health Outcomes and Behavior](https://www.moffitt.org/research-science/research-programs/health-outcomes-behavior/ "Health Outcomes and Behavior")
  * [Immuno-Oncology](https://www.moffitt.org/research-science/research-programs/immuno-oncology/ "Immuno-Oncology")
  * [Molecular Medicine](https://www.moffitt.org/research-science/research-programs/molecular-medicine/ "Molecular Medicine")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-37)[Divisions and Departments](https://www.moffitt.org/research-science/researchers/eric-padron#mm-37)
  * [Basic Science](https://www.moffitt.org/research-science/divisions-and-departments/basic-science/ "Basic Science")
  * [BioEngineering](https://www.moffitt.org/research-science/divisions-and-departments/bioengineering/ "BioEngineering")
  * [Clinical Science](https://www.moffitt.org/research-science/divisions-and-departments/clinical-science/ "Clinical Science")
  * [Population Science](https://www.moffitt.org/research-science/divisions-and-departments/population-science/ "Population Science")
  * [Quantitative Science](https://www.moffitt.org/research-science/divisions-and-departments/quantitative-science/ "Quantitative Science")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-37)[Centers and Institutes](https://www.moffitt.org/research-science/researchers/eric-padron#mm-37)
  * [Centers of Excellence](https://www.moffitt.org/research-science/centers-and-institutes/centers-of-excellence/ "Centers of Excellence")
  * [Institutes](https://www.moffitt.org/research-science/centers-and-institutes/institutes/ "Institutes")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-37)[Community Outreach and Engagement](https://www.moffitt.org/research-science/researchers/eric-padron#mm-37)
  * [About COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/about-coe/ "About COE")
  * [Advisory Boards](https://www.moffitt.org/research-science/community-outreach-and-engagement/community-advisory-boards/ "Advisory Boards")
  * [Catchment Area](https://www.moffitt.org/research-science/community-outreach-and-engagement/catchment-area/ "Catchment Area")
  * [Data](https://www.moffitt.org/research-science/community-outreach-and-engagement/data/ "Data")
  * [Outreach](https://www.moffitt.org/research-science/community-outreach-and-engagement/outreach/ "Outreach")
  * [Research and Clinical Trials](https://www.moffitt.org/research-science/community-outreach-and-engagement/research-and-clinical-trials/ "Research and Clinical Trials")
  * [Get Involved With COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/get-involved-with-coe/ "Get Involved With COE")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-37)[Shared Resources](https://www.moffitt.org/research-science/researchers/eric-padron#mm-37)
  * [Analytic Microscopy](https://www.moffitt.org/research-science/shared-resources/analytic-microscopy/ "Analytic Microscopy")
  * [Biostatistics and Bioinformatics](https://www.moffitt.org/research-science/shared-resources/biostatistics-and-bioinformatics/ "Biostatistics and Bioinformatics")
  * [Cancer Pharmacokinetics and Pharmacodynamics](https://www.moffitt.org/research-science/shared-resources/cancer-pharmacokinetics-and-pharmacodynamics/ "Cancer Pharmacokinetics and Pharmacodynamics")
  * [Chemical Biology](https://www.moffitt.org/research-science/shared-resources/chemical-biology/ "Chemical Biology")
  * [Collaborative Data Services](https://www.moffitt.org/research-science/shared-resources/collaborative-data-services/ "Collaborative Data Services")
  * [Flow Cytometry](https://www.moffitt.org/research-science/shared-resources/flow-cytometry/ "Flow Cytometry")
  * [Gene Targeting](https://www.moffitt.org/research-science/shared-resources/gene-targeting/ "Gene Targeting")
  * [Molecular Genomics](https://www.moffitt.org/research-science/shared-resources/molecular-genomics/ "Molecular Genomics")
  * [Participant Research, Interventions, and Measurement Core (PRISM)](https://www.moffitt.org/research-science/shared-resources/participant-research-interventions-and-measurement-core-prism/ "Participant Research, Interventions, and Measurement Core \(PRISM\)")
  * [Proteomics and Metabolomics](https://www.moffitt.org/research-science/shared-resources/proteomics-and-metabolomics/ "Proteomics and Metabolomics")
  * [Quantitative Imaging Core](https://www.moffitt.org/research-science/shared-resources/quantitative-imaging-core/ "Quantitative Imaging Core")
  * [Small Animal Imaging Lab](https://www.moffitt.org/research-science/shared-resources/small-animal-imaging-lab/ "Small Animal Imaging Lab")
  * [Tissue](https://www.moffitt.org/research-science/shared-resources/tissue/ "Tissue")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-37)[Academic and Industry Partnerships](https://www.moffitt.org/research-science/researchers/eric-padron#mm-37)
  * [Office of Innovation](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/ "Office of Innovation")
  * [Academic Partnerships](https://www.moffitt.org/research-science/academic-and-industry-partnerships/academic-partnerships/ "Academic Partnerships")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-37)[Administration](https://www.moffitt.org/research-science/researchers/eric-padron#mm-37)
  * [Non-Therapeutic Research Office](https://www.moffitt.org/research-science/administration/non-therapeutic-research-office/ "Non-Therapeutic Research Office")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-1)[Training & Education](https://www.moffitt.org/research-science/researchers/eric-padron#mm-1)
  * [ Education ](https://www.moffitt.org/education/)
  * [ Medical Education ](https://www.moffitt.org/education/medical-education/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-55)
  * [ Research Education and Training ](https://www.moffitt.org/education/research-education-and-training/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-57)
  * [ Nursing Education ](https://www.moffitt.org/education/nursing-education/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-59)
  * [ Health Professional Education ](https://www.moffitt.org/education/health-professional-education/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-61)
  * [ Other Educational Programs ](https://www.moffitt.org/education/other-educational-programs/)


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-53)[Medical Education](https://www.moffitt.org/research-science/researchers/eric-padron#mm-53)
  * [Our Training Programs](https://www.moffitt.org/education/medical-education/our-training-programs/ "Our Training Programs")
  * [Program Staff/Contact Us](https://www.moffitt.org/education/medical-education/program-staffcontact-us/ "Program Staff/Contact Us")
  * [Salary and Benefits](https://www.moffitt.org/education/medical-education/salary-and-benefits/ "Salary and Benefits")
  * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-53)[Research Education and Training](https://www.moffitt.org/research-science/researchers/eric-padron#mm-53)
  * [Office of Postdoctoral Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-postdoctoral-affairs/ "Office of Postdoctoral Affairs")
  * [Office of Graduate Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-graduate-affairs/ "Office of Graduate Affairs")
  * [Office of Undergraduate and Visiting Scholar Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-undergraduate-and-visiting-scholar-affairs/ "Office of Undergraduate and Visiting Scholar Affairs")
  * [Pre-College Programs](https://www.moffitt.org/education/research-education-and-training/pre-college-programs/ "Pre-College Programs")
  * [What We Provide](https://www.moffitt.org/education/research-education-and-training/what-we-provide/ "What We Provide")
  * [Contact Us](https://www.moffitt.org/education/research-education-and-training/contact-us/ "Contact Us")
  * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")
  * [News](https://www.moffitt.org/education/research-education-and-training/news/ "News")
  * [Where Are They Now](https://www.moffitt.org/education/research-education-and-training/where-are-they-now/ "Where Are They Now")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-53)[Nursing Education](https://www.moffitt.org/research-science/researchers/eric-padron#mm-53)
  * [Ambulatory Care Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/ambulatory-care-oncology-nurse-residency-program/ "Ambulatory Care Oncology Nurse Residency Program")
  * [Nurse Anesthetist](https://www.moffitt.org/education/nursing-education/nurse-anesthetist/ "Nurse Anesthetist")
  * [Nurse Practitioner](https://www.moffitt.org/education/nursing-education/nurse-practitioner/ "Nurse Practitioner")
  * [Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/oncology-nurse-residency-program/ "Oncology Nurse Residency Program")
  * [Registered Nurse](https://www.moffitt.org/education/nursing-education/registered-nurse/ "Registered Nurse")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-53)[Health Professional Education](https://www.moffitt.org/research-science/researchers/eric-padron#mm-53)
  * [Advanced Pharmacy Practice (APPE)](https://www.moffitt.org/education/health-professional-education/advanced-pharmacy-practice-appe/ "Advanced Pharmacy Practice \(APPE\)")
  * [Anesthesiology Assistant](https://www.moffitt.org/education/health-professional-education/anesthesiology-assistant/ "Anesthesiology Assistant")
  * [Dietetic Technician](https://www.moffitt.org/education/health-professional-education/dietetic-technician/ "Dietetic Technician")
  * [Dietitian](https://www.moffitt.org/education/health-professional-education/dietitian/ "Dietitian")
  * [Genetic Counseling](https://www.moffitt.org/education/health-professional-education/genetic-counseling/ "Genetic Counseling")
  * [Introductory Pharmacy Practice (IPPE)](https://www.moffitt.org/education/health-professional-education/introductory-pharmacy-practice-ippe/ "Introductory Pharmacy Practice \(IPPE\)")
  * [Master of Public Health Field Experience](https://www.moffitt.org/education/health-professional-education/master-of-public-health-field-experience/ "Master of Public Health Field Experience")
  * [Medical Assistants](https://www.moffitt.org/education/health-professional-education/medical-assistants/ "Medical Assistants")
  * [Nuclear Medicine](https://www.moffitt.org/education/health-professional-education/nuclear-medicine/ "Nuclear Medicine")
  * [Occupational Therapy Intern](https://www.moffitt.org/education/health-professional-education/occupational-therapy-intern/ "Occupational Therapy Intern")
  * [PGY1 Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-1-residency/ "PGY1 Pharmacy Residency")
  * [PGY2 Oncology Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-2-oncology-residency/ "PGY2 Oncology Pharmacy Residency")
  * [Oncology Pharmacy Technician Trainee Program](https://www.moffitt.org/education/health-professional-education/pharmacy-technician-extern/ "Oncology Pharmacy Technician Trainee Program")
  * [Physical Therapy](https://www.moffitt.org/education/health-professional-education/physical-therapy/ "Physical Therapy")
  * [Physical Therapy Assistant](https://www.moffitt.org/education/health-professional-education/physical-therapy-assistant/ "Physical Therapy Assistant")
  * [Physician Assistant](https://www.moffitt.org/education/health-professional-education/physician-assistant/ "Physician Assistant")
  * [Psychology](https://www.moffitt.org/education/health-professional-education/psychology/ "Psychology")
  * [Radiation Therapy](https://www.moffitt.org/education/health-professional-education/radiation-therapy/ "Radiation Therapy")
  * [Radiography Therapy](https://www.moffitt.org/education/health-professional-education/radiography-therapy/ "Radiography Therapy")
  * [Respiratory Therapy](https://www.moffitt.org/education/health-professional-education/respiratory-therapy/ "Respiratory Therapy")
  * [Social Work](https://www.moffitt.org/education/health-professional-education/social-work/ "Social Work")
  * [Sonography/Ultrasound Student](https://www.moffitt.org/education/health-professional-education/sonographyultrasound-student/ "Sonography/Ultrasound Student")
  * [Speech Therapy](https://www.moffitt.org/education/health-professional-education/speech-therapy/ "Speech Therapy")
  * [Wound Ostomy](https://www.moffitt.org/education/health-professional-education/wound-ostomy/ "Wound Ostomy")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-1)[Give](https://www.moffitt.org/research-science/researchers/eric-padron#mm-1)
  * [ Give ](https://www.moffitt.org/give/)
  * [ Why Give? ](https://www.moffitt.org/give/why-give/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-65)
  * [ Ways to Give ](https://www.moffitt.org/give/ways-to-give/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-67)
  * [ Get Involved ](https://www.moffitt.org/give/get-involved/) [](https://www.moffitt.org/research-science/researchers/eric-padron#mm-69)


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-63)[Why Give?](https://www.moffitt.org/research-science/researchers/eric-padron#mm-63)
  * [About the Moffitt Foundation](https://www.moffitt.org/give/why-give/about-the-moffitt-foundation/ "About the Moffitt Foundation")
  * [FAQ](https://www.moffitt.org/give/why-give/faq/ "FAQ")
  * [Financials and Stewardship](https://www.moffitt.org/give/why-give/financials-and-stewardship/ "Financials and Stewardship")
  * [Contact the Foundation](https://www.moffitt.org/give/why-give/contact-the-foundation/ "Contact the Foundation")
  * [You Can Make a Difference](https://www.moffitt.org/give/why-give/you-can-make-a-difference/ "You Can Make a Difference")
  * [Impact Report](https://www.moffitt.org/give/your-impact/2022-annual-foundation-impact-report/ "Impact Report")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-63)[Ways to Give](https://www.moffitt.org/research-science/researchers/eric-padron#mm-63)
  * [Cash, Stock or Other Assets](https://www.moffitt.org/give/ways-to-give/cash-stock-or-other-assets/ "Cash, Stock or Other Assets")
  * [Planned Giving](https://mymoffittlegacy.org/ "Planned Giving")
  * [Philanthropic Foundation Giving](https://www.moffitt.org/give/ways-to-give/philanthropic-foundation-giving/ "Philanthropic Foundation Giving")
  * [Corporate Partnership](https://www.moffitt.org/give/ways-to-give/corporate-partnership/ "Corporate Partnership")
  * [Employer Matching Gifts](https://www.moffitt.org/give/ways-to-give/employer-matching-gifts/ "Employer Matching Gifts")
  * [Endowment Gifts](https://www.moffitt.org/give/ways-to-give/endowment-gifts/ "Endowment Gifts")
  * [Other Ways to Donate](https://www.moffitt.org/give/ways-to-give/other-ways-to-donate/ "Other Ways to Donate")
  * [Breast Cancer Funding Opportunities](https://www.moffitt.org/give/ways-to-give/breast-cancer-funding-opportunities/ "Breast Cancer Funding Opportunities")
  * [Support the Pentecost Family Myeloma Research Center](https://www.moffitt.org/give/ways-to-give/support-the-pentecost-family-myeloma-research-center/ "Support the Pentecost Family Myeloma Research Center")
  * [Partners In Discovery](https://www.moffitt.org/give/ways-to-give/partners-in-discovery/ "Partners In Discovery")


[](https://www.moffitt.org/research-science/researchers/eric-padron#mm-63)[Get Involved](https://www.moffitt.org/research-science/researchers/eric-padron#mm-63)
  * [Become a Member](https://www.moffitt.org/give/get-involved/become-a-member/ "Become a Member")
  * [Volunteer Your Time](https://www.moffitt.org/give/get-involved/volunteer-your-time/ "Volunteer Your Time")
  * [Miles for Moffitt](https://www.moffitt.org/give/get-involved/miles-for-moffitt/ "Miles for Moffitt")
  * [Magnolia](https://www.moffitt.org/give/get-involved/magnolia/ "Magnolia")
  * [Mission Possible Sarasota Luncheon](https://www.moffitt.org/give/get-involved/mission-possible-sarasota-luncheon/ "Mission Possible Sarasota Luncheon")
  * [Discovery Series Webinars](https://www.moffitt.org/give/get-involved/discovery-series-webinars/ "Discovery Series Webinars")
  * [Fundraise for Moffitt](https://www.moffitt.org/give/get-involved/fundraise-for-moffitt/ "Fundraise for Moffitt")


[](https://www.moffitt.org/research-science/researchers/eric-padron#page)
